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A bstract
Positron Emission Tomography (PET) is considered as the fastest expanding diagnostic 
imaging system in the world, and has become one o f the major tools in diagnosis and staging 
in oncology. Although all the European countries together do not have yet as many scanners 
as the USA, they have almost completed Phase One o f the PET/Computer Tomography (CT) 
Services Plan. For example, the number o f PET/CT scanners in England has increased by a 
factor o f three during the last three years and the focus is now on the advanced PET/CT 
system. Combined PET and CT scanning is an advanced imaging modality that offers high 
patient throughput, but results in increased occupational radiation dose exposure. In addition, 
mobile PET/CT systems have been used to overcome space and money limitations. However, 
the working environment in a mobile scanner unit places particular constraints on space, 
patient handling and workflow. These factors stimulated us to investigate the occupational 
radiation exposure doses for a number o f static and mobile PET and PET/CT services 
provided by NHS hospitals and private companies. The vital goal o f this work was to 
determine staff doses in both static and mobile PET/CT environments and examine the 
influence o f shielding and design by Monte-Carlo simulation.
The PET/CT workflow for staff was divided into six phases that were given operational 
definitions, and start and end points. Using stopwatches, dose rate meters, electronic personal 
dosimeters (EPDs) made by Thermo and portable LaBr3 spectrometers and dosimeters made 
by Canberra, exposure time, dose rate, gamma ray spectrum and dose measurements were 
performed over a period o f time varying between 1 day and 5 weeks by various technologists 
working in 3 static and 3 mobile PET/CT units. Measurements o f exposure rate from more 
than 1250 patient procedures in total were collected and analysed. Experimental studies 
concluded that the occupational back ground was quite high (>3 pSv/8hours) in some 
locations and that injected patients were released with high dose rates exceeding 60 pSv/h in 
the close contact position (< 40 cm). In addition, in designs where the hot-lab room was 
located between the reception desk and control room without proper shielding, the exposure 
dose rate in the air exceeded 15 pSv/h at 120 cm from the wall o f the hot-lab. The use o f a 
portable LaBr3 detector was important because it has an excellent energy and timing 
resolution, superior intrinsic spatial resolution and high detection efficiency.
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Existing occupational doses recorded previously were analysed and provided information that 
was used in the experimental design o f more detailed measurements. Although these results 
indicated that occupational background is very high in most units, all staff members currently 
working in Medical PET and PET/CT units are within the regulatory limits for non-classified 
occupational exposure (<6 mSv per year). However, many of the staff would exceed the 
classification level if  the occupational background was not subtracted.
The average exposure time for staff working in static and mobile environments was around 
15 minutes and 25 minutes per patient respectively for all 6 defined workflow phases. The 
corresponding average exposure dose was 5.0 pSv (static) and 5.7 pSv (mobile) per patient.
High exposure times and doses were seen to occur during the injection phase and the 
scanning phase, where staff members are in prolonged close contact with radioactive patients. 
In addition, on the mobile PET/CT unit, accompanying the patient to the toilet prior to the 
scan also incurred a high dose, in particular when patients needed additional assistance. It 
was found that at least 10% o f the total dose was not attributable to any o f the defined tasks 
in the workflow, and instead was attributed to unexpected occupational exposure as well as 
carelessness.
Monte Carlo simulation was used to check the dose map inside the unit and to certify the 
shielding calculation and design. Also, the simulation was used to compare the staff effective 
dose per patient. Two types o f tallies were used as a cross check and showed excellent 
agreement.
Based on the findings o f the experimental and numerical studies, a number o f strategies for 
reducing occupational exposures in all workflow phases are suggested.
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1 Chapter 1: Introduction
1.1 Cancer statistics in the UK
More than 200 types o f cancer have been recognised, o f which four are particularly common 
in the UK. Around 293,000 new cases o f cancer (excluding skin cancer) are registered 
annually in the UK [1], and the risk o f developing some form of cancer during a person’s life 
time exceeds 1 in 3. The rate o f newly diagnosed cases o f cancer increased by more than 30% 
between 1977 and 2007, as seen from Figure 1 which shows the increase in newly recorded 
cancer cases in the UK during the last 28 years [1, 2]. In the year 2007, one in four deaths in 
the UK, equivalent to more than 155,000 cases, was due to cancer [2]. However, earlier 
diagnosis o f cancer could save thousands o f lives each year, especially with the new 
diagnostic technologies. Although there are a variety o f diagnostic methods and systems, 
such as blood tests, computer tomography (CT) and magnetic resonance imaging (MRI), 
positron emission tomography (PET) is one o f the most promising imaging modalities in 
oncology due to its ability to monitor different types o f cancers by injecting the patient with 
appropriately labelled material containing positron emitting radionuclides [1,2].
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Figure 1-1: Newly diagnosed cases o f cancer in the UK from 1979-2007 [2]
18
In 1927, Dirac suggested the theoretical existence o f the positron. Five years later, Anderson
experimentally demonstrated that the positron exists. Not long after, researchers began to
consider medical applications for positrons, and their special properties for diagnostics have
now been recognised [3]. In 1951, positrons were used to locate a brain tumour by using
PET. PET uses a positron emitting radioisotope (see Chapter 2) with a short half-life,
attached to a tracer, to test abnormal biochemical processes. In 1997, l8F-fluorodeoxyglucose 
18 • • •( FDG) was licensed as a radiopharmaceutical for routine clinical applications. Although 
PET has been in use as a research tool for over 30 years, its effective clinical role has only 
been recognised during the last 10 years. One o f the latest developments in imaging 
modalities is the hybrid PET/CT scanner, which was introduced in 1998. X-ray CT scans 
provide anatomical images, while PET presents functional images [4]. The first clinical 
application to combine these two exciting modalities (PET/CT) was introduced in 2001 [5]. 
The PET/CT system has made image registration easier, as data from both scanners are 
collected using the same patient couch position. Such a system has solved the fusion problem 
that resulted from combining two registered images to create a fusion image by using 
hardware instead o f software [6]. The predominant clinical applications o f PET/CT are in the 
areas o f oncology, as it has the ability to monitor different types o f cancers. Other clinical 
applications, e.g. in cardiology and in neurology, have also used PET/CT. PET scans are now 
carried out in large numbers annually as PET/CT patient throughput has grown rapidly [7].
Table 1-1: PET and PET/CT scanners numbers over the world in 2004 [8, 9]
1.2 H istory  and D ev e lo p m en t o f  PE T  and PE T /C T
Region PET PET/CT Total
USA 1500 355 1855
EU 291 92 383
Others 59 63 122
World 1850 510 2360
Table 1-1 shows the distribution o f PET and PET/CT scanners around the world in February 
2004. The total number o f PET scanners was 1850 worldwide, which made PET the fastest 
expanding imaging modality [4]. In Europe, there were about 300 PET scanners in2004. 
However, the US has recorded a faster expansion in the number o f PET/CT scanners used
[9].
19
1.3 PET/CT Clinical role
PET/CT involves two separate invasive and non-invasive tests that are combined to provide 
useful information about the physiological and anatomical state o f the body. PET/CT has its 
main role in cancer applications, where it is used to detect disease and to determine the 
effectiveness o f therapy. In a PET/CT procedure, CT images concurrently allow clinicians to 
measure the exact size, shape, and location o f the diseased tissue or tumour. When the results 
o f the scans are combined together, they present more information than either examination 
alone. Although the system has two separate sections, both are controlled from a single work 
station [5]. The PET and CT modalities o f the device can be used separately if  required, 
although this is infrequently the case. In the UK and USA, oncology currently accounts for 
over 90% of all PET/CT studies, while cardiology and neurology applications cover the 
remainder [9]. PET/CT scanners have quickly become the preferred technology for imaging 
in cancer diagnostics, as the integration o f the functional PET images with the anatomical 
visualization o f CT has allowed more accurate and faster diagnosis [10]. While PET/CT 
comprised about half o f all imaging scanners in 2003, 90% of the PET units planned for 
purchase over the next five years will be PET/CT scanners Figure 1-2 and Figure 1-3 [8].
1.4 Growth of static and mobile PET/CT units in the UK
PET/CT scanning is increasing rapidly in the UK, the USA and in other European countries. 
In the USA, the number o f PET studies exceeded 700,000 cases in 2003, with the number o f 
PET imaging sites reaching 1500 [9]. In 2008 the total number o f PET and PET/CT patient 
studies achieved in the U.S. was 1.52 million scans, an increase o f only 4% above the 1.48 
million procedures performed in 2007. This can be compared to the average annual growth 
rate o f 10.4% from 2005 to 2008, according to the IMV survey o f around 2,000 sites with 
mobile and static PET and PET/CT units. PET/CT has become the common choice o f cancer 
diagnostics as a result o f its ability to combine metabolic and anatomical diagnostic 
information in one image [11]. According to the Siemens/CTI report published in March 
2010, the number o f PET/CT scanners installed in the United States reached approximately 
2,000, while around 350 were installed in Europe. Considering that the populations o f the 
United States and Europe are about 307 million and 830 million, respectively, the United 
States has installed about 6 times as many scanners as the whole o f Europe even though it has 
only one third the population[12].
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Figure 1-3: PET sites/studies and PET/CT sites/studies, in 2005 and 2008 in the USA [11]
In 2003, the document “Positron emission tomography- A strategy for provision in the UK” 
was issued by the Intercollegiate Standing Committee on Nuclear Medicine (ICSCNM). They 
strongly recommended the usage o f PET/CT. The Department o f Health (DOH) identified the 
need for a comprehensive strategic approach for the delivery o f PET services in a 
consultation document in 2004.
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In February 2005, the National Institute for Clinical Excellence (NICE) and the National 
Collaborating Centre for Acute Care (NCCAC) published guidelines for the NHS in England 
and Wales on the diagnosis and treatment o f lung cancer.
PET imaging is recommended in a number o f situations relating to diagnosis, as well as pre- 
surgical and pre-radiotherapy staging. PET has a similarly important role in other cancers. 
The guidelines also recommend that every cancer network should have a system of rapid 
access to FDG-PET scanning for eligible patients [13].
In March 2009, the Customer Service Centre o f the NHS, and the Cancer Programme 
Medical Directorate at the DOH in London, reported that there are currently more than 30 
clinical scanners available across 41 cities in England: 22 scanners (19 PET/CT, 3 PET) 
offering PET/CT imaging services to patients within the NHS and the private sector; 15 
private mobile scanners (14 PET/CT, 1 PET) available to NHS patients across 27 cities and 
towns in England; and 6 scanners (1 PET/CT and 5 PET) dedicated exclusively to research. 
Although the NHS reached 12,500 scans per year during 2005 in England, they have recently 
increased the number o f PET/CT scans by a factor o f four in less than four years [14, 15].
The number o f PET/CT scanners in the UK is expected to continue to rise significantly as 
evidence grows supporting the clinical application o f PET/CT in serious diseases, as is 
already happening in the USA and Europe. Although the usage o f mobile units commercially 
started in the UK in 2004 with 1 mobile PET unit, the number o f mobile units expanded 
rapidly by factor o f 15 in the subsequent five years. This increase was due to the significant 
demand for PET imaging as well as because o f the space limitation in hospitals and the high 
cost o f building a static unit. The mobile PET or PET/CT has been considered as a good 
alternative.
1.5 Mobile PET/CT Units
There are basically two types o f PET/CT units on the market: static and mobile. The static 
units are built and setup in a particular place in a hospital or a diagnostic centre. In the case o f 
the static units the patient often needs to travel considerable distances, which is inconvenient 
for patients. Also, building a PET/CT unit is often too costly. However, in the case o f mobile 
units, this type o f imaging services can be offered at several sites as there are generally few 
geographical limitations. Portable PET/CT scanner units have saved ill patients time and have 
reduced lengthy journeys to receive diagnosis and monitoring [6, 16].
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The use o f mobile PET/CT is gaining popularity in the UK, as it offers the same scan 
functionality and saves money, time, and effort. This means that in remote locations where 
patients do not have easy access to hospital facilities, mobile PET/CT units can be provided 
relatively near their place o f residence. However, the downside o f mobile units is their 
smaller facility environments within which the staff members have to operate, presenting a 
challenge in terms o f managing the workflow, the efficiency o f operation, management skills 
and space. Although there are differences in the structures and layouts o f different units, for 
example in the use o f physical space and in the use o f dispensing and injection rooms, the 
patients will generally have easy access to diagnostic facilities[17, 18].
1.6 Cost of PET/CT units
The number o f PET/CT scanners has been growing rapidly worldwide since 2005, due to the 
high diagnostic value o f PET/CT in clinical medicine. The PET/CT scanner has been 
considered as the fastest growing imaging modality in the medical field [8]. Although a 
PET/CT scanner currently costs around £1.5M, the cost o f construction and shielding doubles 
this price due to the requirements o f unit design, shielding and unit location as well as space. 
In total, a complete installation typically needs more than four million pounds. However, the 
total value o f a mobile PET/CT unit is £2,500,000 including shielding, scanner, etc., and 
offers PET/CT diagnostic services to many hospitals across the UK. This cost has been 
calculated for either a static or a mobile PET/CT unit including setting up and running.
In both mobile and static units the cost o f equipment used in the hot lab and control room are 
almost the same. Having a static cyclotron unit for FDG production within a short distance 
from the PET/CT unit is advantageous as it avoids exposing workers to radiation during 
isotope transportation. However, the total price o f a cyclotron unit is more than three and half 
million pounds (all prices exclude the operations costs and are up to date according to GE and 
Siemens offers to a selection o f NHS trust hospitals and private imaging centres). In late 
2008, the first FDG mobile production unit appeared on the market for commercial use at a 
price o f £2M. This is less than the static cyclotron unit price by about £1.5M and is free from 
space and geographical limitations[19].
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1.7 The effect of growth of PET/CT units and radiation expousre of the worker
There is clearly a fundamental need to increase the number o f PET/CT units across the UK in 
order to deliver excellent services to cancer patients. However, achieving the planned excess 
o f 48,000 scans per year is not easy and has led to increases in the workload o f staff 
members. Indeed, there is a finite limitation in the number o f dedicated PET/CT technologists 
and there are no statistics shows the exact number o f PET staff members. During this project, 
visits to 8 static and 3 mobile PET/CT units across England allowed meetings with around 30 
radiographers, mostly female, and o f which 50% were nuclear medicine staff members.
M ost o f the hospitals with a Nuclear Medicine (NM) department circulate some o f the NM 
staff on a fortnightly basis to the PET/CT unit to cover the need. However, this cannot be 
achieved smoothly due to the shortage o f space, budget, experience o f staff and restricting 
regulations. According to the International Commission on Radiological Protection (ICRP) 
recommendations in Report number 60, the dose limit o f a staff member should not exceed 
the classification level, which is one third o f the annual dose limit o f 20 mSv/year [20]. 
Exceeding 6 mSv o f the annual dose may affect workflow in the PET/CT unit, as well as the 
reputation o f private centres amongst the community o f radiographers and technologist 
available for recruitment. There were many aims for this project, but reducing the 
occupational dose for workers in PET environments was the main goal. Three principal 
factors control staff dose: design and dimension o f the unit, skills and techniques o f the staff, 
and type o f unit and equipment. This report examines scan procedures, staff dose records and 
dosimeter positioning in order to understand the workflow patterns and to determine how 
staff doses can be reduced.
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2 Chapter 2: Dosimetry and Background
2.1 Activity, half-life and average lifetime
In order to understand safety in radiation environments, it is essential to introduce the concept 
o f radioactivity and its related terms. Activity (A) can be defined in terms o f the number o f 
radioactive atoms A  decaying per unit time (t). The formal expression is:
AN 
A — — At
2-1
The unit o f activity is the Becquerel (Bq), defined as one disintegration per second (1 Bq = 1 
s '1). However, it is a measure only o f quantity o f radioactive material and is not identical to 
the total number o f radiations emitted per second, as can be seen from the following example:
Cobalt-60 (60Co) is a beta emitter, and each disintegration yields one beta-negative ((3') 
particle and two gamma photons, giving a total radiation emission o f 3/s/Bq.
The old unit o f activity was the curie (Ci), which was originally the activity ascribed to 1 g o f 
226Ra and is still used predominantly in the USA. Note that 1 Ci = 3.7 x 1010 Bq [21].
The activity o f a radionuclide decreases exponentially with time. If N  represents the number 
o f atoms o f a radionuclide in a sample at any given time, then the change dN in that number 
during a short time dt is proportional to N  and to dt.
dN = -XNdt
2-2
where X is the decay constant.
The decay rate, or activity, A, is given by:
- d N  
A = dt
2 - 3
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By separating the variables,
dN 
= —XdtN 
2 - 4
and integrating both sides gives
InN — —Xt + c 
2 - 5
Where c is an arbitrary constant o f integration. If  Na atoms o f the radionuclide are present at 
time t = 0, then equation (2-5) implies that c = In N0, and
N N
In — ~ = —Xt and —— = e At 
No No
2-6
Equation (2-6) describes the law o f exponential radioactive decay. Since the activity o f a 
sample and the number o f atoms present are proportional, activity follows the same rate o f 
decrease:
A — Aoe x t  
2 - 7
where A0 is the original activity at time t = 0.
To express time Tm (known as the half-life, which is the time required by a radioisotope for 
its original activity to be reduced by one half, and which is unique for each isotope) [22] in 
terms o f X, we can write Equation (2-7) at time t —T as
2-8
26
Then, taking the natural logarithm of both sides gives
—X T y = lnl /2  = Ini — ln2
2 - 9
and therefore,
In 2 
T l/ = —r— /2 X
2-10
hence,
N  _  _  — 0 . 6 9 3 3 t / T i /
N o ~  A o ~  6
2-11
and therefore,
A = Ao
2-12
Note that the average lifetime \  is the average time it takes each atom to transmute.
The half life o f the atoms in the radionuclide is therefore about 70% o f the mean life time:
T l, = 0.693t/ 2
2-13
From the definition o f half-life, the fraction o f a radioisotope remaining after n half-lives can 
be calculated by the following expression:
A 1
Ao  2 n
2 -1 4
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From Equation (2-13), n should be given by:
n = —3.3 log —  Ao
A
From Equation 2-15, when the remaining activity is 1%, n is equal to 7.
2 - 1 5
2.1.1 Specific activity (SA)
The specific activity can be defined as the number o f Bq per unit mass or volume o f a pure 
radioisotope. From the transformation constant 2, atomic weight o f the isotope AWi Avogadro 
number Nav (6.03 X 1023 atoms/mole) and half-life T\n [18], the specific activity SA can be 
calculated by:
1 gx 6.03 x 1023 atoms/mole
Aw g/mole  
2 - 1 6  
SA = AN 
2 - 1 7
Then, from Equation (2-10),
4.18 x 1020
SA = — — ----MBq/mg¿w 7*1/
2 - 1 8
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In order to understand the physical basis for radiation shielding and dosimetry, we need to 
understand the interaction o f radiation with matter. Photons and particles interact with matter 
in several ways that must be considered in nuclear medicine. However, the level o f energy 
that we are concerned with is less than 1 MeV. Therefore, we will discuss the two major 
types o f photon interaction with matter, which are the photoelectric effect and Compton 
scattering. In most interactions, energy is transferred from the incident radiation to the 
absorbing medium. The relative importance o f the transfer depends on both the energy (Ey = 
hv) and the atomic number Z o f the absorbing material. Where h is Plank's constant and v is 
frequency in Hz [23].
2 .2  Interactions w ith  m atter
Figure 2-1: The relative importance o f the three major gamma-ray interactions [24].
The predominance o f each interaction depends on the energy o f the incident photon and the 
atomic number (Z) o f the material. In Figure 2-1 the relative importance o f the three 
interactions are shown over broad ranges o f energies (hv) o f the incident photon and atomic 
number (Z) o f the absorber. Photoelectric absorption predominates for materials with 
relatively high Z and low energy while Compton scattering predominates for energies 
between 0.7 and 5 MeV and low Z absorbers. A third interaction type, pair production, 
predominates at higher energies [24].
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However, pair production takes place only at energies above 1.022 MeV, which represents 
the total rest mass o f the electron and positron pair produced in the interaction between the 
incident gamma-ray and the electric field surrounding the nucleus [22]. In PET, pair 
production does not play any role.
2.2.1 Photoelectric Effect
The photoelectric effect is the most important interaction between low-energy photons (less 
than 0.08 MeV) and matter [24]. It is defined as an atomic absorption process in which an 
orbital electron completely absorbs the energy o f an incident photon. The photon disappears 
and the energy absorbed is used to eject the orbital electron from the atom (see Figure 2-2). 
The ejected electron is called a photoelectron and is most likely to be derived from the K- 
shell. The electron receives kinetic energy Epe, equal to the difference between the incident 
photon energy E0 and the binding energy o f the electron shell from which it was ejected. If  a 
K-shell electron is ejected, the kinetic energy o f the photoelectron is:
Epe E0 Kg
2 -1 9
where Kb is the K-shell binding energy for the atom from which it is ejected. Nevertheless, 
photoelectrons cannot be ejected from an electron shell unless the incident photon energy 
exceeds the binding energy o f that shell; for low energy photons L or M shell photoelectric 
effect is more likely. The ejected electron creates a vacancy in an orbital electron shell, which 
in turn leads to the emission o f characteristic X-rays These X-rays are, in turn, likely to be 
absorbed within the medium during another photoelectric interaction. In some fraction o f the 
cases, the absorption o f the characteristic X-rays within the medium leads to the ejection and 
subsequent absorption o f Auger electrons, which are electrons emitted from the atom due to 
the energy released when filling a vacancy in the inner shell with another orbital electron (see 
Section 2.3.4 below). The photoelectric effect is favoured by low-energy photons and high Z 
absorbers. The photoelectric absorption coefficient T is a function o f the energy o f the 
radiation as well as the atomic number o f the target. In low Z elements, such as those 
commonly found in body tissues, binding energies and characteristic X-ray energies are only 
a few keV or less. Thus binding energy is a small factor in photoelectric interactions in body 
tissues [22, 23].
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The photoelectric effect is most likely to occur when the difference between the photon 
energy and binding energy o f the electron is smaller:
t  a
E3
2-20
Where is the Z atomic number and E is the photon energy.
Incident
photon
Figure 2-2: Photoelectric effect and the photoelectron [25]
2.2.2 Compton Scattering
Compton scattering is a collision between an incident photon and a loosely bound outer shell 
orbital electron o f an atom. Both momentum and energy are conserved in the collision. This 
interaction predominates for low-Z materials (e.g. tissue) and is in the region 0.7 to 10 MeV 
(see Figure 2-3). Since the incident photon energy greatly exceeds the binding energy o f the 
electron to the atom, the interaction appears as a collision between the photon and a free 
electron [22]. However, the photon doses not disappear; instead it is deflected through a 
scattering angle (0). Part o f its energy is transferred to the recoil electron; thus, the photon 
loses energy in the process. The wavelength o f the scattered photon increases due to its 
decreased energy.
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The wavelength change is known as the Compton shift. The energy o f the scattering photon is 
related to the scattering angle (0 ) by consideration o f energy and momentum conservation 
according to:
2-21
2 T* T"1Where m 0C , E 0 and E sc are the electron rest mass (0.511 MeV), and the incident and
scattered photon energies in MeV, respectively.
The energy o f the recoil electron, E re is thus,
Ere =  E 0 -  E sc
2-22
The amount o f energy transferred to the recoil electron ranges from nearly zero for 0 ~ 0° up 
to some maximum value £*™axwhich occurs at 0 = 180 °. The minimum energy for scattered
photons, E ™in n can be calculated from equation (2-22) with 0 = 180° [23].
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Figure 2-3: Compton scattering [26]
The estimated relative probability for the occurrence o f Compton scatting is given by
According to the Klein-Nishina equation for a free electron, Compton interactions in soft 
tissue are much more inportant than photoelectric absorption for photon energies less than 70 
keV.
2.2.3 Positron Annihilation
In 1928, Dirac postulated that a subatomic particle existed which was equivalent in mass to 
an electron but which carried a positive charge. Anderson experimentally observed these 
particles, which he called positrons [27]. Radioactive decay by positron emission occurs in 
proton-rich nuclei, where, a proton (p+) in the nucleus is transformed into a neutron (w), and a 
positron ((3+) and a neutrino (v) are ejected from the nucleus, as follows:
g  a Z/E
2 - 2 3
P + -> n  4- /?+ +  v +  E n e r g y
2-24
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The positron has a positive charge e+, spin Vi and the same mass (me) as an electron. The 
process o f positron-electron annihilation occurs when the total mass o f both beta particles 
before the annihilation are converted into one, two, or three photons [28]. After ejection from 
a proton-rich nucleus, a positron will lose all its kinetic energy in collisions with the atoms of 
the surrounding material, and will come to rest before undergoing annihilation with a free 
stationary electron see Figure 2-4.
The result o f a positron (e+) combining with an electron (e‘) in an annihilation reaction is the 
production o f two 511 keV gamma photons (y) travelling in almost opposite directions 
(Figure 2-5) [27]:
e + +  e~ =  2 y
2 -2 5
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Figure 2-5: Diagram illustrating annihilation reaction[29]
The transition energy is divided among the kinetic energy o f the positron, neutrino and the 
nuclear recoil. The two annihilation photons allow a PET scanner to localise their origin 
along a line between the two face-to-face detectors using annihilation coincidence detection, 
as can be seen from Figure 2-6. Detection o f a pair o f annihilation photons in opposing 
detectors can define the volume from which they were emitted. In a PET scanner, this is 
accomplished by designing the electronics to attach a digital time stamp to record each 
detected event. In general, this is done with a precision o f about 1 or 2 xlO 9 s [5].
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Positron emitting 
isotope
Figure 2-6: Positron Emitter Coincident Detection [30]
The coincidence processor examines the time stamp of each event in comparison with events 
recorded in the opposing detector. A coincidence event is assumed to have occurred when 
pairs o f events are recorded within a specified coincidence-timing window, which typically is
6 - 1 2 x 1 0 '9s [5].
2.2.4 Electron Capture
Electron capture (EC) is a radioactive decay process and may occur when an orbital electron 
is close to an unstable nucleus. In proton rich unstable parent nuclei, EC occurs as a way to 
reduce the number o f protons by capturing an electron. However, EC requires that the mass 
o f the parent M (Z, A) exceeds the mass o f the daughter by a minimum o f one electron mass.
2.3 Photon Interaction with Absorbers
2.3.1 Characteristic X-rays
An atom has a nucleus which is surrounded by negatively charged particles called electrons 
(e-). The electrons are housed in shells (K, L, M, N) and sub shells (Li, Ln, LmJ. Each shell 
has a unique binding energy for each material e.g. in tungsten (7 4W) with an atomic number 
74, the K shell binding energy is 70 keV [31]. If an orbital electron has a sufficient energy 
from a collision with another electron or an incident photon to be ejected from its orbit, the 
new electron vacancy will be filled with an outer shell’s electron. The energy differences 
between the two shells will be emitted as an X-ray Figure 2-2.
ONeutrino
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However, in some cases the electron may be decelerated by the field o f force around the 
nucleus, which also results in the emission o f an X-ray, which in this interaction is called 
bremsstrahlung, German for "braking radiation" (Figure 2-7). All degrees o f electron braking 
are possible and, thus, the resulting X-rays have a continuous range o f all energies [32]. Each 
incident electron can potentially undergo many such interactions in absorbers. Both X-rays 
and gamma rays are electromagnetic radiation, consisting o f photons with no mass or charge 
that travel at the speed o f light. However, the difference between the two types is in their 
production, because gamma rays are emitted from a nucleus in association with alpha and 
beta particles while X-rays are produced from interactions with orbital electron[24].
O e ’
Figure 2-7: Bermsstrahlung “Braking Radiation” X-Ray production [33]
2.3.2 Isomeric Transition (IT)
An isomeric transition is a radioactive decay process that occurs in an atom where the 
nucleus is in an excited meta state (e.g. following the emission o f an alpha or beta particle), 
for example:
" £ T c  (6 .01  h) -> U T c
2-26
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The extra energy in the nucleus is released by the emission o f a gamma ray, returning the 
nucleus to the ground state. This process is therefore similar to a gamma emission but differs 
in that it involves excited meta-states. The gamma-ray may transfer its energy directly to one 
o f the most tightly bound electrons causing it to be ejected from the atom, a process termed 
the photoelectric effect (above). There is no change in Z or A [34].
2.3.3 Internal Conversion or (IC)
Internal conversion is defined as a nuclear de-excitation if the de-excitation energy is 
transferred almost in full to an orbital electron from the nucleus o f the same atom. The IC 
occurs mostly within the K-shell electrons [35]. The decay energy o f the IC (Qic) and IC 
process is as follows:
Qic = QY — Eb ~ (Ek)ic + (Ek)d
2 -2 7
where
Qy= The energy difference between the two excited nuclear states,
E b= The binding energy o f the electron in the atomic shell,
E ic= The kinetic energy o f the IC electron ejected from the atom,
E d= The kinetic energy o f the daughter nucleus.
For example,
%575Cs -» 13?slBa (2.6m) -* ‘¡¿Ba
2 -2 8
2.3.4 Auger Electrons
The transitions between electronic orbits do not necessarily result in characteristic X-ray. 
Instead, they may result in an Auger, Coster-Kronig, or Super Coster-Kronig effect. Auger 
electrons are produced when a characteristic x-ray is produced by an electron filling an inner 
shell vacancy. The X-ray is reabsorbed by an orbital electron, which is then ejected as an 
electron called an Auger electron [35].
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In all three effects the released radiation is reabsorbed by an electron, and the Auger effect 
occurs between two interior shells. In the case o f super Coster-Kronig electrons, the released 
radiation is absorbed by an electron in the same shell [35, 37]. The kinetic energy o f these 
particles is given by
Figure 2-8: Production o f an Auger electron [36]
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where Ere =  kinetic energy o f ejected electron, Ein =  energy released from the primary 
interaction, and Ebin =  binding energy o f the ejected electron
2.3.5 Linear attenuation and mass absorption coefficients
The linear attenuation coefficient (p) is the most important parameter used for 
characterization o f gamma ray penetration into absorbing media. It depends on the energy o f 
the photon (hu) and atomic number (Z) o f the absorber. This coefficient can be described as 
the total probability that a photon o f a particular energy will undergo some kind o f interaction 
with matter when travelling a unit distance through a particular substance. The value o f p 
( c m 1) generally increases as the Z o f the absorber is increased, because photoelectric 
interactions are stronger in high Z materials, especially for low energy photons.
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The most useful method for determining radiation exposure is the mass absorption coefficient 
([ten /p ) , with units (cm2 g*1), where p is the density in g cm"3. The mass energy absorption 
coefficient is commonly used for radiation dose calculations. However, the attenuation 
coefficient is used for radiation shielding calculation[38], for example:
I = IQ e~^enfp^ x 
2 -3 0
2.3.6 Attenuation of an Optimum Geometry (Parallel Beam) Photon Source
If  Iq is the initial intensity o f a parallel beam o f monoenergetic photons, then the beam 
intensity /  after passing through an absorber o f thickness x will be given by:
I = l0e~^x
2-31
The value o f p increases as Z o f the absorber increases, because photoelectric interactions 
and pair production are increased in high Z materials.
Figure 2-9: Attenuation o f y-ray intensity with absorber thickness [39]
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2.3.7 Attenuation of a Scattered (Poor Geometry) Photon Source
Under a narrow beam o f radiation or (good geometry) conditions only the radiation photons 
that are transmitted through the absorber reach the detector (primary radiation). In actual 
detection measurements there are two types o f radiation reaching the detector: the primary 
photons and the secondary radiation resulting from scattering in the absorber between the 
source and detector, where geometry is poor [40]. Equation 2-31 describes the linear 
attenuation coefficient o f a narrow beam (or good geometry) without taking into account the 
secondary radiation. Equation 2-32 describes the attenuation after taking into account the 
primary and secondary photons:
I  =  Blge
2 -3 2
where B is called the build-up factor, which is a simple correction that depends on the energy 
o f the source, since source energy will affect the transmitted and scattered photons being 
detected, and on the experiment-specific geometry. The build-up factor for a thick absorber 
o f thickness x is equal to the thickness o f the absorber measured in mean free paths (mfp).
2.3.8 H alf Value Layer (HVL)
The half value layer (HVL) is a factor used to describe the penetration ability o f specific 
materials. It is important to find the HVL to estimate the thickness o f a shielding material 
required to reduce the radiation intensity for radiation protection purposes by half [40]. The 
thickness o f the HVL (Figure 2-9) can be calculated from:
ln2
X l -----
2= I*
2 -3 3
where JI is the absorber attenuation coefficient at the energy o f interest [22]. Therefore,
0 .6 9 3  
HVL =  --------
2-34
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2.3.9 Tenth Value Layer (TVL)
The thickness o f a homogeneous absorber that attenuates the narrow beam intensity to one 
tenth o f the original intensity is called the Tenth -V alue Layer (TVL). It is often used in 
radiation protection in room shielding calculations. The TVL calculation is similar to that o f 
the HVL:
ZnlO
X l  =  ---------10 T
2 -3 5
which can be written:
2 .3  
TVL =  —  
T
2 -3 6
2.3.10 Mean Free Path (mfp)
The photon mean free path is defined as the average distance a photon o f energy ho travels 
through an absorber before undergoing an interaction. Material thickness will determine the 
number o f mean free paths, and material with the thickness o f one mean free path will 
attenuate 37% (1/e) o f photons. This concept is closely related to HVL [35].
2.4 Radiation Absorbed Dose
Absorption o f energy from ionising radiation can cause damage to living tissues. This is used 
to advantage in radionuclide therapy, but it is a limitation for diagnostic applications because 
it is a potential hazard for the patient [23]. Therefore, it is essential to calculate the energy 
deposition in body tissues to understand the potential risks. The quantity o f radiation energy 
deposited in a target per unit mass o f absorber material is called the absorbed dose D. This 
quantity applies to any type o f absorber material, including body tissues [23]. The Gray (Gy) 
is the basic unit o f radiation absorbed dose, where,
1 Gy = 1 Joule o f  energy  deposited per kg absorber
2-37
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2.4.1 Dose Equivalent and Radiation Weighting Factor
The concept o f dose equivalent was introduced by the International Commission on 
Radiological Protection (ICRP), the International Commission on Radiological Unit and 
Measurements (ICRU), and the National Council on Radiation Protection and Measurements 
(NCRP). Dose equivalent {Hr) can be defined as a quantity that takes into account the 
Relative Biological damage or Effectiveness (RBE = the ratio o f the absorbed dose o f a 
reference radiation, usually X-ray, to the absorbed dose o f a test radiation required to produce 
the same level o f effect ) caused by radiation interacting with tissue. Tissue damage per Gy o f 
absorbed dose depends on the type and energy o f radiation. The SI unit o f equivalent dose is 
the Sievert (Sv). Table 2-1 illustrates the weighting factor Q for different radiation types in 
the calculation o f equivalent dose [41].
Equivalent does is correlated to absorbed dose D by,
I .D Q
2 - 3 8
For radiation o f interest in nuclear medicine (X-ray, y-ray, electrons and positrons) the 
weighting factor is equal to 1. Therefore, the equivalent dose in Sv is numerically equal to the 
absorbed dose in Gy[42]
Table 2-1 : Weighting factor for different radiation types[23]
Type of radiation Weighting factor, Q
X-ray 1
y-ray 1
Neutrons:
< 10 keV 5
10-100 keV 1 0
>100 keV to 2 MeV 2 0
>2-20 MeV 1 0
>20 MeV 5
Protons >2 MeV 5
a particles 2 0
* Adapted from [23]
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The effective dose, Dejf, introduced in Publication 60 o f the ICRP, is defined by a weighted 
sum o f tissue equivalent doses as:
Def f  — Y Ht tv7 = Y tv7 Y HQ
2 - 3 9
The effective dose equivalent is used to compare radiation doses o f different body parts. The 
effective dose (A #) is found by calculating a weighted average o f the equivalent dose {Hi) 
with the weighting factors (wj) designed to reflect the different radiosensitivities o f the 
tissues, where £  wj = 1. The unit for effective dose is also the Sievert (Sv)[43].
The sum is performed over all organs and tissues o f the human body considered to be 
sensitive to the induction o f stochastic effects. These w j values are chosen to represent the 
contributions o f individual organs and tissues to overall radiation detriment from stochastic 
effects. The SI unit o f effective dose is J k g 1. The unit is the same for equivalent dose and 
effective dose as well as for some operational dose quantities [44]. The organs and tissues for 
which wj values are specified are given in Table 2-2.
2.4.2 Effective Dose Equivalent
Table 2-2: Comparison between the ICRP report P I03 & P60 [20, 45]
Tissue 1993 xvt 2007 wT
Bone-marrow (red), Colon, Lung, Stomach 0.12 0.12
Breast 0.05 0.12
Gonads 0.20 0.08
Salivary glands, Brain 0.01
Bladder, Oesophagus, Liver, Thyroid 0.04
Bone surface, Skin 0.01 0.01
Remaining tissues and organs* 0.05 0.12
* Adrenals, Extra thoracic region, Gallbladder, Heart, Kidneys, Lymphatic nodes, Muscle, Oral mucosa, Pancreas, 
Prostate, Small intestine, Spleen, Thymus, Uterus/Cervix
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Although there has been no significant change in the value o f the tissue weighting factors wt 
for most o f the organs in Table 2-2, the breast weighting factor has increased by more than 
200%. Meanwhile, the gonads wt factor has decreased by 60%. Reasons for the significant 
change in both breast and gonads Wt are as follows. The follow-up studies o f the survivors o f 
the atomic bomb dropped on Japan in 1945 provide the main source o f data on cancer risk for 
the older report. However, the most recent report detailing recommendations o f  w>t is based 
on cancer incidence for both males and females in all age groups. Also, the new report is 
based on estimates o f disease in the first two generations o f the Hiroshima survivors. Finally, 
breast cancer is increasing in most o f the developed and non developed countries [46, 47].
2.4.3 Specific Gamma Ray Constant (T)
Estimates are often required o f the exposure rate at a given distance from a radionuclide 
emitting X-or gamma rays. Such calculations may be necessary for planning radiation 
protection measures around radioactive sources or for radioactive patients. The factor relating 
activity and exposure rate has been given various names: the k factor, the specific gamma ray 
constant, exposure rate constant and gamma ray constant [48]. Conversion to SI units 
required that this factor be replaced by the air kerma rate constant T which is now defined as 
the gamma radiation exposure rate from a point source o f unit activity at unit distance. The 
specific gamma ray constant is calculated from:
r  — HL-
~  A  d t  
2-40
where d is the distance between the source and the point o f interest in meter, A is activity in 
Bq and (dKair /  dt) is the air kerma rate. The Kinetic Energy Released in M atter (kerma) is the 
amount o f energy transferred by radiation (e.g. X rays) to a charged particle in the medium of 
interest per unit mass. The kerma rate is measured in Gy [41].
K <P —  E P
2-41
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where pen!p is the energy absorption coefficient in m2/kg, E is the energy in MeV, and P or y  
is the emission yield o f radiation at a particular energy. <E> is the fluence, which is defined as 
the number o f photons or particles which intersect a unit area, with units o f m '2.
The kerma rate, dK/dt, is obtained from the kerma by substituting the flux ip for the fluence <D 
in Equation 2-41:
dK Hen t-, n—— =  lb  E P
d t p
2 -4 2
where the flux is expressed in m "V l. The quantity ip is derived from the activity, A, o f  a 
radiation source at distance d from the detector or point o f interest, and we assume that the 
source is isotropic:
Aip =
A nd2
2 -4 3
From equations 2-40, 2-41, 2-42, and 2-43
2 -44
However, {peJp) in air for a range o f energies between 0.1 ~ 2.0 MeV is almost constant [49] 
at (pen/p) = 0.0027 m2/kg [21].
From Equation 2-44, the following equation is obtained for T in pSy m2 (h MBq) -1
r =  0.141
2 -4 5
By multiplying the gamma constant for a certain isotope, the dose rate is the product o f the 
calculation yielding the constant 0.141:
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! • 6 x  10-13 ( m W )  x 106 ( ®  x 3 .6  X 10^ (* )  x 0 .0 0 2 7  ( g  x l  14
    ----------------------------------------  =  0 .1 4 1
4 n
where 1.14 is a conversion factor and x is the multiplication symbol [50]
2.4.4 Dose rate Calculations
For hand calculations o f dose rate in pSv/h we can use formulae 2-40 and 2-43, and from 
i^eJp) ~ 0.0027 m2/kg [21] we find:
A'ZEP
Doserate = „ =  r  A d~z7 d2
2 -4 6
where
A— Activity MBq 
E -  Energy M eV
P= Gamma emission yield or probability
d- Distance in meters
The unit o f dose rate is jaSv/h
2.5 Personal monitoring dosimeters
2.5.1 Thermoluminescent dosimeter (TLD)
Current thermoluminescent dosimeters contain specific crystalline materials. Activators are 
added to the crystal to allow energy to stay trapped within the conductance and valance band. 
When these crystals are irradiated, the absorbed energy is stored inside the crystal lattice; the 
bound electrons in the valance band are then excited and produce free electrons. These 
electrons receive energy and move to the conduction band, where they are trapped in energy 
gaps until they obtain sufficient energy to escape.
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The crystal lattice vibrates when the crystal is heated, releasing the trapped electrons in the 
process, which return to their original ground state and release the stored energy as visible 
light. In practice, the emitted light is measured by a photo multiplier tube (PMT) that 
converts the light to electric currents. Dose measurements are calculated by detecting the 
amount o f emitted light. The main three types o f crystals used in TLDs are lithium fluoride 
(LiF), the most commonly used in medical field as it is tissue equivalent; calcium fluoride 
(CaF2) and aluminium oxide (AI2 O3). These thermo-luminescent crystals can be used in the 
form o f powder, rods, chips, and cards. In the UK, most users use TLDs due to UV 
sensitivity, price, fade rate, and dose measurement threshold. LiF has very low UV-sensitivity 
and a fade rate of 5% per year at 20°C [21].
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Figure 2-10: Thermo-luminescence mechanism [24]
The TLDs are based on inorganic crystals, mostly o f lithium fluoride (LiF). When the crystal 
is exposed to the incident radiation an electron is moved from the valence to the conduction 
band where it is then captured in trapping centres. Continued exposure to radiation sources 
causes continuous build up o f trapped electrons. The thermoluminescence induced can be 
measured by placing the dosimeter on a heated support. As a result o f  this process the 
temperature is raised and when the trapped electrons have sufficient thermal energy they are 
re-excited back to the conduction band[23].
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There are many kinds o f electronic personal dosimeters (EPDs). such as MK2 and Mini 6100 
(see Figure 2-11), but the physics behind the EPDs is almost the same. Most EPDs detect 
radiation with multiple silicon PIN diodes (see Figure 2-12) and calculate the doses from the 
signals with four-channel parametric algorithm processing. Two quantities for individual 
radiation monitoring are calculated: the individual dose equivalent penetrating Hp(I0 which 
is defined as the dose equivalent in 1 0  mm depth o f an individual, and Hp(o.o7), which is 
defined as the dose equivalent in 0.07 mm depth o f an individual. Their expression as Hp(io) 
and Hp(o.o7)follows general convention for the personal dose equivalent at d-mm tissue depth, 
Hp(<j). Accumulated doses with 1 pSv resolution are automatically saved to an internal 
memory with flexible time intervals. The saved accumulated dose data can be read as a 
function o f the elapsed time. The EPD has visible and audible alarm functions for a dose or a 
dose level higher than a programmable threshold.
2.5.2 Electronic Personal Dosimeters (EPDs)
Figure 2-11: Different kinds o f electronic personal dosimeters [51-53]
In a heuristic sense, nuclear radiation is the effluence from a nuclear radiation source that 
consists o f energy in the form of particles or waves. The waves are represented as photons or 
quanta o f radiant energy. A radiation detector may be exposed to neutrons (particles), gamma 
rays, X-rays, or other radiation energy. The radiation can vary in energy density, wavelength, 
and duration. When semiconductor material is exposed to a radiation, the energy quanta (Er) 
is absorbed by the elements o f the lattice structure if Er is equal to or greater than the band 
gap energy (Eg) o f the material. A hole-electron pair is generated for each quantum absorbed. 
For Silicon, Eg =1.1 eV, which corresponds to a photon o f 1.1 p wavelength [42, 54].
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Lower energy quanta (or longer wavelengths) are either transmitted through the material or 
interact with free electrons or lattice site atoms, increasing their steady-state energies.
The predominant reactions o f high energy quanta with Silicon are inelastic collisions with 
electrons and elastic collisions with lattice site atoms. In the former case, the electrons absorb 
enough energy (1.1 eV) to travel from the valence band to the conduction band, generating a 
pair o f carriers (transient effect) that will exist for a time referred to as the recombination 
time or minority carrier lifetime [34].
Bulk recombination time is typically several microseconds in Silicon PIN diodes. If Er > Eg, 
secondary ionization effects can occur. If Er is extremely large ( > 15 eV), lattice site 
reaction can eject silicon atoms from their equilibrium sites, producing permanent defects in 
the lattice. The presence o f such damage after exposure to radiation adds to the number of 
carrier recombination sites within the lattice and permanently reduces the minority carrier 
lifetime of the device. Lifetime can be decreased by a factor o f 10, depending on the 
resistivity o f the Silicon and the intensity o f the radiation. The device can still function as a 
radiation detector because lifetime is not a significant parameter when the PIN diode is fully 
reverse biased [22, 55, 56].
Figure 2-12: Schematic o f PIN Silicon diode[57]
2.5.3 Gamma Ray Spectroscopy and Detectors
In general, gamma rays o f a range o f energies and intensities are produced by radioactive 
sources. When these emissions are collected and analysed with a gamma spectroscopy 
system, a gamma energy spectrum can be created. The spectrum is typically used to 
determine the identity and quantity o f gamma emitters present o f the source. By contrast, a 
Geiger Muller (GM) counter determines only the count rate, which is the number o f gamma 
rays hitting the detector in one second [58, 59].
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The most static gamma spectroscopy system consists o f a radiation detector, multichannel 
analyser (MCA), electronics to collect and process the signals produced by the detector, and a 
computer with processing software to generate, display, and store the spectrum. Gamma 
spectroscopy detectors wait for a gamma interaction to occur within the detector volume.
There many interaction mechanisms between the matter and photon, however the most 
important interaction in energy bands lower than 1 MeV are the photoelectric and the 
Compton effect (see section 2.2 in this chapter).
The photoelectric effect is the preferred interaction, as it absorbs all o f  the energy o f the 
incident gamma ray. Full energy absorption is also possible when a series o f interaction 
mechanisms take place within the detector volume [60]. When a gamma ray undergoes a 
Compton interaction a portion o f the energy may escape from the detector volume without 
being absorbed. This will contribute to the background area in the spectrum, because the 
count will appear in a channel that is lower than that corresponding to the full energy o f the 
gamma ray. Not all gamma rays passing through the detector will produce a count in the 
system. The voltage pulse produced by the detector (or by the photomultiplier in a 
scintillation detector) is shaped by a multichannel analyser (MCA). The multichannel 
analyser output is sent to a computer, which stores, displays, and analyses the data.
The number o f channels can be changed in most modern gamma spectroscopy systems, but is 
typically a power o f two; common values are 512, 1024, 2048, 4096, 8192, or 16384 
channels [56]. The choice o f the number o f channels depends on the resolution o f the system 
and the energy range being studied. A variety o f software packages are available from several 
manufacturers e.g. Genie 2000, and generally include spectrum analysis tools such as energy 
calibration, peak area and net area calculation, and resolution calculation. There are many 
types o f radiation detectors on the market, o f which the most common are the sodium iodide 
(NaI:Tl) scintillation counters and high-purity germanium detectors (HpGe) [22].
2.5.3.1 Semiconduactor Detector (Germanium)
In a semiconductor detector, gamma photons are absorbed in a semi-conductive material to 
produce electron hole pairs. Electrons are raised from the valence band to the conduction 
band and an equivalent number o f holes are created in the valence band. The number o f 
electron-hole pairs depends on the energy emitted by the radiation to the semiconductor. 
Under the influence o f an electric field, electrons and holes travel to separate electrodes, 
where they give rise to a pulse that can be measured in an outer circuit.
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The radiation is detected by the free electric charges that are produced along the path o f an 
ionising particle, in combination with a high voltage and electrodes to collect the produced 
electrical charges [56, 61].
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Figure 2-13 : Band structure o f a semiconductor showing a full valence band and an empty
conduction band[62]
Germanium (HpGe) is a semiconductor detector which works at nitrogen temperatures to 
avoid thermal noise or leakage current. The thermal noise comes from the excited electrons in 
the valence band, where the band gap is small (aroundl-2eV in most the semiconductors 
materials and 0.667 eV in HpGe).
Under normal conditions e.g. room temperature, thermal noise is present because there will 
be a small population o f electrons in the conduction band and the material will display a 
limited degree o f conductivity.
The relationship between the temperature in Kelvin (K) and the low leakage current is 
proportional [37]. Although, the HpGe detector has a sufficient resolution it is not settable for 
our measurements as it has to be run in 77K. Consequently, there is no space for MCA or a 
high voltage power supply.
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Scintillator detectors employ the same mechanism as the thermoluminescent dosimeter. 
When gamma rays interact with the crystal, atoms in the crystals emit light. The amount o f 
light produced is proportional to the energy deposited in the crystal by the incident photon.
The detectors are joined to photomultipliers that convert the light into electrons and then 
magnify the electrical signal provided by those electrons (see Figure 2-14). Thallium doped 
sodium iodide (Nal(Tl)) is the most common detector material, and has two principal 
advantages: ( 1 ) it can be produced as large crystals, yielding good efficiency, and (2 ) it 
produces more intense bursts o f light than other spectroscopic Scintillator. Nal(Tl) is also 
convenient to use and is simplified to sodium iodide (Nal:Tl) detectors. Other advantages are 
that the Scintillator detector is able to work at room temperature, and it has high efficiency 
which means the acquisition time can be lower. The Scintillation detector is based on light 
production, and is therefore encased in light-tight box because its internal photomultipliers 
are also sensitive to light [22, 56].
2.5.3.2 Scintalator Detectors
2.5.3.3 Detector Efficiency
There are two measures o f the detector efficiency: intrinsic efficiency and absolute 
efficiency. The efficiency with which a radiation-measuring instrument converts emissions 
from a radiation source into signals in the detector is referred to as detection efficiency. The 
detection efficiency needs to be as high as possible to obtain a maximum counting rate for 
minimum activity. However, detection efficiency is mostly affected by absorption and 
scattering o f the radiation within the medium or the source itself [4][37].
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2.5.3.3.1 Absolute full energy photopeak efficiency
Absolute efficiency values represent the probability that a gamma ray o f a specified energy 
passing through the detector will interact and be detected. The absolute full energy photopealc 
efficiency is defined as:
Cot
e« = I F e !°o%
2 -4 7
where Cot is the number o f counts under the full energy photopeak area, and t is the time of 
acquisition. A is the source strength and PE is the probability o f emission at Energy E. The 
activity or source strength may need to be corrected because o f the decay from the date o f 
preparations by equation 2-7 [56].
2.5.3.3.2 Intrinsic full energy photopeak efficiency
The intrinsic full energy photopeak efficiency depends on the solid angle, detector material, 
the shape and size o f the detector material, the energy o f the incident radiation and the 
distance between detector and the source. In a non-attenuating medium, the relationship 
between the intrinsic and absolute efficiency can be calculated from:
Et
4 nEa
a
2 -4 8
where i l  is the solid angle o f the detector, defined as:
No of particles em ittied  the  space defind /
/N o of particles incident on the  detec to r
a = ------------------------------------------- —-------------------------------------------
ape
2 -4 9
Figure 2-15 demonstrates how the solid angle is obtained. We assumed that a point isotropic 
source is fixed at a distance id) from a detector with circular aperture (radius = r). The solid 
angle in this case is mathematically given as:
H = 2 n ( l  — cosO)
2-50
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Where
cosQ =  ------------
J  (d2 + r2)
2-51
From 2-47, 2-46, and 2-44
Ei =
2nEr
( 1 -
d
J  (d2 + r 2) )
2 -5 2
Figure 2-15 : Calculating intrinsic efficiency using the solid angle [64]
(dJ + r!)^
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Relative efficiency values are often used for germanium detectors, and are compared with the 
efficiency o f the detector at 1332 keV relative to that o f a 3 in x 3 in NaI:(Tl) detector (i.e., 
1.2x10-3 cps/Bq). Relative efficiency values greater than one hundred percent can therefore 
be encountered when working with very large germanium detectors. An efficiency curve can 
be obtained by plotting the efficiency at various energies. This curve can then be used to 
determine the efficiency o f the detector at energies different from those used to obtain the 
curve.
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A certain level o f radioactivity is present everywhere due to the natural background radiation. 
Environmental sources include cosmic radiation and terrestrial radioactive sources, for 
example radon and building material with unstable nuclides such as potassium and uranium. 
The background spectrum should be analysed when no additional source is present. The 
background radiation must then be subtracted from the actual measurement. Although lead is 
a good absorber and can be placed around the measurement to reduce the background, 
photoelectric absorption generates X-rays from the lead at 80 keV. Also, the Compton effect 
has a contribution because o f the scattered photons. In both cases the relationship between the 
difficulty in detecting gamma-ray lines o f interest from a low activity and high background 
are proportional [61].
2.5.3.4 Detector Resolution
Gamma rays can be detected in a spectroscopic system because they produce peaks in the 
spectrum. The width o f these peaks is determined by the resolution o f the detector. Detector 
resolution represents the ability to distinguish two close gamma peaks or lines. The peak 
shape is usually a Gaussian distribution. In most spectra the horizontal position o f the peak is 
determined by the gamma rays’ energy, and the area o f the peak is determined by the 
intensity o f the gamma rays and the efficiency o f the detector [2 1 ].
The most common measure o f detector resolution is the full width at half maximum 
(FWHM). This is the width o f the gamma ray peak at half o f the highest point on the peak 
distribution. Resolution figures are given with reference to particular gamma ray energies. 
Resolutions can be expressed in eV, keV or MeV. For example, a germanium (HpGe) 
detector may have a FWHM of 1.48 keV for the 1332 keV peak o f 60Co, and 0.45 keV for the
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122 keV peak o f Co. Resolution values can be expressed in absolute terms (in keV) and in 
relative terms (percentages) by dividing the FW HM in keV or MeV by the energy o f the 
gamma ray and multiplying by 100. For example, the resolution o f a sodium iodide (NaI:Tl) 
detector at 662 keV is 12.5% or 82.75 keV for 1 3 7Cs.
2.6 Radiation dose limits
Most countries have adopted the dose limits recommended by the International Commission 
on Radiological Protection (ICRP). Table 2-3 illustrates the recommended annual dose limits 
for the body and body parts. There is no recommendation for Hands & Feet dose limit for the 
public as there is no close contact with radioactivity [65].
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Table 2-3 Dose limits recommended by ICRP 60[20]
Application Occupational (mSv/year) Public (mSv/year)
W hole body 20 1
Eye lens 150 15
Skin 500 50
Hands and feet (H&F) 500 -
* Adapted from [20]
The limit on effective dose for occupational exposure is associated with an acceptable long­
term risk compared with most other occupational hazards; the limit for the public is 
considered to be acceptable, because it is comparable to variations in natural background 
radiation [20]. In the UK, the 1999 Ionising Radiation Regulation adapted the recommended 
limits o f the ICRP 60 and gave more specific definitions o f radiation dose levels. For 
example, if radiation dose levels exceed one third o f the annual recommended equivalent 
dose, the staff member working in such conditions will be treated as a classified person 
whose dose records will be kept on file for 50 years and who will be required to have annual 
medical check-ups.
Radiation dose limits must not be exceeded at any time. However they should not be 
considered as thresholds below which exposure to radiation is o f no concern. Any reasonable 
technique for reducing radiation may have potential benefits in the long term. Regulatory 
bodies recommend keeping radiation doses "as low as reasonably achievable" (ALARA)[6 6 ]. 
ALARA principles can be applied to the handling o f radiation sources and patients, to storage 
and shielding techniques, and to the design o f departments [23]. In the UK the definition o f 
ALARA is ALARP, which means As Low as Reasonably Practicable, which takes into 
account a balance between the risks and benefits and considers that the workers exposure 
should be under the dose limits. The legislation in the UK is set in the Ionising Radiation 
Regulation (IRR99) that adopted the (ICRP60) recommendations for dose limits and came 
into force in 2000. For more specification o f the annual occupational exposure limits, the 
(IRR99) regulations state that if the personal annual equivalent dose exceeds the one third o f 
the recommended one which about 6 mSv, then the staff member will be treated as a classified 
person (Table 2-4). The IRR99 regulations for a pregnant employer recommend that the 
equivalent dose should not exceed 1 mSv during the pregnancy[20, 67]. Table 2-3 gives the 
annual dose limits according to the latest ICRP recommendations released in 2007.
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The ICRP adopted the ICRP60 recommendations for dose limits, which includes the public 
and occupational dose limits. The natural sources o f radiation and exposure received from 
medical treatment are not included in the dose limits[6 8 ].
Table 2-4: Classification limits[6 8 ]
Dose limit (mSv/y) Public (mSv/y) Classified Worker(mSv/y)
Effective Dose 20 1 6
Eye Dose 150 15 45
Skin Dose 500 50 150
According to the IRR99 regulation part V “Classification and monitoring o f persons” 
Regs20, all employees aged 18 or over who are likely to receive a per annum effective dose 
greater than 6  mSv or an equivalent dose greater than 45 mSv (eye), 150 mSv (skin) or 150 
mSv (hands, forearms, feet and ankles) must be designated as classified persons and informed 
o f such. Where this is the case, the employer should provided written arrangements to ensure 
that working practices are planned and the radiation doses to individuals are below those 
levels that would require them to be designated as classified persons. The fact that an 
employee works within a Controlled Area is not in itself reason enough for their 
classification, particularly where the work is intermittent or takes place in one small part o f 
the area. However, by the IRR99 regulations any classified person cannot deal with 
radioactive sources unless a certification issued by an appointed doctor confirmed that s/he is 
fit in a health for a such work or is no longer employed by the same employer in a capacity 
which is likely to result in significant radiation exposure during the remainder o f the calendar 
year. Exposure should be regarded as significant if the staff member is likely to receive an 
effective dose o f more than lmSv in that calendar year [69]. There are additional 
requirements, for example when there is a classified person at work, the employer must 
request the Approved Dosimetry Service (ADS)[70].
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By the regulations the ADS must carry out all o f  the following:
• Keep the dose records for 50 years from when they were made
• Provide the employer with dose summaries at suitable intervals
• Provide individual dose records at the request o f  the employer
• Provide a 'termination record' to the HSE for any classified person leaving his current 
employer, and provide a copy to that employer
• Provide the Health and Safety Executive HSE with annual dose summaries within 
three months o f the end o f the calendar year.
•  The ADS is required to send a copy o f all dose records received from the employer to 
HSE and the employer must provide a copy to the individual concerned.
• Provide any out-side worker with a valid 'radiation passbook'. The passbook shall 
contain dose record details, which shall be kept up-to-date during his/her employment 
with that employer, and is not transferable to any other worker.
2.6.1 Occupational exposure in PET/CT
When monitoring occupational exposures to external radiation, individual dosimeters 
measure Hp (10) at a depth d = 10 mm, which is the personal dose equivalent. For the skin, 
hands, and feet, the personal dose equivalent Hp (0.07) at a depth d = 0.07 mm is used. This 
calculated value is taken as an estimate o f the effective dose under the assumption o f uniform 
whole body exposure. For internal exposure, committed effective doses are generally 
determined from an assessment o f the intakes o f radionuclides from bioassay measurements 
or other quantities (e.g., activity retained in the body or from daily excreta). The radiation 
dose is determined from the intake using recommended dose coefficients [71]. In the past few 
years, there has been continuous growth in PET/CT implementation in the UK, a trend that is 
expected to continue (see Chapter 1), thus raising the issue o f occupational exposure dose 
[8 ].Several studies have been published assessing the radiation dose received by technologists 
who work in multi-imaging modalities departments or dedicated PET and PET/CT 
departments. According to the results o f most published work, in general the whole body 
doses received by technologists who work in PET and PET/CT units are greater than those 
received by the technologists who work in general nuclear medicine departments. A number 
o f studies that highlight these results, o f which a selection are summarised below in 
Table 2-5.
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A study by Cheisa et al (1997) o f the radiation dose to technicians per nuclear medicine 
procedure compared technetium "m T c, gallium 6 7Ga, and iodine 13lI radiotracers with 
fluorine-18 fluorodeoxyglucose FDG[72]. The average whole body dose per PET scan was 
5.90± 1.2 pSv, which was subdivided into many phases. These were 0.11 ± 0.04 pSv for 
daily quality assurance, 2.9 ± 3 .0  pSv for two transmission scans, 0.3 ± 0 .1  pSv for syringe 
preparation, 2.8 ± 1 .8  pSv for injection and guiding the patient to waiting room, 1.7 ± 1.5 
pSv for whole body emission scan, 7.7 ± 5 .2  pSv for two emission scans, and 0.8 ± 0.2 pSv 
for patient departure. In this study, an electron pocket dosimeter was used.
In a study published by Cronin et al. (1999), each staff member working in a PET centre was 
issued with a dose rate meter (EPD-Aloka), and the daily dose received was recorded. On 
average, each technologist administered 831 MBq or two patients per day. The mean whole 
body dose per MBq injected was 0.02 pSv/MBq. The average time o f close contact (<2 m) 
with a radioactive source per day was 32 minutes. The average effective dose per minute o f 
close contact was 0.5 pSv/min, that resulted in a mean daily effective dose o f 14.4 pSv. In 
this study, no technologist received greater than 60 pSv in any one day, and doses received 
were less than 6  mSv per year [73].
Linemann et al. (2000) aimed to identify steps with the highest radiation exposure for 
medical personnel and to evaluate the effectiveness o f  radiation protection devices. Electronic 
personal dosimeters and thermo-luminescent dosimeters were used. The mean personal dose 
resulting from syringe preparation was 1 ¡iSv/syringe from injection, 3 pSv/patient and from 
positioning and handling o f the patient 6  pSv/study [74].
A study o f whole body radiation doses to PET technologists performing 100 I8F-FDG 
imaging procedures was carried out by Biran et al. (2004) using two types o f TLD badges, 
one finger-ring TLD and one EPD. 18F-FDG was handled either with unshielded or with 
viewing window tungsten shielded syringes. The resulting doses using unshielded syringes 
were 13.8 ± 0.8 p.Sv/370 MBq and 14.3 ± 0.4 pSv/370 MBq, measured with TLD 100 and 
TLD 700H/600H, respectively. For the same series o f measurements, the doses obtained 
using shielded syringes were 10.7 p.Sv/370 MBq and 7.2 p.Sv/370 M Bq with TLD 
700FI/600H and EPD, respectively. The TLD ring showed that the dose to the right hand 
from shielded syringes was 69.3 pSv/370 MBq. All o f these values are within the ICRP 
recommended dose limits [75]. However, it should be noted that the TLD measurement was
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In 2005 Guillet et al. published a study assessing the technologist whole body dose in a PET 
department during five 18F-FDG steps starting at syringe filling and ending at the patient 
departure. The final results show that the mean ± SD o f the total effective doses received by 
the technologists per patient, through the whole procedure of five steps with injected activity 
(345 ± 84 MBq) measured using EPDs and TLDs were (3.24 ± 2.1 pSv) and (3.01 ± 1.4 pSv), 
respectively. The daily whole body dose received by the technologist with injected activity 
(294 ± 78 MBq) measured using TLD was (2.98 ± 1 .8  pSv). The doses received by the 
fingers o f the left and right hands using two different preparation techniques o f the FDG 
syringe with (345 ± 93 MBq) injected activity were (204.9 ± 24 pSv) and (198.4 ± 23 pSv) 
with multidose vials, respectively. With monodose vials o f (302 ± 43 MBq) injected activity 
the finger doses were (127.3 ± 76 pSv) and (55.9 ± 47 pSv) for the left and right hands, 
respectively [76].
Another study by Roberts et al. (2005) showed that the total average whole body dose o f a 
PET staff member is more than that o f a staff member working in general nuclear medicine, 
who experience mean doses o f 771 ±123 pSv and 524 ± 123 pSv per quarter, respectively. 
The estimated dose per PET procedure was 4.1 pSv (11 nSv/MBq). Using a primary shielded 
syringe reduced the. average dose by 44%. A similar study was carried out at Austin Health in 
Australia to measure the occupational exposure in PET over 18 days. Two full-time staff 
members scanned 134 patients using 18 FDG. The mean administered activity was 418 MBq, 
and the total time spent at less than 2 m from patient was measured. It was found that the 
injection phase could take between 2 and 5 minutes. However, the mean daily dose was 
around 32 pSv, and the dose obtained while in close contact was 1 pSv per minute [77].
In 2006, Seierstad et al. published a study that investigated the dose received by the 
technologist working in a dedicated PET/CT centre. The average dose per day was 36 pSv 
with an average administered activity o f 1450 M Bq per day. The average dose rates the 
technologist received were 105 pSv/h in the hot lab, 39 (iSv/h in the injection room and 
33|iiSv in the imaging room. The average dose rate was 9 pSv/h per 4 hours work. The study 
showed the direct handling o f 18F contributes to 50% o f the total dose received, while the 
patient interaction contributes to 41% o f the dose [78].
significantly higher than the EPD measurement.
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In 2006, Pant and Senthamizhchelvan published a study which estimated the average dose 
received by workers in a PET/CT facility. The measurement was recorded with an electronic 
pocket dosimeter during two phases: injecting and scanning the patient. The average doses 
received at the chest and wrist levels in the injection phase with an injected activity o f 
370MBq were 3.34 pSv and 10.24 pSv, respectively, while average doses received at the 
scanning phase were 0.62 pSv and 1.29 pSv, respectively. The average doses received while 
injecting the patient with 370 MBq were (0.26 ± 0.4 mSv/h) and (4.2 ± 0.7 mSv/h) at the 
chest and wrist levels respectively. The mean doses per MBq of 18F-FDG injected at the chest 
and wrist level were 8.76 nSv/MBq and 27.68 nSv/MBq respectively. The exposure rates 
around the scanning room were between 3.6 pSv/h and 5.3 pSv/h and in the control room 
between 0.1 pSv/h and 0.5 p.Sv/h[79].
In a study published by Alsafi et al. (2007), each staff member working in a mobile PET/CT 
unit was issued with a dose rate meter (EPD-Mk2), and the daily dose received was recorded. 
On average, each patient was injected with 400 MBq per scan. The mean whole body dose 
per staff member per patient was 5.7± 1.9 pSv. On average, 8  patients were scanned each 
day. In the mobile unit, accompanying the patient to the toilet prior to the scan also incurred a 
high dose 1.1±1.0 pSv per patient, which was found to be around five times greater than in 
the static unit. Nevertheless, 12% o f the total dose was not attributable to any o f the defined 
tasks in the workflow and is attributed to unexpected occupational exposure such as going to 
the hot lab for injection preparation while an injected patient was going to the scanning room, 
and to the limitations o f the EPD measurements. In this study, no technologist received 
greater than 60 pSv in any one day, and doses received were less than 6  mSv per 225 day 
working year [80].
In February 2010, a study was published by Svggorn, where the four staff members wore 
electronic dosimeters (EPD MK2) at the belt level. The reading was recorded after each task 
for the four technologists at the PET/CT unit, serving four patients each. The results showed 
that the average staff dose per patient was between 4 and 5 pSv. The largest contribution to 
the total dose was from the injection (1~2 pSv). However, escorting the patient to the 
scanning room and assisting the patient on the couch, in total was between 2 and 4 pSv [81]. 
In this study all the staff members were within the recommended annual dose limits.
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Table 2-5: Recent studies measuring dose rates experienced by PET staff
Svegborn[81J 2010 4 up to 5 MK2 6>
Alsafi[80] 20 0 7 5 .7±  1.9 M K 2 6>
Pant[79] 2006 3.26± 0.08 18.5 ±3.9 EPD 6>
Roberts[82] 2005 4.1 EPD 6>
Linemann[74] 2000 6.0 EPD 6>
Cronin [73] 1999 7.2 A lok a 6>
Cheisa[72] 1997 7.7 ± 5.2 .. . . EPD 6>
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3 Chapter 3: Staff-dose M easurements M ethodology and Equipment
3.1 Introduction
This chapter consists o f three major sections, which are the PET/CT procedures, the 
equipment used, and the measurements carried out. The majority o f the published work 
reported in Chapter 2 was carried out in hospitals with a PET/CT unit or where there were 
PET/CT dedicated technologists. This staffs have access to the unit without any further 
requirements and there are no time limits to usage. However, in my case as a student and 
from a different organisation there are many requirements which must be met. The easiest 
and fastest condition which had to be fulfilled was the medical check-up, since the rest o f the 
documentation and administration process took around 120 days. This delay focussed my 
attention as well as motivating me to design pilot measurements as a first step. A visit to three 
PET/CT units was arranged, and pilot measurements had to be carried out over two days as a 
maximum time concession in both the static and mobile PET/CT units. During the visit my 
main concern was to find out how the technologists operate the units. Observing the 
procedures in a full load working day was an excellent opportunity that helped me to design 
the pilot measurements. The primary study was based on what had been seen during the visit, 
as well as from the several many discussions I held with the unit staff. I therefore gained a 
clearer picture as to how the staff members served the patients and how they ran the 
procedures. The conclusion o f this step was the design o f an efficient measurement strategy 
to cover five main areas as follows:
The unit size 
The unit type
The number o f staff members on board 
The average daily work load
Staff knowledge about the principles and practise o f radiation protection
From the above five areas, five protocols were developed: two for mobile and three for static 
PET/CT units. There were no significant differences between the five protocols, but those for 
the static units were focussed on the work load, unit design and location, patient release as 
well as the number o f technologists in the unit. Mobile unit protocols also considered the hot 
WC location and the pathway to it.
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The protocol contents also note patient sex, weight, injected activity, and date and time o f 
each task. For the privacy o f the patients, the staff members, and site name numbers, initials, 
and abbreviations are used throughout.
3.2 PET/CT procedures in mobile and static units
The PET and PET/CT workload has increased with the rapid growth o f demand for 18F-FDG 
in PET applications and high patient throughput. Because o f the high specific gamma ray 
constant o f the strongly penetrating photons o f 511 keV energy, there has been a resulting 
debate regarding the higher radiation exposure to PET/CT technologists as raised in Chapter 
one [79]. The PET and PET/CT procedures vary from one department to another but the main 
concepts are the same. The PET/CT procedure starts with the registration o f the patient at the 
reception.
Usually, the technologist will collect the patient from the reception area and accompany them 
to the waiting area, where they are weighed. The patient is asked to go into the changing 
room to change their clothes and remove any metal items. Then he/she is taken into the 
injection room where a medical history is taken, and to confirm that the patient is in a fasting 
state. Also the scan procedure is explained to the patient, and questions may be asked by the 
patient. A blood sample is taken to check that blood sugar is within acceptable levels 
(<200mg/dl). I f  the sugar level is lower than the level by 15-20% then the scan will be 
rescheduled [83].
The technologist then prepares the patient’s FDG dose in the hot lab, and returns with it to the 
preparation room to inject the patient via an intravenous cannula or butterfly. The tracer 
uptake period is typically 60 minutes but in some PET/CT facilities is as little as 45 minutes. 
During the uptake time, it is strongly recommended that the patient is left for relaxation 
quietly in the injection room. The technologist returns to the hot lab to measure and record 
the residual activity from the injection. Just before the end o f the uptake time, the patient is 
directed to go to the “hot” toilet to empty their bladder. Once the patient is ready for the scan 
they are accompanied into the scanner room, or alternatively may be asked to wait in the 
waiting area until the room is ready. In the scanner room, the technologist sets the patient up 
on the scanner bed. The entire scanning unit and scanner bed can be controlled remotely from 
the acquisition computer in the console room or directly from controls on either side o f the 
scanner.
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The technologist then starts the scanning sequence from the console room. The scan time 
depends on the type o f the examination and the patient in the scanner room will be observed 
from the console room throughout the scan. The final stage is to remove the patient from the 
scanner and ask them to change in the change room ready for departure. A colour-coded 
PET/CT workflow diagram is shown in Figure 3-1.
Figure 3-1 :Colour-coded PET/CT workflow diagram [84]
The red in Figure 3-1 illustrates the phases during which the technologist is directly exposed 
to a source o f radiation (e.g. patient or tracer). The PET/CT scanning procedure described in 
Section 3.2 was divided into several defined phases in order to allow an average value for the 
radiation dose in each phase to be measured (see Figure 3-2). This helps to identify whether 
high exposures result from a particular phase, so that a recommendation can be made to 
reduce the dose. Patient dose rate was also measured for some phases. The measurements had 
to be designed so as not to interfere with the existing workflow in the PET/CT departments.
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MethodologyMethodology
Figure 3-2 : PET/CT phases[80]
3.2.1 Operational definitions o f phases
Discussions took place with the units’ staff members about the PET/CT workflow to 
determine the operational definitions as well as the start and end points for each phase (see 
Table 3-1). Three separate locations were also defined: the hot lab, the injection room, and 
the scan room. After reviewing the workflow, it was found that unexpected exposures may 
occur in the area between rooms during the separate phases; as a result, it was decided to start 
and end some o f the phases in the console room. The background levels were measured and 
subtracted from the dose o f each phase.
Table 3-1 : Operational definitions o f tasks [85]
Tasks Operational Definition
Unpacking Transferring the FDG vial from shielded box to dispensing unit in the hot lab
Dispensing Drawing the estimated volume for one patient (400 ± 10% MBq of FDG) in a syringe 
and measuring the activity in the dose calibrator
Injection Collecting patient dose from the hot lab, moving to the injection room, and making the 
injection (may include putting on a butterfly)*
Residual Measuring the amount of FDG left in the syringe and completing the necessary 
paperwork
W.C Informing the patient to go to the W.C. (may include escorting them)*
Scanning Bringing the patient into the scanning room and positioning them on the bed
Departure (A) Helping the patient get off the bed and sending them to the changing room
Departure (B) Waiting for final discharge of patient1
~r~ -----------   ;------ -------------- ------- -- -------------
Dose rate and duration was recorded 1 metre from the injected patient.
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Phase 1 started from the time o f entrance to the hot lab for unpacking or dispensing and 
ended on exiting the hot lab. Phase 2 started on exiting the hot lab and ended on exiting the 
injection room. Phase 3 started on exiting the injection room and ended on exiting the hot lab, 
after measuring the residuals. Phase 4 started on entering the console room and ended on 
returning to the console room. Phase 5 started in the console room and ended on returning to 
it. Phase 6 , part A started in the control room and ended on returning to the console room; 
part B started in the console room and ended on returning to the console room (Table 3-2).
Table 3-2 Operational definitions o f workflow phases [85]
N Phase Main Task Start End
1 Hot Lab (1) Unpacking, dispensing Entering the Hot Lab Exiting the Lab
2 Injection Room Injection Exiting the Lab Exiting the Room
3 Hot Lab (2) Residual measurement Exiting the Room Exiting the Lab
4 W.C. Taking the patient to W.C. Exiting Console Room Console Room
5 Scan Room Set up the patient on the 
bed
Console Room Console Room
6 Departure Guiding the patient Console Room Console Room
3.2.2 Description of phases and staff comments
The first phase o f the PET/CT workflow was the hot lab (1) where radioisotopes are 
unpacked and dispensed. Unpacking involves transferring the vial containing a number o f 
patient doses from the shielded transport box to the dispensing unit in the hot lab. This 
usually happens twice a day at any PET/CT unit if the number o f patients is more than 4. The 
task is generally carried out at the same time as dispensing a patient dose, and is therefore 
difficult to distinguish from the dispensing phase. Also, unpacking will only contribute a very 
small dose to the overall dose obtained in the hot lab phases. For these reasons, unpacking 
and dispensing were taken as a single phase.
Dispensing involves filling a well-shielded syringe with the FDG. This task is complex as the 
technologist has to decide on the amount o f FDG to draw up for an activity o f 350-450 MBq, 
which may require re-dispensing several times until the required activity is reached.
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The injection phase involves injecting the patient with FDG. At this stage there are several 
factors that increase the complexity o f the phase and that can affect the exposure rate and 
time. The most common cases recorded by the technologists are patients with poor veins or 
high anxiety, or patients who require additional information. Also, if  the technologist is using 
a cannula to gain venous access, they are able to leave the injection in the hot lab, until the 
patient is ready for injection. If  using a butterfly needle, the dose needs to be readily available 
in the preparation room. This may have an impact on the exposure rate during the injection 
phase. The scanning phase also has some potential difficulties that were noted by the staff 
such as patient claustrophobia, difficulty o f removing some accessories that required help 
from the staff, and disabled or older patients who need additional assistance in positioning. In 
addition, any patient movement during the scan may require the staff to reposition the patient.
During the W.C phase any wheelchair or disabled patients will require additional assistance. 
In the W.C phase on the mobile units, patients may need additional assistance when using the 
stairs or the lift, which will require the staff to spend longer in closer contact with patients 
while they ensure their safety. Moreover, some injected patients avoid being far from the staff 
as much as they can. Furthermore, patient communication problems may lead to closer 
contact to improve hearing, especially while walking through crowded or open areas.
Finally, unexpected exposure may occur due to many reasons. For example, an injected- 
patient who is making telephone calls in the waiting areas or any exposure dose due to 
unnecessary close contact with an injected patient outside o f the defined workflow phases.
These preceding comments will assist the reader in understanding the source o f variability in 
the results as well as allowing the author to more clearly present the data in this chapter and 
give recommendations in the last chapter.
3.3 Equipment
Choosing equipment for measuring staff doses in PET/CT environments was challenging 
because o f the criteria o f the unit as well as a lack o f space. All the measurements were 
planned to be performed in the PET/CT unit during working hours in an environment with 
many patients and where every technologist is busy with a patient. It was vital to employ 
devices that were small in size as well as portable. These criteria allowed the project to be 
performed in private and non private sectors. An additional restriction was to avoid 
interfering with work flow or patients’ privacy.
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Five colour coded EPDs MK2 model Figure 3-3 were used for the dose measurements. The 
EPD was manufactured by the Thermo Electron Corporation in the UK. It is a digital monitor 
based on diode detectors with radiological performance between 15 keV and 10 MeV. The 
dose response o f the EPD was calibrated for photons with energies between 20 keV and 6  
MeV and for electrons with energies from 0.250-1.5 MeV. The angle-dependent fluctuation 
o f the response is ± 30% for both photons and electrons. The sensitivity o f the EPD to 
neutrons is negligibly small (< 2%). It has a display unit (LCD) with a minimum 1 pSv 
resolution o f accumulated doses. Each EPD has a detection window (beta window), control 
button, sounder and infrared transmitter on the front face. On the top o f the EPD an LCD 
display is located which shows the reading in pSv. The EPD back face consists o f a clip to 
affix the EPD. Finally the right side o f the EPD has a battery-saving facility (Figure 3-4).
3.3.1 Electronic personal dosimeters (EPDs)
Figure 3-3 : Electronic Personal Dosimeters (EPDs-MK2)
The main reason o f using the EPDs instead o f the TLDs for the dose measurements, even 
though TLDs are extensively used, is that TLDs require several months to analyse the 
measurements as well as access to a TLD reader facility. Moreover, TLD results provide 
accumulated absorbed dose for a period o f time o f minimum three months. By contrast, the 
EPD has a LCD which allows the user to obtain the absorbed dose for each task individually.
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The MK2 model has been selected for measurements for many reasons: it is portable (30 x 63 
x 8 6  mm) and can be placed in any position (see Figure 3-5) without any difficulty. It has a 
weight o f 170 g including an AA battery.
When operated by a lithium chloride battery inside the magnesium-alloy case, the device can 
continuously work for 12 months without recharging. The EPD comes with a data 
connectivity module which can instantly transfer the recorded data to a computer with the 
EPD sync software called Easy EPDs. The data transfer procedure occurs via infrared 
communication. The EPD is commercially produced in the UK and has been used at most 
facilities. This makes the use o f the device even more appropriate.
Figure 3-4: EPDs MK2 model photo and description[53]
Although the EPD operates over a wide energy range and is sensitive to all beta and gamma 
radiation it has limitations which need important consideration. Firstly, when using the device 
it should be worn with the record button facing outwards to avoid errors in measurement; 
secondly, the display unit does not show fractions.
Figure 3-5: EPD locations [84]
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EPDs are readily available as they are manufactured in the UK, making them the most 
appropriate dosimeter to use for these studies. Also, Thermo UK was very supportive and 
flexible in terms o f after sales support. The EPDs allow the dose reading to be recorded 
immediately because it can be connected to a personal computer. The infrared reader is 
suitable for the office environment and mobile applications, and facilitates access to all 
dosimeter functions. The software allows reading o f the measurement fractions, the 
accumulated finger and whole body doses, dose rates and durations. The technologists in 
most locations where the measurements have been obtained are usually wearing an EPD and 
are familiar with using EPDs as dose monitors. However, EPDs can be fixed at different 
positions depending on the measurement protocol as show in Figure 3-5.
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Figure 3-6: Easy EPD Software dose rate screen shot
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Figure 3-7: Easy EPD Software control page screen shot
A quick test was done to check the response time of the EPD as well as to provide a 
comparison between three EPD positions and to find the linearity o f response. A marked 
board was used in the test along with a l37Cs (9.6 MBq) point source and FDG with 23.9 
MBq activity.
(A) (B)
Figure 3-8:( A) Marked board & (B) Response time and linearity test for the EPD
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Figure 3-9: comparison between three EPDs in different positions to check the linearity
The 137Cs source was fixed at 25 cm distance from the EPD for 19 minutes to find the 
differences between the three positions. Figure 3-9 shows the accumulated doses and reveals 
that the differences between left and right positions are not large, which increases confidence 
in the measurements.
oO
Time in min
Figure 3-10: Response time o f the EPD.
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The 18F source (23.9 MBq activity) was fixed at 25 cm distance from the EPD for 112 
minutes. It can be seen from Figure 3-10 that the EPD dose rate reading is affected by the 
decay time. For a source with low dose rate (< lOpSv/h) the EPD LCD will show a zero 
reading, and it may take 1 2 0  to 180 s or more to start counting as it does not show fractions. 
Employing the EPD software avoids these problems.
3.3.2 EPD limitations: Readings and Errors
As mentioned above, the EPD is limited in terms o f the display unit (LCD). It does not 
display fractions, which means that if  the accumulated dose is less than 1 pSv then zero will 
be displayed. Also, when comparing with calculations, it was found that the difference is 
within the accepted range (less than 15%). However, with low source activity (dose rate less 
than 10 pSv/h) the difference was doubled. This was to be expected with a weak source. All 
the measurements here were carried out with a I37Cs point source (60 MBq) at 0.5 and 1 m 
distances. Equation 2-46 was used in both calculations.
3.3.3 Radioactive Isotopes used in PET
Several positron emitters are used in PET. Some are isotopes o f major elements in the human 
body that are “non artificial” such as n C, i3N, and 1 50 . The most commonly used worldwide 
in PET/CT scanners is t8F in the form o f de-fluorodeoxyglucose (FDG). 18F-FDG is similar 
to glucose, but the oxygen at the C-2 position is replaced by 18-fluorine. FDG behaves 
similarly to glucose in many situations, and relaxation after injection is strongly 
recommended in order to reduce muscle absorption. FDG also has a long half life in 
comparison with 1 50 , 13N, and UC as well as a lower Specific Gamma Ray Constant by 
around 3%. The long half-life avoids the requirement for an on-site cyclotron. The 
opportunity for using PET/CT scans with FDG is increasing as in many recent studies the 
PET/CT scan with FDG has been considered as a good replacement for " mTc now that many 
reactors have stopped the production o f 99M o[8 6 ]. However, there are also new isotopes, 
such as zirconium (89Zr) which is a promising positron emitter (see Table 3-3).
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Table 3-3: Radionuclides used in PET
" c 20.4 min
(3+ (99.76) 
EC (0.24)
199.5 0.385 & 0.511 0.144
'3N 1 0 . 0  min
EC(0.2)
P+(99.8)
199.6 0.492 & 0.511 0.144
I5o 2.04 min
EC (0.1) 
P+(99.9)
199.8 0.735 & 0.511 0.144
I8p
1 1 0  min
EC (3.27) 
P+(96.73)
193.46 0.250 & 0.511 0.141
89Zr 4700 min p+( 1 0 0 ) 99.04 , 45.5 0.395 & 0.909, 0.511 0.300
* p+= Positron decay ; EC= electron capture 
T= Specific Gamma Ray Constant in pSv MBq 'at 1 meter calculated by Equation 2-45
3.3.4 Portable Lanthanum Bromide (LaBr3 :Ce) Detector and Dosimeter
3.3.4.1 Introduction
Working in PET/CT is challenging because o f the limited space, particularly in a mobile unit. 
This has led to an intense search for a device that is small but with the ability to obtain a 
gamma spectrum. There are several further reasons for this search. The first is that the EPD 
records any incident radiation, whatever its source e.g. a source without any shielding, natural 
background, or from the occupational background (the background due to the presence o f a 
radioactive source in the place o f work that goes to zero or the natural background when the 
cause is removed). Another reason is that some injection rooms have two or more (up to six) 
injection beds, a feature that has become significantly more widespread across both mobile 
and static PET/CT facilities in the UK. O f the five static units and three mobile units visited 
during the project, most o f the units had only curtains separating the beds, and only one had a 
gypsum/lead barrier between beds; consequently two PET/CT staff received doses exceeding 
the classification levels and had to be transferred to the nuclear medicine department.
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In light o f these problems, it was essential to obtain the spectra o f the FDG in the unit in such 
a way as to make the source o f radiation as clear as possible, and this required that the 
detector be portable.
3.3.4.2 Portable Lanthanum Bromide ( LaBr3 :Ce) Detector Inspector 1000
As was mentioned above, a portable detector with good efficiency as well as sufficient 
energy resolution was required. An internet search for portable detectors which can obtain the 
necessary spectra yielded three type o f detectors: HpGe, Nal(Tl), and LaBr3:Ce (the first two 
from Ortec and last from Canberra). Both companies were contacted and Canberra agreed to 
provide the detector on a loan basis. Canberra supplied manuals, the detector with the 
portable MCA and LaBr3:Ce probe, and included Genie 2000 software together with power 
and computer cables. The weight o f the probe and Inspector 1000 was 680 g and about 1750 
g, respectively. The whole suite could be easily fitted into a 14 inch laptop case. According to 
the manual the range of energy sensitivity is from 30 lceV to 3 MeV and the crustal size is 1.5 
by 1.5 inches. The Scintillator is [LaBr3 :(Ce)] and includes a nuclide identification feature 
based on ANSI data. The system works with excellent stability in a wide range o f 
temperatures (-20 ~ 50 °C) as well as in humidity up to 80% and can also measure the dose 
rate in pSv/h up to 20,000 pSv/h. Inspector 1000 has an alarm which starts working if  the 
dose rate exceeds 10 (iSv/h, however the alarm can be set to silent mode and in this case the 
background light o f the screen informs the user that the dose rate is going high by flashing. 
Although it has a portable battery, the battery life is 9 hours. The system has high resolution 
colour display unit and can be connected to the computer via dedicated software (Inspector 
Maintenance). Calibration files can be saved and recalled at any time (see Figure 3-11).
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Figure 3-11 : Inspector 1000 and the LaBr3 :Ce probe [87]
3.3.4.3 LaBr3:Ce Resolution
The system was calibrated by two sources: 137Cs and 60Co. The calibration file was then 
saved and recalled the next day at different locations in the same lab to ensure that the 
Inspector was working correctly. For this step a 22Na source was used. There was good 
agreement between the manual data and the measurements in terms o f efficiency and 
resolution. Also, a comparison between the NalTl normal detector and the Inspector was 
carried out to ensure that the Inspector system had a similarly high efficiency.
Table 3-4: Sources used in calibration o f the LaBr3:Ce detector & dose rate comparison
N Registration number source Location ActivityMBq
Dose rate pSv/h 
(at lm)
Dose rate pSv/h 
(at 10cm)
Dr' Dr* Dr' Dr*
1 S029.RG (30.04y) ,37Cs 04BC34 1.19 0.10 0.12 9.56 11.10
2 S082.RG (5.27y) 60Co 04BC34 1.35 0.48 0.57 48.30 54.50
3 S305.PH (2.61y)
22Na 04BC34 0.146 0.05 0.06 4.61 05.53
*= Average dose rate measurements by Inspector 1000; i = Dose rate by hand calculation of equation 2-46
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Measurements show that the Inspector 1000 has a 3.1% resolution at 0.662 MeV. The 
measured resolution is in good agreement with published values [8 8 , 89]. With a FWHM 
resolution o f approximately 3% at 662 (keV), the lanthanum bromide (LaBr3:Ce) scintillator 
offers a considerable enhancement over the sodium iodide scintillator, whose resolution is 
approximately 7% with similar sizes [90]. Figure 3-13 shows the efficiency o f the detector.
Energy (keV)
Figure 3-12: Detector Resolution vs energy
Figure 3-13: LaBr3:Ce Efficiency calibration curve as obtained by the Inspector system.
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LaBm Ce was equivalent to or better than Nal(Tl) in all performance categories. Most 
importantly, it had 60% higher light output and better energy resolution. The enhanced 
energy resolution could also allow the Compton scattering background to be reduced from 
35% to as low as 25%. The LaBr3 :Ce calculated intrinsic efficiency was 37% at 40 cm from 
l37Cs (0.662 MeV) at room temperature. Figure 3-13 and Figure 3-15 show the efficiency o f 
the detector. Both equations 2-47 and 2-52 were used in the calculation. From Table 3-4 it 
can be clearly seen that there is a good agreement between hand calculation and 
measurements. Figure 3-14 shows the detection o f 137 Cs (0.662 MeV) by the LaBra Ce 
detector (Inspector 1000). The photo-peak is very clear, as well as the Compton edge and the 
backscatter peak too. The area before the backscatter peak (5-65 keV) is higher because the 
detector was self-contaminated with ,38Br. However, the 1470 keV peak is absent because the 
137 Cs source was o f high activity.
3.3.4.4 Intrnsic and Absolute Efficiency
Figure 3-14 : Spectrum o f l37Cs with around 3% resolution
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F i g u r e  3 - 1 5 :  T h e  E f f i c i e n c y  c u r v e  o f  t h e  I n s p e c t o r  1 0 0 0  a s  o b t a i n e d  b y  t h e  I n s p e c t o r  s y s t e m .
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3.4 Measurement form
Table 3-5: Measurement form
Staff Nam« 1Data / Jul/2005 Timo of Uarting Dose at start of the dawN staff Tima of and Dose at end of the dav
Parimi:
Stoowatchtime Dosa at Starr Task is m m v a a m m comments
HOT LAB (1) unpacking Paper workDi spenyng Other
M l . . AnswenngEspiammo
HOT LAS (3) ResiduaiPaperwork
W.C DisabledHelping
Sramh» dim Setup HetpmoÉttlfliflMM
Dtpartur« Answering OmdingHelping
Parimi :
_ : ■ . ; .. , ,■ ' ! kivM'Iulül comments
HOT LAB (1) MHPikfohfl. Paper workD spensi no Other -J
1} mint Injecting Answering nExplaining Helping
MOT LAB tf) Residua*Paperwork
W.C DisabledHelping
« ■ « Setup HelpingExplamino
Depart«» Answering GiadingHelping __
The total exposure dose depends on two factors: time of exposure in each phase and the 
measured dose. Thus, a measurement form was designed to match the logical sequence o f the 
PET/CT workflow. The measurement form created for this study was designed to record two 
kinds o f data: numeric and text. The numeric datum records the start and end times as well as 
the start and end doses for each phase. The date and the start and end dose for the 
accumulated daily dose were also recorded. The text data record the name of the staff 
member, any comments made, the kind o f task carried out in the phase, and the names o f the 
patients. These data allowed us to determine which tasks caused the highest doses. A colour 
coding system was used to easily identify each staff member’s measurements, as shown in 
Table 3-5. In addition the background radiation produced from natural radiation and other 
radioactive sources within the department was measured. The measurements were collected 
while the PET/CT unit was in engineering service and during downtime. Background 
exposure was measured for 3 days in each area o f the PET/CT facility.
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4 Chapter 4: PET/CT site Planning and Shielding Requirements
4.1 Introduction
There is no debate that the number o f positron emission tomography PET/CT scanners has 
been increasing substantially since 2005 in the U.K. as well as in the rest o f the w orld [ll]. 
This trend has probably been boosted by the recent advent o f readily available tracer isotopes 
from regional cyclotrons and the availability o f the mobile PET/CT units [13]. The PET/CT 
centre can be either free-standing, e.g. a private diagnostic company or a part o f an NHS trust 
hospital. Several locations in the country have more than one PET/CT scanner in the same 
hospital, e.g. NHS trust hospitals in London and Surrey.
The design o f any PET/CT facility hinges on many factors which play a vital role and may 
increase the cost o f either changing a normal unit in a hospital to a dedicated PET/CT unit or 
o f building a new centre. These factors include the site, floor loading, room sizes, estimated 
workload, equipment and installing shielding in the unit to match the Ionising Radiations 
Regulations 1999 (IRR99), the National Council on Radiation Protection and Measurements 
(NCRP) report Nos. 147 and 151 and the Ionising Radiations (Northern Ireland) Regulations 
2000 [48,91-93].
Any reference to IRR99 can be taken as also including the Northern Ireland Regulations [67].
In this chapter some o f the main factors have been discussed. In general, the shielding 
techniques discussed here can be applied to other situations by compensating for different 
workloads, amounts o f injected isotope, choice o f isotope, and other operating parameters. 
PET uses radioisotopes that have one common feature: they all emit 511 keV photons. The 
more penetrating the emission, the more shielding is required. The design and construction o f 
the shields increase in complexity as the mass o f material needed increases. Further 
complicating the situation, the shielding may be required as a retrofit to an existing space. 
Both construction methods and material costs need to be considered more carefully. The 
cyclotron unit has been excluded from the calculation.
Estimating the quantity o f shielding material required is accomplished using well-established 
computational methods. These methods represent the “standard o f care” in shielding design. 
At lower imaging energies or lower levels o f facility utilization, existing building materials 
(concrete, brick) are often sufficient to provide the level o f protection needed. At higher 
imaging energies or levels o f utilization more shield material is necessary.
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However, the thickness o f shield material can often be combined with common building 
products to greatly simplify installation; for example, lead and gypsum wallboard. 
Alternatively, the shielding material may possess qualities that allow it to be added into the 
building structure (e.g., concrete) [48]. The physicist uses shielding methods based on taking 
advantage o f more realistic assumptions regarding source geometry, workload, and 
acceptable levels o f exposure. It would be “conservative” enough to allow flexibility with 
regard to both source size and patient load. Currently, there are many types o f studies o f PET 
examination in clinical practice where 18F-FDG is used, such as whole body or head and 
neck [94]. Whole body studies predominate in both static and mobile units. Therefore, here 
we focus on site planning for a facility performing whole-body FDG scans as its principal 
business [13].
4.2 Site Planning
The PET/CT unit consists o f six main areas or rooms which are a control room, injection and 
preparation room, scanner room, hot-lab, hot W.C, and waiting area and reception. To build a 
PET/CT unit or convert an existing installation to a dedicated PET/CT facility is not an easy 
task, and is time consuming because o f the required documentation and architectural 
blueprint. It is more challenging to setup a PET/CT scanner in an existing facility (such as a 
nuclear medicine department) than in a new area. Logically it is preferred to install the unit as 
far away as possible from busy areas. In all the cases, due to the heavy weight o f the 
shielding as well as the scanner (around 3500 kg); the unit needs to be installed on the ground 
floor or at basement level. An example site plan is shown in Figure 4-1, where the location o f 
hot W.C may lead to unnecessary exposure to staff members. The whole site is considered as 
a controlled area according to the IRR99 regulations and the NCRP recommendations[67, 
93].
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Figure 4-1 : PET/CT site Planning[95]
4.2.1 Controlled, supervised, and uncontrolled areas
According to NCRP report No 151 and the IRR99 regulations there are three levels o f area 
monitoring where radioactive sources are used. These three levels have been categorised by 
the exposure dose rate in air in pSv/h and the dose limits per annum.
4.2.1.1 Controlled Area
This is an area where it is necessary to follow special procedures to restrict exposure to 
ionising radiation, or an area where any person is likely to receive 3/10th o f the dose limit or 
more. Before anyone can enter a controlled area, they must either be a classified worker or 
have read and understood the local rules.
4.2.1.2 Supervised and Uncontrolled Areas
A supervised area is an area where any person is likely to receive 1/10th o f the dose limit or 
more.
The Uncontrolled area is usually where there is no unnatural radioactive source and any 
person is unlikely to receive more than the natural background dose (see Table 4-1).
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Table 4-1: Types o f areas and dose limits [67, 91]
Area of Body Supervised Area Uncontrolled Area
Whole Body Effective Dose 1 mSv Normal Back ground
Lens of eye 15 mSv Normal Back ground
Skin and other organs 50 mSv Normal Back ground
4.2.2 Passageways
Passages are one o f the locations that may be associated with unnecessary dose exposure to 
staff operating the PET/CT unit and can consequently increase staff doses. The route inside 
the unit should be wide enough to avoid the technologists from having close contact with 
injected patients. Also, the hot-lab should have two doors: one near to the injection rooms 
and the other on the far side near a corridor ending by a highly secure entrance for FDG 
delivery, residual activity collection and radioactive waste disposal. This would avoid 
unnecessary exposure for all staff, including the receptionist.
The route to the W.C must be sufficiently wide as the best location for staff is on the left or 
right-side o f the patient, while the worst position is behind a slim patient (see Table 4-2, 
showing a summary o f measurements made with a Geiger dose rate meter). Every unit should 
have two doors: one for the entrance which is considered as a cold area close to the waiting 
area or reception, and another other door for patient departure, which is considered as a hot 
area because it is believed that when most patients leave they still emit a high dose rate, 
according to estimated dose rates (see Figure 4-2). Although the mobile units have limited 
space, the new mobile design with a supporting vehicle unit overcomes this problem.
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Table 4-2 : Injected patient dose rate (before going to the W.C)
Distance (cm)
100
R-side L-side Front Back
±SD Dr ±SD ±SD Dr ±SD
76 241 67 302 73 294 78
87 19 82 15 108 23 92 16
15 3 14 5 22 5 17 4
Dr = measured dose rate in pSv/h at the specified distance.
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Figure 4-2: Estimated dose rate at the release o f an injected patient
4.2.3 PET /C T S can n in g  Room
In the scanner room, where the scanner is located and the scan is performed, dimensions are 
based on the size of the scanner. However, the difference in dimensions o f the PET/CT 
scanner from different vendors does not vary [96]. A room with a floor size o f 7 m x 9 m, 
can be optimally used to set up a PET/CT scanner from any manufacturer [91]. However, 
under special circumstances, such as in a space-limited mobile PET/CT, the scanner can be 
accommodated in 5.3 m x 7.8 m room [97] (see Figure 4-3).
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There is also a support room for the scanner where all electrical units and the cooling system 
are kept; this is called the electronics or utility room and is located close to the scanner, 
usually near the PET ring and with a minimum size o f around 2 m x 2 m [91]. All rooms in 
the PET/CT unit require an air conditioning system; however, the system capacity in the 
utility room should be sized to handle all the exhaust heat in the room. The scanning room is 
considered to be a controlled area where the dose rate can reach 7 pSv/h or more at any time 
during working hours [67].
Figure 4-3: Mobile PET/CT scanning room
4.2.4 Control Room
The console room, where the control unit o f the scanner is installed, should be wall to wall 
with the scanning room, for many reasons. Safety is the most important one as in this stage 
the injected patient has been placed on the scanner couch for scanning and may need 
emergency help at any time. Through a lead glass window the operator observes the patient 
during the study and is also informed about the next phase via an audio system fixed in both 
rooms. The dose rate in this room must not exceed 2 mSv/year.
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Figure 4-4: Control Room at a PET/CT unit[48]
4.2.5 Hot-lab
The hot-lab is used to store FDG containers and for preparation o f patient injections. It is 
equipped with a well shielded dispensing unit which is shielded by an L-shaped shield. It has 
also a well shielded disposal unit wherein the residual syringes are disposed, thus minimizing 
the radiation exposure. The dose calibrator is also located in the hot-lab, usually behind the 
L-shield or on the right hand side. The role o f the calibrator is to measure the injected dose as 
well as the residues (see Figure 4-5). According to the 1RR99 any area where a radioactive 
material is kept for some time is considered as a controlled area [67]. Flowever, because o f 
the high activity o f FDG (> 5 GBq) which is delivered to the hot-lab on a daily basis, as well
1 ^ 7as a Cs source for daily quality control tests, the radioactive material is often kept in a high 
security level to restrict access, which then requires an additional special safe box.
Figure 4-5: Dispensing unit, Safe Box, and Calibrator in a hot-lab
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Here, the patient is injected with the tracer and asked to wait for about 60 minutes. This time 
delay allows the tracer to be taken up in the body. A seat and bed are provided for comforting 
the patient and the patient chair or bed has a special call facility button, which upon 
activation will call the clinician in the control room for assistance. The size o f the room 
depends on the intended occupancy. The recommended number of injection rooms with a 
single bed per scanner is in the range o f 4-6 because o f the high exposure rate from patients 
injected with FDG. Closed circuit TV (CCTV) is also required to monitor the patient during 
the uptake time[91]. The size o f the room can vary, however good shielding is required. In 
addition, one o f the injection rooms should ideally have a window with iron bars for patients 
who are prisoners. This avoids non medical staff (police guards) from long exposures. In this 
case the patient bed or chair must have double sided security bars fixed between the bed legs 
to hold a handcuff. This security is particularly important if the PET/CT unit located near 
prisons or within the region. In old mobile unit designs the hot-lab and uptake room have 
been merged in one room.
4.2.6 Injection Room
Figure 4-6: Mobile PET/CT where the injection room and hot-lab have been merged
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4.2.7 Hot W.C
The W.C for use only by PET/CT patients should be located inside the facility within a short 
distance from the injection room and the scanning room. This is not available on the mobile 
PET/CT units, but these have been designed to have a supporting W.C unit. In some static 
locations the hot W.C is outside the hot area because o f a shortage in space. In this case signs 
explaining the limited access are placed on the door, and a lock must be used to ensure that 
members o f the public have no access to it. The waste pipe should be clearly marked with a 
sign indicating presence o f radioactive waste and must be plumbed directly into the external 
drain network. The size o f the hot W.C should be big enough (2.0 m x 2.2 m) to 
accommodate a patient with a wheelchair as well as a staff member. The hot W.C door 
should be wide due to the above considerations^ 1]. Shielding is highly recommended.
4.2.8 Reception and waiting area
In mobile units there is neither a waiting area nor a reception on board. Often, the PET/CT 
staff member collects the patient from the hospital. Neither the reception nor the waiting 
areas should be located inside the hot area where there is a high probability o f exposure to 
radiation, and instead are considered as cold areas where the annual accumulated dose should 
not exceeded the individual dose limit (2 mSv)[45]. There is no particular recommended size 
for either the waiting area or the reception desk.
4.3 The Workflow
The workflow for all PET/CT scans is fundamentally the same. All the procedural details are 
given in Chapter three. However, the day starts when the FDG is received. The amount o f 
activity required for an injection is, on average, 375 MBq±10%. Figure 3-1 shows the 
workflow; phases coloured in red may involve contact with radioactive material. The six 
phases are dispensing, injection, W.C, scanning, departure 1, and departure 2. However the 
workload or the throughput depends on the scanner type. The most commercially used 
scanners are Bismuth Germanate (BGO), Lutetium Oxyorthosilicate (LSO), and Germanium 
Oxyorthosilicate (GSO). LSO is the fastest because it has a higher light output per photon 
[98]. With a BGO PET/CT scanner the average estimated number o f patients who can be 
scanned is 8 , but with the LSO scanner, this figure may reach 16 in a 9 hour shift [99].
91
4 .4  Design goals and the occupancy factor
4.4.1 Shielding design guidelines
The classification of annual dose limit according to ALARP principles is 6 mSv/year for 
occupational exposed workers [67]. However, there is another limit of 5 mSv/y used in 
shielding design guidelines for the controlled areas in the measurements. For example, the 
design of a PET/CT facility is considered as an insufficient match with the PET/CT design 
guidelines if  the occupational background in the control room exceeds the individual dose 
limit per day (1 pSv/day).
4.4.2 The occupancy factor
The occupancy factor is defined as the fraction of the time spent by a staff member or 
individual in a particular area or room [45]. When there is only one injection room with one 
bed, which is occupied continuously by one patient, the occupancy factor is one. The 
occupancy factor is proportional to the time spent by staff in the room where there is a 
radioactive source (an injected patient or radioactive source).
4.5 Shielding calculations in the P E T /C T  unit
4.5.1 Introduction
Although PET has been available in a number of centres across the world for more than 20 
years, it has only become widespread in the last 6 years [11]. The power of PET or PET/CT 
has come from three factors: powerful radiotracers, confidence in detection, and study 
reimbursement. The most common radiotracer in PET studies is FDG with a 110 min half-life 
emission of two high energy photons (0.511 M eV) Table 3-3. Consequently, shielding 
requirements have been considered as an important part of the design of the PET/CT or PET 
facility because of the high energy of the annihilation radiation [96], There are many positron
• ii Io it
emitters e.g. C, N, and O, but shielding calculations have been focussed on units using 
FDG. With respect to all radiotracers, FDG has been selected because of the following 
reasons:
1 - It is already the most commonly used tracer
2- It has long half-life compared to most other nuclides
3- FDG has been recommended as a replacement for the " mTc used in some studies to cover 
the shortage of " mTc [100].
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For example, in early 2009 the National Research Universal (NRU) reactor in Chalk River, 
Ontario, Canada, which is operated by Atomic Energy of Canada Limited (AECL) announced 
that NRU shutdown would extend into the first quarter of 2010 and later on the shutdown was 
extended to the end of 2010. However, on the 17th of June 2010 they announced that soon the 
production line of " mTc would be reopened.
Im portant Note:
I t  should be noted that positron em itting radionuclides w ith  longer half-lives  
and w hich have high energy gam m a emission in addition to the tw o photons 
from  the annihilation, e.g. 89Z r  (78 .4h  h a lf-life , 2 x  0.511 M e V  and 0 .909 M e V )  
are not effective ly  shielded in a F D G  im aging fac ility  because the specific 
gam m a ray constant is higher than that o f  the F D G  by a factor o f  2 (Tab le  3-3).
4.5.2 Factors affecting the amount o f shielding required for any diagnostic unit
The amount of shielding required in a dedicated PET/CT facility is usually dictated by seven 
major factors as follows:
1- Average number of administered patients per week
2- Injected activity per scan
3- Procedure duration
4- The location of the unit
5- The occupancy factor
6- The design goal
7- Type of radiation and level of energy
The shielding calculations for both static and mobile units depend on key factors which have 
been mentioned above (Chapter 2). Importantly, patients injected with FDG should also be 
considered as a primary source. There are several methods for performing shielding 
calculations. However, the most recent published report is the Blue Book or the Design of 
Diagnostic Medical Facilities where Ionising Radiation is used, published by the Radiological 
Protection Institute of Ireland (RPII) at the end of 2009. The blue book code is based on the 
NCRP 2004 as well as Radiological Protection ACT, 1991 (Ionising Radiation ) ORDER, 
2000 (S.I.No.125 of 2000) [91]. The NCRP methodology is based on the AAPM task group 
108: PET and PET/CT Shielding.
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The design goal (P) is defined as the maximum accumulated dose per week at a certain point 
beyond a shielding barrier which should not be exceeded the permitted limit at this area. The 
design goal is often given for a weekly time frame and its unit is Sv week'1 [92]. The 
occupancy factor (T) for an area is defined as the assumed fraction of time that a person may 
be exposed to radiation in that area [93]. The transmission factor is the required thickness of 
any shielding material, such as lead, to reduce the dose rate inside an area down to a required 
level.
4.5 .3  D e f in it io n s
Table 4-3: Summary of Dose Parameters [96]
Parameter Definition Formulation
Ao Administered activity (MBq)
t Time (h)
tu Uptake time (li)
ti Imaging time (h)
D(t) Total dose for time t(fiSv)
D( 0) Initial dose rate (¿¿Sv/h)
T*l/2 Radionuclide half-life (h)
R, Dose reduction factor over time t 
Dose reduction factor over uptake time
=1.443 X (Tm/t) X [1 -exp(~0.693//7’t/2)]
Rtu time t
Dose reduction factor over imaging
=1.443 X (Tu2/tu) X (1 -exp(-0 m t vlTm))
Xu time t =1.443 X (Tmltj) X [1 -exp(-0.693///7V2)]
\ Nw Number of patients per week
d Distance from source to barrier (m)
Fv Uptake time decay factor (/¿Sv) =exp[ -0.693/t,/T1/2)]
T Occupancy factor
P Weekly dose limit
Transmission factor (uptake room) 
Transmission factor (scanner
=10.9 X P X d2/[TX Nw X Ao X t^h) X RlV]
B room) =12.8 X P X (fi/[TXNw XAoXFyX f;(/i) X R„]
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4.5 .4  T h e  A A P M  s h ie ld in g  c a lc u la t io n
A special challenge has been presented in the shielding of PET or PET/CT units because of 
the 511 keV annihilation photons associated with positron decay. The American Association 
of Physicists in Medicine (AAPM) has produced a detailed report on PET and PET/CT 
shielding [96]. Three factors must be clarified before doing any calculations. First is the 
gamma constant, calculated from Equation 2-46. T is based on the sum of the source energies 
multiplied by the emission fraction. For i8F, T is around 0.141 pSvm2/h MBq. Our value is in 
close agreement with what has been published by the AAPM, as they recommend using the 
gamma dose rate constant 0.143 pSvm2/h MBq. The task group recommends using a patient 
dose rate of 0.092 pSvirr/MBqh immediately after injection. This number has been derived 
from several published papers. The patient dose rate corresponds to effective body 
absorption. During the project the dose rates at different distances were measured at the end 
of several tasks e.g. injection, scanning and release (see Table 4-4). The data were obtained 
from 150 patients over 19 days. From the dose rate after injection at 1 m, patient dose rate 
constant can be calculated by dividing the measured dose rate immediately after injection by 
the injected activity. In that case the patient dose rate was (43.64/400) = 0.109 pSvm2/MBq.h. 
The difference between the two readings is around 18%. From the previous step, effective 
body absorption was calculated by using the decay rate to find the expected activity, then 
multiplied by the patient dose rate and divided the product by the measured dose rate. 
However, each PET/CT unit has its own design and should be treated as a new case.
Table 4-4: Average dose rate in pSv/h from patients injected with l8F-400MBq at NHSTH-1
Distance in cm Dose Rate after injection Dose Rate after Scanning Dose Rate at release
mean ±SD mean ±SD mean ±SD
30 180.76 14.66 86.76 8.52 65.98 6.8
100 43.64 5.32 22.93 4.12 16.32 2.23
200 18.76 3.9 9.86 2.19 7.11 1.09
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The uptake room is where an injected patient is kept for 45-60 min after injection. For 
shielding calculations we need to find out the total dose at a point d meters from the source or 
the patient during the uptake time, from the following formula:
4 .5 .4 .1  In je c t io n  ro o m
D (tu ) = ( 0 .1 0 9  ^ S V m 2 / M B q h  )  A 0 (M B q)  (
where
T iRtu — 1.443 V t t )
and N w is the estimated number of patients per week (or the workload). 
Thus, the total weekly dose is
Total weekly dose = D(tu) Nw
and the transmission factor (B) required is
B =  (10.9 P d (m 2) ) / ( ( T  Nw A0 (MBq))tu(h) Rtu )
where P is weekly dose limit in juSv and T is the occupancy factor.
4 - 1
4 - 2
4 - 3
4 - 4
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The scanning room is where the injected patient is scanned for 30-45 min. For shielding 
calculations we need to determine the total dose at a point d  m from the source or the patient 
during the scanning time as before. However, every R,u should be replaced with ^„such that 
the final formula is :
12.8 P d 2 
B - ( T N w A0 (MBq)Fu t iW R a  )
4 - 5
From these calculations the required shielding thicknesses are presented in Table 4-5.
4 .5 .4 .2  S c a n n in g  ro o m
Table 4-5: Transmission Factors for Lead, Concrete and Iron at 0.511 MeV [96]
Transmission Factors
Thickness“’1* Lead Concrete0 Iron
0 1 1 1
1 0.8912 0.9583 0.7484
2 0.7873 0.9088 0.5325
3 0.6905 0.8519 0.3614
4 0.6021 0.7889 0.2353
5 0.5227 0.7218 0.1479
6 0.4522 0.6528 0.0905
7 0.3903 0.5842 0.0542
8 0.3362 0.518 0.0319
9 0.2892 0.4558 0.0186
10 0.2485 0.3987 0.0107
12 0.1831 0.3008 0.0035
14 0.1347 0.2243 0.0011
16 0.099 0.1662 0.0004
18 0.0728 0.1227 0.0001
20 0.0535 0.0904
25 0.0247 0.0419
30 0.0114 0.0194
40 0.0024 0.0042
50 0.0005 0.0009
“Thickness in mm for Lead, bThickness in cm for concrete, ‘Concrete 
density = 2.35 g/cm3
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Commercial grade lead (82Pb) and aluminium ( I3A1) sheets were used to investigate their 
shielding properties for 511 keV gamma rays. Thin sheets of lead (0.5 mm) and aluminium 
(0.7 mm) thick were used. The two materials were cut into small sheets of size 125 mmxl30 
mm. Experimental equipment included:
1- Na (TI) 20x20 mm Scintillator (Bicron, USA) gamma ray detector.
2- High voltage power supply.
3- Software (Genie 2000/ Gamma Acquisition analysis) supplied by Canberra industries.
4- Multi channel analyser (MCA).
• • 185- Radioactive source ( F).
The Nal(Tl) detector was encased in a 50 mm thick lead-copper shielding to lower the 
background radiation.
4 .5 .5  S h ie ld in g  m a te r ia ls
Figure 4-7: Diagram of the system used to investigate the shielding material
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4.5.5.1 Detector Calibration
The detector was calibrated with low activity of 18F according to the following procedure:
1- The experiment was set up as illustrated in Figure 4-7 without an added shielding sheet.
2- The high voltage power supply and the amplifier were turned on. The computer and the 
software were started.
3- The radioactive source was positioned in front of the detector at 75 mm from the detector 
window.
4- The gamma spectrum was acquired for 300 s to determine the full energy photopeak 
position in the accumulated spectrum.
5- The region of interest in the M C A  was adjusted to the beginning of the X-ray peak for the 
lower setting (6.9 lceV) and to 660 keV for the upper setting.
6- The 511 keV gamma energy peak was selected and saved.
7- The energy spectrum was calibrated so that the M CA channel at the centre of the 511 keV 
peak was set to 511 keV.
4.5.5.2 M easurements o f material attenuation properties
The attenuation measurements were made by collecting the gamma ray energy spectrum from 
a 10 MBq 18F point source in a P-6 vial. The source was moved to the lab in a shielded box to 
avoid unnecessary exposure. The experiment was set up illustrated in Figure 4-7 and the 
counts were collected with and without an added shielding material. The radioactive source 
was positioned at a distance of 75 mm from the detector window and aligned carefully using 
a paper template. The counting time was set to 300 s (live time) to achieve adequate and 
consistent counting statistics, with a dead time < 6%. The number of counts in the 511 keV 
peak and the total number of counts between the lower and upper set limits were recorded.
The first lead (Pb) sheet was positioned between the detector and the source in front of the 
detector window at a distance of 30 mm from the detector crystal; the count was collected 
and recorded for 300 s. The same procedure was repeated for a range of lead thicknesses 
between 1.5 mm and 15 mm. When a 90% reduction in radiation intensity was achieved, 
aluminium sheets were added between the lead and the detector window, and the counts 
collected and recorded for 300 s. For the lead characteristic X-ray window the region of 
interest in the M CA was adjusted, so the lower setting was at 39.2 keV and the upper setting 
was at 69.7keV. An 18F source with 5 MBq activity was used and the count was collected for 
600 s. The number of counts in the X-ray peak (70 lceV) and the total counts between the
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lower and the upper set limits were recorded for a range of aluminium thicknesses between 
0.7 mm and 28 mm. Most PET and PET/CT tracers have short half lives, so the total radiation 
count rate N(t) recoded over a period of time Tr is less than the product of N(0)Tr. Therefore, 
the count rates need to be corrected. The reduction factor (decay correction factor) was 
calculated to correct the l8F decay during the measurements from the following formula:
DC* = I l k .In2 7V
-0.6937V
(1 - e T1/z)
4 - 6
where Tm is the radioactive source half life and Tr is the elapsed real clock time during 
measurements [101].
4.5.5.3 Results and Analysis
The first part of the experiment to evaluate the shielding was needed to reduce the radiation 
to the lowest practical value. Table 4-6 shows a significant reduction in the count rate with 
increasing lead thickness.
Table 4-6: Variation in count rate with lead thickness
Thickness(mm) Counts at 511 keV peak
0 36325.42 125934 ±354.8
0.5 32254.09 109176 ±330.4
1.5 27226.39 87924 ± 296.5
2 24787.39 72084 ± 268.4
3 21362.71 56977 ±238.7
4 18192.69 44038 ± 209.8
5 15472.16 33450 ±182.9
6 13274.65 25255 ± 158.9
7 11124.7 18685 ± 136.6
8 9496.19 13468 ±116
9 8027.63 10274 ±101.3
10 6746.72 7495 ±86.6
11 5735.49 5584 ±74.7
12 4865.38 4133 ±64.2
13 4027.26 2891 ± 53.7
14 3428.77 2135 ±46.2
15 2872.52 1505 ±38.8
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Table 4-6 shows that a lead thickness of 12-13mm is sufficient to reduce radiation intensity to 
10%. The half value layer thickness was about 4 mm, which is sufficient to reduce the 
radiation intensity to about 50% of the incident radiation. However, there was a significant 
increase in the lead characteristic X-rays with the increase in lead thickness.
4 .6  Pot position and thickness
Measurements in the vicinity of the vial in a 17 mm thick lead pot were repeated using the 
portable dose rate meter. These are shown in Table 4-7.
These readings were used to calculate the additional lead thickness required to reduce the 
annual dose to 300 uSv. The dose rate, £>2 , varies with additional thickness of lead T as,
D 2 = D 1e - ( ln l 0 ) T / L
4 - 7
Where D\ is the dose rate measured for the 17 mm thick pot and £ is the tenth value layer, 
which is 17 mm. Therefore, the additional thickness of lead needed to reduce the dose rate to 
the preferred £ > 2  is given by,
L  7T  =  In
In 1 0
A L
A
4 - 8
The additional thicknesses of lead to reduce the TADR2000x2000 to below 300 /¿Sv/y are 
given in Table 4-7 and show that a 45 mm thick lead pot will be ample to keep the dose rates 
below the acceptable limit. However, the vial is delivered to the PET/CT unit in a 30 mm 
thick lead pot. The dose rates for a 45 mm and 30 mm thick lead pot were calculated using 
equation 2, and are shown in Table 4-7.
A  vial of 12 GBq has not been delivered since the PET/CT suite has been in clinical use. In 
practice an average of 3.7 GBq is delivered each day with a maximum of 9.6 GBq. Currently, 
a highly active vial is only left on the bench in the 30 mm thick lead pot with the lid on. The 
dose rates at each position were also calculated with the vial in a 30 mm thick pot containing 
3.7 GBq and are shown in the last column of Table 4-7.
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After suitably shielding the vial, the dose rates in the control room were still slightly higher 
than desired. Therefore, lead blocks were positioned along the wall between the position of 
the vial on the bench and the control room.
Table 4-7: Further dose rate measurements due to the activity in the lead pot.
Control room 
control console
4336.74 19.72 97.75
30 mm 
Lead Pot 
(12 GBq 
delivered) 
744.34
30 mm 
Lead Pot 
(3.7 GBq 
delivered) 
229.51
B1 Control room, 
wall surface at 
corner
9034.88 25.14 203.64 1550.72 382.51
Cl Control room, 
chair at PC
8260.47 24.48 186.19 1417.80 437.15
D1 Reception, 
desk chair
3097.67 17.24 69.82 531.67 163.93
E l Reception, wall 
surface
2065.12 14.24 46.55 354.45 21.86
When the vial was left on the bench in the PET lab, the pre-acceptance dose survey showed 
that if 12 GBq 18F were delivered daily, there would be unacceptable annual doses in the PET 
lab and adjacent rooms. This occurs both when the vial is both inside and outside the 17 mm 
thick lead pot Calculations showed that a 45 mm thick pot would be necessary to reduce these 
doses below the acceptable limits. However, on average only 3.7 GBq l8Fwas delivered daily, 
in a 30 mm thick lead pot, and at this activity a 30 mm thickness is adequate to reduce the 
annuals doses to acceptable levels.
Both the pre- and post-acceptance measurements showed that the annual dose at the desk in 
the IT  office above the injection room would be over 3/10th the annual dose limit. Further 
monitoring confirmed that if  6 patients were scanned daily then a person at their desk for 100 
% of the working day could receive a dose of 508 pSv/yr. However, 6 patients is the 
maximum number of patients the PET/CT suite is currently capable of scanning per day and a 
person is unlikely to be at their desk 100% of the time. Therefore, 508 pSv/yr is the absolute 
maximum dose they could be exposed to per year and it was deemed unnecessary to shield 
this desk further. I f  the PET/CT scanning capacity were to increase in the future extra 
shielding should be considered.
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Measurements made in the corridor above the PET lab when a 6 GBq vial was left in the lead 
pot without the lid on highlight the necessity to replace the lid to the lead pot when the vial is 
not in use.
As expected, high dose rates were measured in the vicinity of patients. An evident conclusion 
is that technologists should perform tasks involving close contact with the patient rapidly to 
reduce their exposure. It was also shown that if  active material is left in the calibrator, dose 
rates in the control room increase, because the opening of the calibrator is unshielded. 
Therefore, similarly to whenever the lid to the lead pot is removed, dose rates will increase in 
the PET suite and in the corridor above the lab (as will be shown in Section 5). Therefore, 
whenever possible the active vial should be kept in the lead pot with the lid on. It was also 
observed that i f  a patient was sat on the chair by the door to the control room, there were high 
dose rates at the reconstruction console. Therefore, the duration of these situations occur 
should be kept as short as possible. The average technologist’s annual dose rate was 2.6 mSv 
in the first year, which is lower than these measurements would suggest. This reduction may 
be attributed to the staff rota system and their good working practice. A ll annual doses to 
staff and public in the vicinity of the PET/CT suite were kept below the limits of 1 mSv/year 
for the public and general hospital staff and 20 mSv/yr for staff working in the PET/CT suite.
It has been shown that, with few exceptions, the annual doses in the vicinity of the PET/CT 
suite are kept below 3/10th of the annual dose limits. Staff in the PET/CT suite were using 
good working practice and the rota system to minimise their annual dose. Doses in the 
corridor above the PET lab remain low provided care is taken to replace the active vial in the 
pot with the lid on when it is not in use. The annual dose at the desk above the injection room 
may reach 500 pSv/year when 6 patients are scanned daily. Shielding to the IT  office must be 
considered if  more than 6 patients per day were to undergo PET/CT scans in the future.
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5 C h a p te r  5: P E T /C T  U n i t  D e s ig n  a n d  M e a s u rm e n ts  
5.1 Static Design A
Design A illustrates the static PET/CT unit in the Private Medical Imaging Centre in London 
(PMICL). PMICL houses a PET/CT scanner (Siemens Biograph LSO duo) in a shielded 
room in the basement level of a multi-modality independent diagnostic centre. The average 
number of patients scanned during the first half of 2005 in the PET/CT unit was 8 patients 
per day. The PET/CT department has a dispensing or “hot lab” room where the technologists 
unpack and dispense the tracer, as well as two shielded “preparation” rooms for patient 
injection and uptake. The unit layout provided by the company is shown in Figure 5-1. Note 
that this schematic, as well as others presented below, are not to scale. This is due to 
company policy.
StoreRoom Prep Room 2 Prep Room 1
ChangeRoom
CleanersRoom Dispensing Lab
Stairs
Power Room
ConsoleRoom
UnusableArea
Stairs
L
Refuse Room
PET/CT Scanner
StaffToNet
PETPowerRoom
HotToHet
Boiler Room
Figure 5-1: Schematic diagram of PET/CT department in PMICL (not to scale)
Figure 5-2 presents box plots of the daily EPD doses recorded by 5 PET/CT technologists 
working at PMICL during a period of six months in 2006. The box plot is a convenient way 
to represent data, as it shows the median, the range and potential outliers. Staff members A, B 
and C each worked in excess of 50 days, whereas staff members D and E only worked at 
PMICL on 30 days.
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The total monthly whole body doses for the same period for the 3 full-time members of staff 
are shown in Figure 5-3. From these two graphs, it can been seen that there is considerable 
variability in the daily (13 ± 6 to 24 ±9 pSv) and average monthly (181 ±57.73 to 270 ± 
154pSv) whole body doses per staff member. However, there are no data regarding the 
number of patients actually handled by each individual staff member. Therefore, no comment 
can be made at this stage about the reason for variations in doses between the different 
technologists.
A B C D E
Staff Members
Figure 5-2: Box Plots of daily staff doses at PMICL for a period of 6 months in 2006
The expected annual dose for each technologist is shown in Table 5-1 and is based on the 
assumption of the same level of work activity and 225 working days per year. The limit of 
exposure dose for non-classified workers is 6 mSv, and it can be seen that the estimated 
annual dose for each member in Table 5-1 is below this limit. It is also noted that these values 
are within the range of values reported elsewhere (see Chapter 2).
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Table 5-1 : Expected annual dose for PMICL technologists
Staff Mean daily dose (pSv) ±STD Expected Annual Dose (mSv)
A 13.6 5.8 3.06
B 17.4 6.5 3.92
C 22.8 7.1 5.14
D 19.7 7.7 4.43
E 24.0 9.0 5.40
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Figure 5-3: Total monthly staff doses (full time staff) at PMICL for the first six months of
2006
5.1.1 Variation of staff doses with number of patients scanned at P M IC L
The variation in average total daily dose with scanned patient numbers for all staff members 
working at PMICL is shown in Figure 5-4. The relationship between the number of patients 
and the staff dose is seen to be linear.
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Figure 5-4: Average total doses for all staff versus number of patients.
5.1.2 Effect of different numbers of staff
Figure 5-5 shows the relationship between the number of patients scanned and the average 
total staff doses for the cases where 2 or 3 staff members were working within the department 
at the same time. For the case of two members of staff, the linear relationship between dose 
and patient number is maintained until more than 8 patients per day are scanned, when there 
is a larger increase in dose. To facilitate the higher throughput of patients in the department 
(8 and above), 3 members of staff generally work in the department. From Figure 5-5, it can 
be seen that the dose when 3 staff are present is consistently higher than for 2 staff members, 
until more than 8 patients are scanned, at which point a dose reduction is seen. This 
unexpected result could be due to a number of reasons (such as unplanned close contact with 
patients) but insufficient data were available to investigate such possibilities further. Data 
presented in Figure 5-4 and Figure 5-5 data were recorded by the staff members in the static 
unit at PAMICL.
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Figure 5-5: Average total doses vs number of patients for 2 and 3 staff members at PMICL
The total number of patients undergoing PET/CT scans in PMICL during the period of the 
measurement was 54 patients, of which 5, 18 and 31 patients were handled by 3, 1, and 2 
different staff members respectively. Table 5-2 compares the whole body dose and exposure 
time obtained while 1 and 2 staff members were sharing the handling of the patients during 
the PET/CT procedure. The case of 3 staff sharing the procedure was ignored, as there were 
only 5 patients. It can be seen from Table 5-2 that when 1 staff member deals with a patient, 
there was a consistently lower dose recorded in the majority of the phases. There may be 
advantages to staff working in this “isolated” method with one staff member dealing with an 
individual patient. Since all the dose readings were obtained from the LCD’s EPD, in some 
cases the STD was higher than the average reading. The EPD shows dose the integer part of 
the dose reading (i.e. without fractions), which affects the STD calculations.
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Table 5-2: Comparison between the exposure time and dose against number of staff
PHASES i STAFF MEMBER HANDLING 2 STAFF MEMBERS SHARING THE
EACH PATIENT HANDLING OF EACH PATIENT
DOSE
(pSv) ±STD TIME(s) ±STD DOSE (pSv) ±STD TIME(s) ±STD
DISPENSING 0.7 0.9 163 68 0.6 0.7 166 82
INJECTION 2.7 0.9 329 107 2.8 0.9 324 119
RESIDUAL 0.1 0.3 165 71 0.1 0.3 143 50
W.C 0.1 0.3 57 40 0.3 0.7 67 75
SCANNING 0.9 0.7 139 65 1.3 0.7 176 67
DEPARTURE 0.5 0.6 113 67 0.5 0.7 119 77
Total Average 4.6 1.9 878 236 5.5 1.5 971 199
Table 5-3: Average daily dose for staff working with either 1 or 2 other members of staff
Fulltime Staff Members at PMICL Mean (pSv) ±STD
A working with 2 others 14.0 5.8
B working with 2 others 18.1 4.9
C working with 2 others 23.3 7.0
A working with 1 other 15.5 4.5
B working with 1 other 19.3 8.5
C working with 1 other 25.8 5.8
The average daily dose per fulltime staff member is tabulated in Table 5-3 and related to the 
number of other staff members working in the department. This table gives an indication of 
the relative dose exposure of each staff member. From this information, it could be proposed 
that the staff member with the lowest average dose (staff member A) be observed in their 
workflow dealing with patients and radioactive sources, and that these “optimal” techniques 
should be transferred to other staff members by training.
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However, this cannot be concluded unless we know exactly how many parts of the PET/CT 
procedure staff member A performed on each day relative to the other staff members. In other 
words, Table 5-3 would be a useful indicator if we could confirm that the workload for each 
phase of the procedure was the same for all staff members and if we knew how much dose 
each staff member received during each phase. With this in mind, a new set of measurements 
were collected at PMICL and in the mobile units.
5.1.3 Whole body dose for different phases at P M IC L
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Figure 5-6: The whole body dose per task per patient from all phases in PMICL
It is important to illustrate the whole body dose per task per patient to show the variability in 
exposure dose per patient. Figure 5-6 shows the whole body dose recorded for each phase of 
the PET/CT workflow for all 54 patients scanned at PMICL during the period of the study. 
Again, variations in total dose are seen. Note that some data are missing for patient 26, and 
that in some cases (e.g. the dispensing and residual phases) the doses were below the l pSv 
display resolution of the EPD. This "rounding error" has important implications for the 
results presented in this section. The maximum measured whole body dose per patient was 11 
pSv, similar to the results previously published by Biran et al. (2004) regarding average 
whole body dose to staff per patient. The cause of variations in the measurements can be 
attributed to staff performance and patient-staff interactions. Staff performance is based on 
individual skills and knowledge. On the other hand, patient-staff interaction depends on 
patient age, knowledge about the scan procedures and state of health.
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Averages of the exposure dose have been calculated for all measurements, and the standard 
deviation for all the phases is shown in Figure 5-6. For all 54 patients, the average dose per 
phase per patient was 5.4 ± 2.3 pSv, which is within the range published by Robert et al. 
(2005). The highest dose was received in two areas: injection and scanning. This is due to the 
close contact with injected patients as well as the longer exposure time in these phases. Small 
dose contributions were found in the WC and residual phases. Monthly records from PMICL 
over the 6 month study period show the average injected activity in PMICL was 374 MBq. 
The mean whole body dose per MBq injected was 0.01 pSv/ MBq, very similar to the result 
published by (Roberts, 2005).
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Figure 5-7: Average whole body dose (pSv) per phase per patient in PMICL
The value of "others" was 0.77 ± 0.4 pSv per patient, which is higher than the background 
levels in the environment. This dose represents the dose that is not allocated to any particular 
phase, and was calculated from the total daily dose that the staff members have recorded. 
Despite expecting differences between the daily sums of doses from all the phases and the 
total daily dose for the staff to be within the range of the daily background, the dose in the 
“other” category was found to be >10% of the total dose. It is therefore assumed that the 
“others” dose was received from unexpected exposure. Most of the measured doses were 
similar to or less than the published values, such as those for injection and dispensing doses 
[82] and [75].
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The aim of this section was to find the average whole body dose per patient per staff member 
and to calculate the maximum number of patients that can be scanned per day per staff 
member. According to the ICRP regulations (see Chapter 2) the maximum annual dose per 
staff member is 6 mSv to ensure the staff member remains below the level for classification. 
PMICL staff work 45 weeks per year, 5 days per week, giving a total of 225 days per year. 
The maximum dose limit per day is 26.7 pSv, which would allow up to 5 patients per day per 
staff member (see the calculations in Box 3.1).
Box 3.1: Calculations o f number of patients per day per staff in the static centre
Dose limit = 6000 jaSv/Staff/year
Number of working weeks/ year/staff = 45 weeks
Number of working days/week = 5 days
Total working days/ year = 5 days X 45 weeks = 225 days/year
Maximum total exposure dose pSv/Day/Staff = 6000juSv -*■ 225days = 26.7 jaSv /day
Average dose is 5.4 juSv/Patient
26 jaSv/day -*■ 5.4 juSv/patient = 5* patients/day/Staff
* Each staff member can handle a maximum of 5 patients without exceeding the dose limits.
5.1.4 Exposure times for different phases at PMICL
Figure 5-8 shows the time taken for different phases of the PET/CT workflow for all 54 
patients scanned at PMICL during the period of this study as a stack columns chart. These 
results are based on time in seconds and number of patients, to give the total time of all the 
phases during the PET/CT scan for each patient. It can be seen that there are significant 
variations in the exposure times. The mean time was 931± 215 s per patient. There are a 
small number of instances of missing data where records were not obtained, possibly due to 
stressful situations developing during the course of the measurements. The cause of 
variations in the measurement can be attributed to staff performance and patient-staff 
interactions. Staff performance is based on individual skills and knowledge. Patient-staff 
interaction depends on patient age, knowledge about the scan procedures and state of health 
as well as the circumstances described in the last chapter.
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Figure 5-8: Total exposure time per patient for all phases in PMICL
Figure 5-9 shows the average exposure time in the different phases per patient procedure. The 
maximum time is the injection phase, which required ~5 minutes per patient per injection.
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Figure 5-9: Average time per phase per patient in PMICL
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5.2 Static Design B
Figure 5-10: Layout of a PET/CT department with Golding colour at PMICLB
Design B illustrates the static PET/CT unit in Private Medical Imaging Centre in Surrey 
(PMICLB). PMICLB houses a PET/CT scanner (GE) in a shielded room on the ground floor 
level of a multi-modality independent diagnostic centre. The average number of patients 
scanned during the first half of 2007 in the PET/CT unit was 5 patients per day. This number 
has increased by a factor of two since late 2008. The PET/CT department has a dispensing or 
“hot lab” room where the technologists unpack and dispense the tracer, as well as two 
shielded “preparation” rooms for patient injection and uptake. The total number of patients 
undergoing PET/CT scans at PMICLB during the period of the measurement was 140 
patients, with an average 9.00±2.76 patients per day handled by 2 staff members. The average 
total whole body dose was 4.97 ± 0.93 pSv per patient. As mentioned above, the EPD only 
displays integer readings, so to avoid this affecting calculations of the mean and standard 
deviation a random generator function was used to correct zero readings. Uncorrected and 
corrected readings are shown in Table 5-4 and Table 5-5.
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Table 5-4: Uncorrected measurements
Dis In j C.O W C  Scanning Departure Others Total
Task
Mean pSv 0.46 1.67 .047 0.32 0.93 0.69 0.67 5.14
±  STD pSv 0.80 0.98 0.50 0.69 0.84 0.73 0.62 5.21
Uncertainty
±pSv
0.54 0.47 0.49 0.43 0.70 0.63 0.57 4.3
Dis = Dispensing, Inj= Injection, C.O= Cannula out,
Table 5-5: Measurements corrected with the random generator
Dis In j C.O W C Scanning Departure Others Total
Task
Mean pSv 0.85 1.53 0.78 0.72 1.1 0.89 0 5.87
±  STD pSv 0.56 0.69 0.29 0.58 0.70 0.57 0 3.39
Uncertainty
±pSv
0.45 0.62 0.24 0.40 0.44 0.35 0 2.50
Dis = Dispensing, Inj= Injection, C.O= Cannula out,
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5.3 Static Design C
The PET/CT unit at the NHS Trust Hospital (NHSTH-1) in England was established in 2003 
and began operation in February 2004 with three staff members scanning an average of 44 
patients per month. However, these numbers increased sharply. The number of technologists 
increased from 3 to 7 between 2004 and 2006 respectively. By 2006, the number of patients 
scanned increased to over 70 per month (Figure 5-11) due to the reputation of NHSTH-1 as 
having one of the best oncology centres in Europe and due to staff training. From comparison 
with the demand of this service in the UK, a high patient throughput was expected, and an 
unpublished NHSTH-1 report has estimated that an average of 9 patients are scanned per 
day.
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Figure 5-11: Workload at NHSTH-1 during 2004-2007
During the period between 2004 and 2007, staff member workload and doses show 
significant increases in the number of scanned patient per month. Table 5-6 shows the 
workload per month of each PET/CT staff member, as well as the cumulative number of 
patients scanned per staff member. Over the last 3 years, the NHSTH-1 completed more than 
2000 PET/CT scans. The range of scanned patients per month per staff member varied 
between (mean ± SD) 14±10.5 and 28±9.38 due to many reasons, e.g. patient numbers 
increasing and the shift of technologists on a rota between the nuclear medicine NM  and PET 
departments.
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Table 5-6: Staff members’ workload and TLD dose reading from 2004-2007
STAFF Mean Dose 
jxSv/Patient
±SD Total number of 
scanned 
patients
Total 
accumulated 
dose mSv
Number of 
working 
months
6.4 4.1 115 1.0
14.1 8.5 305 3.6
20.1 12.6 312 5.6
15.0 11.8 333 3.9
17.8 8.5 404 6.6
16.7 5.4 111 2.3
18.6 6.0 99 1.8
The average dose per month from TLD badge records indicates that all staff doses were 
below the level of classification (6 mSv per year). However, several months of raw data are 
missing for staff members 1, 2 and 5, and one staff member scanned more than 50 patients 
with no dose record. Moreover, accumulated doses for staff 3 and 4 show that the total dose 
for staff 3 is double that of staff 4 who scanned 21 patients more.
In routine TLD tests the fixed background dose is subtracted from the measured dose. The 
background is around 0.04 mSv/month (2 pSv/day x 5 days/week x 4 weeks/month = 40 
pSv/month = 0.04 mSv/month). However, the dose of staff number 1 from May 2005 to 
December 2006 was 0 mSv/month and the number of scanned patients was also 0 (excluding 
3 cases). In January 2005 the dose was 0.01 mSv/month and the number of scanned patients 
was 3. Also, in both July 2004 and April 2005 the monthly dose was 0 mSv/month when the 
numbers of scanned patients were 15 and 3, respectively. Finally, in March and July 2005 
there was no scanned patients and the total dose was 0.01 mSv/month. It is hard to explain 
the fluctuations in Figure 5-12, Figure 5-13, and Figure 5-14, however, it can be assumed that 
there are missing data and that the background is different in different areas owing to the data 
having not being recorded with the intention of further analysis. Moreover, the TLD might be 
affected by thermal and radiation history, the time between read-out and exposure, and the 
nature of storage (e.g. brick or wood wall).
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Figure 5-14: Relationship between staff dose and number of patients (2004-2007)
Figure 5-15: Diagram of the PET/CT department in NHSTH-1 (not to scale).
The best available plan of the NHSTH-1 PET/CT suite is shown in Figure 5-15. The main 
sources of radiation in the PET/CT suite are the post-injected patient and the vial in which the 
lgF is kept. The vial of F-18 is kept on the bench in the lab, at position (A). While patients are 
in the suite they spend most of their time either lying on the bed in the injection room, at 
position B, or lying on the PET/CT couch, at position C in the same room (Figure 5-15). A 
high activity F-18 (3.6 GBq) vial was placed at position (A) and measurements were made of 
dose rates (pSv/h) in and around the suite. The whole body dose was recorded for each phase 
of the PET/CT workflow for all 60 patients scanned at NHSTH-1 during the period of the 
study.
5.3.1 Effect of EPD location
The introduction (Chapter 1) indicated that the position of the dose measurement device has 
an impact on the dose recorded. Pilot measurements were carried out to find the differences 
between the positions of the EPD as well as to measure the back dose in the static unit where 
there are usually two patients in the same room. Four EPDs were fixed to the technologist: 
three on the front (breast pocket, both trouser side pockets) and one on the back (trouser belt) 
(Figure 5-16). The upper EPD showed the highest total dose reading for all the phases, 
because the distance between the patient and the EPD at this position is short and this 
position was not affected by the height of the staff member (Figure 5-16).
Figure 5-16: EPD positions (three on the front and one on the back)
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Figure 5-17: Average total doses vs number of patients at different EPD positions
Figure 5-17 shows the relationship between the numbers of patients scanned per day and the 
average total staff doses. There was no significant difference between the L and R position. 
However, the upper position received the highest average dose. Figure 5-18 demonstrates 
why position U gives the highest reading.
B e f o r e  in j e c t  1 0 1 1  r l <  1  b u t  a t t h e  i n j e c t i o n  
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Figure 5-18: The effect of EPD distance at the injection phase
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5 .3 .2  S ta f f  doses d u r in g  P E T /C T  p ro c e d u re s
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Figure 5-19: The total mean dose vs. number of patient due to EPD positions
The average total staff member doses per patient increases with increasing patient numbers. 
The back position dose shows a significant increase of about a factor of two when the number 
of patients increases from 3 to 5, because there was increasing likelihood of 2 patients 
occupying the injection room.
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Figure 5-20: Comparison between the exposure dose on the front and the back
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Figure 5-20 compares doses received by the back and front EPDs during injection. The 
reading was affected by the position of the staff member during the injection, as the injection 
room was occupied by two patients at the same time. The difference between dose readings 
obtained in the back and the front positions varied between 27% and 40% of the front dose 
reading due to the design of the unit as well as the occupancy of the injection room.
5.3.2.1 Staff doses during Dispensing
Table 5-7: Average dose per patient during dispensing
EPD Position Mean Dose pSv ±SD
U 0.33 0.11
■ H i
0.18 0.01
R 0.36 0.11
B 0.09 0.05
The L-block shield is in the hot-lab near the dose calibrator, less than 30 cm from the wall. 
The L-block is fixed on a counter at a height greater than 60 cm (Figure 5-21). The EPD 
reading is therefore affected by the height of the individual staff member as both the R and L 
EPDs are at waist level. From the figure, it can clearly be seen that the EPD is hidden by the 
edge of the counter. Also, because the staff member was left handed, the R EPD position read 
double that of the L position because the R EPD faced the source during dispensing.
Figure 5-21: (A): L-Block shield (B): Staff position when dispensing
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5 .3 .2 .2  S ta f f  doses d u r in g  In je c t io n
Table 5-8: Average dose/ patient during injection
EPD Position Mean Dose pSv ±SD
U 5.21 2.19
L 3.59 2.20
R 2.84 0.87
B 0.56 0.28
The U position shows the highest reading. Also, L and R are not equal because of the position 
of staff during the injection (see observations).
5.3.2.3 Staff doses during the W C phase
Table 5-9: Average dose per patient during the WC phase
EPD position Mean Dose pSv ±SD
U 0.37 0.06
L 0.51 0.12
R 0.29 0.13
B 0.37 0.03
During the WC phase the staff member usually accompanies the patient to the WC, as the 
WC is located outside the unit (Figure 5-15). Passing through the unit door may take time, as 
the unit door is needs a security card to open, which could explain the high L reading.
5.3.2.4 Staff doses during positioning
Table 5-10: Average dose per patient during positioning
position Mean Dose pSv ±SD
U 1.26 1.19
L 1.43 0.45
R 0.97 0.44
B 0.61 0.14
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Figure 5-22: Patient positioning and the effect of distance.
As was explained in the dispensing phase, the L-side EPDs face the bed and therefore 
experience a different angle of detection (Figure 5-22).
The aims of this section were to find the average whole body dose per patient per staff 
member per EPD position and to calculate the maximum number of patients that can be 
scanned per day per staff member. According to the ICRP regulations (see Chapter 2) the 
maximum annual dose per staff member is 6 mSv in order to remain below the level for 
classification. NHSTH-1 PET/CT staff members work 45 weeks per year, 5 days weekly, 
giving a total of 225 days per year. The maximum dose limit per day is 26.7 pSv, allowing up 
to 6 patients per day per staff member (see the calculations in Box 3.2).
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Dose lim it =  6000 pSv/staff/year, Total w orking days/year =  5 days x 45 weeks 
=  225. M ax im u m  total exposure dose p S v/day/s ta ff =  6000 pSv -*- 225 days =  
26.7  (liSv  /day  
The average dose from  the U P  E P D  position was 7.2 pSv/patient 
26 pS v /D ay  7.2 pSv/patient =  4 *  patients/day/staff 
The average dose from  the L  E P D  position was 5.7 pSv/patient 
26 jaSv/Day -*-5.7 pSv/patient = 5 *  patients/day/staff 
The average dose from  the R  E P D  position was 4.5 pSv/patient 
26 p S v /D ay  4.5 pSv/patient =  6 *  patients/day/staff
From the calculations in Box 3.2, each staff member can handle a maximum of 5 patients 
without exceeding the dose limits. However, adding the back dose reading will alter these 
figures.
5.3.3 Whole body dose received by technical staff in different phases at NHSTH-1
B o x  3 .2 : C a lc u la t io n s  o f  n u m b e r  o f  p a tie n ts  p e r  d a y  p e r  s ta f f  based on  E P D  p o s it io n
Table 5-11: the average whole body dose per day for each phase at NHSTH-1
Phase Dispensing Injection
room
W.C. Scanning
room
Departure
EPD position F B F B F B F B F B
average
dose/patient
(pSv)
0.35 0.40 4.0 1.2 0.8 0.5 1.6 0.9 0.6 0.3
±SD 0.20 0.15 2.0 0.6 0.9 0.1 0.9 0.7 0.4 0.2
F= Front position, B= Back position
The average whole body dose readings measured using EPDs positioned on the front and 
back of the technologist for each phase of whole patient procedure of PET/CT scans at 
NHSTH-1 are shown in Table 5-11. The measurements were obtained from scanning 140 
patients with 400 ± 15% MBq l8F-FDG injected activity per patient.
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The highest doses were received during the injection phase with means ± SD of 4.0 ± 2.0 pSv 
and 1.2 ± 0.6 pSv per day for the technologist’s front and back, respectively. Those values 
were followed by the doses received in the scanning room of 1.6 ± 0.9 pSv and 0.9 ± 0.7 pSv 
per day, respectively. Other smaller doses were received at the dispensing, W.C. and 
departure phases, as illustrated in Figure 5-23. The pie chart in Figure 5-24 shows that the 
injection task contributes about 54% of the total dose received per PET/CT procedure, 
whereas the other tasks in total contribute 46% of the total dose. The average whole body 
doses per patient the technologist received, summed over the front waist and the back waist 
levels during the complete PET/CT procedure were 7.4 ± 3.0 pSv and 2.6 ± 0.9 pSv, 
respectively.
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Figure 5-23: The whole body dose per phase per patient in NHSTH-1
Figure 5-24: The whole body dose per task in pSv in each phase at NHSTH-1
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5.3 .4  O c c u p a n c y  le ve l in  th e  in je c t io n  ro o m  a n d  its  e ffe c t on  th e  dose re c e iv e d
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Positions of the ERDs
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Figure 5-25: Occupancy level in the injection room and the dose received by the technologist
The mean whole body doses received by the technologist, with one patient only in the 
injection room, were 3.5 ± l.O pSv and l.O ± 0.4 pSv at the front and back positions, 
respectively. When there were two patients in the injection room these figures increased to 
4.0 ± l.O pSv and 2.0 ± 0.8 pSv, respectively. Figure 5-25 shows that there was no significant 
increase in the average dose per patient at the front of the technologist, while the average 
dose at the back doubled when adding a second patient into the injection room.
5.3.5 Exposure times during different phases of the PET/CT procedure at N H S TH -l
Figure 5-26 shows the percentage of the time spent by the technologist in each phase. Times 
spent performing the tasks involved in all five phases were similar.
■ despencing (min)
■ Injection(min)
□ W.C.(min)
□ Scanning(min)
■ Departure(min)
Figure 5-26: The percentage of the time spent by the technologist in each phase
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5.3.5.1 Exposure time and dose received in the injection room at NHSHT-1
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Figure 5-28: The effect of time spent in the injection room on the dose received by the 
technologist
The length of time spent by the technologist in the injection room was thought to be an 
important factor in the dose being received. Figure 5-28 shows the front and back EPD doses 
obtained over the course of processing 140 patients in the injection room. The dose per 
patient does not seem to have a linear dependence on time spent in the injection phase, and 
high doses occurred for all injection durations.
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Figure 5-29 shows the relationship between the activity used and the background exposure in 
the control room. The average daily exposure in the control room was 4 ±  1 pSv. The same 
measurements were recorded at the reception area (Figure 5-30), where the receptionists 
spend most of their working hours. The dose was measured at the reception area using EPDs, 
for an average 7-8 hour working day for one week. The average daily dose was 2.8 ±  0.4 
pSv. The results show a significant variability in both sets of readings; this is mainly a 
consequence of the statistical error that resulted from the small number of measurements 
taken, due to technical problems and time limitations of this project.
5 .3 .6  R e c e p tio n  a n d  c o n tr o l  ro o m  b a c k g ro u n d  m e a s u re m e n ts
Figure 5-29: The relationship between the used activity and the background exposure
(pSv/day) in the control room
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in the reception area
Figure 5-31 shows that the background exposure in the control room during the working day 
contributes about 10% of the measured whole body dose of 37.0 ± 0.4 pSv per working day 
in the PET/CT units.
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Figure 5-31: The control room background exposure and its percentage contribution to the 
average whole body dose the technologist receives each day.
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Table 5-12 shows the background radiation levels in the different areas of the PET/CT suite 
at NHSHT-1. The measurements were taken during the weekends and during periods when 
the PET/CT unit was undergoing engineering servicing.
5 .3 .7  T h e  b a c k g ro u n d  e x p o s u re
Table 5-12: The background exposure in the PET/CT facility at NHSTH-1
Facility
Dose/day(|iiSv)
Scanning room 
0.64
Control room 
0.45
Injection room 
0.69
5.3.8 Pot position and pot lead thickness
NHSTH-1 in England has a PET/CT unit with a Philips scanner (BGO). It has four rooms 
(hot lab, control room, uptake room, scanning room) and an external hot W.C. (Figure 5-33). 
The red circular area located in the hot-lab is an FDG pot with 2,690 MBq activity, which 
arrived around 8:45 am every. The dose rate and full gamma spectrum were acquired at 
different locations labelled PI to P8. The additional L-P9 location is in front of the elevator in 
a very busy corridor used by patients and staff, that is the only way to reach the diagnostic 
and nuclear medicine department (e.g. for X-rays), as well as the coffee room, staff changing 
room and W.C. The average activity per patient was 380 MBq ± 10% over the study period. 
The average number of scanned patients per day at this unit has increased during the last two 
years by factor of 2 and has now reached 9 patients per day, according to the technologist’s 
log book. A LaBr3 portable detector was used in all the measurements, allowing a full 
energy spectrum as well as a dose rate in pSv/h to be obtained simultaneously. Following 
detector calibration and dose rate comparison with hand calculations, the first measurements 
started at 08:50. This was after the staff members had measured the activity of the FDG, 
which was 2690 MBq. Equation 2-46 was used for hand calculations.
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Table 5-13: Dose rate at different positions
Location Description Dose Rate jaSv/h
PI 1 m from injected patient 30min after injection 28.2
P2 1 m from injected patient lmin after W.C visit 22.5
P3 40 cm from the wall at PC monitor level in reception 0.10-3.6
P4 120 cm from the wall in chair level 0.25 -12.5
P5 1 m from the lead glass window at control room 0.15 -  7.5
P6 20 cm from the L side of the L shield 10.30
P7 20 cm form L shield front side waist level 0.25
P8 20 cm from L-side of a closed lead pot Figure 5-34 10.30
P9 1 m from the lift door (when there were a patient) 14.30
P = Position of the detector according to Figure 5-33
The dose rate at P3 fluctuated between 1 and 3.6 pS/h, peaking when the staff opened the pot 
in the hot-lab or put a syringe with FDG on the plate for injection. The dose rate at P4 
fluctuated between 0.25 and 12.5 pS/h, peaking when the staff opened the pot in the hot-lab 
or measured the activity with calibrator (Figure 5-32 &  Figure 5-35). These values require 
that the shielding calculations be repeated.
Figure 5-32: FDG spectra at P4 when a lead pot in the hot-lab was closed
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Figure 5-33: Layout of PET/CT unit in NHSTH-1 Hospital (not to scale)
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Figure 5-34: L-shield where the FDG pot is kept and where the syringe is dispensed
Figure 5-35: FDG spectra at P4 when a lead pot in the Hot-lab was open
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5.4 Mobile PET/CT Unit Design 1
Mobile PET and PET/CT services are currently provided by a Private Medical Company 
(P M C l) to a number of hospitals around the country, generally on a fortnightly or weekly 
basis. The host hospitals are required to provide a hard standing area, power supply and 
utilities, and telecommunications.
There are significant differences between static and mobile units in terms of design, as shown 
in Figure 5-36. The mobile unit does not have a hot toilet on board, and there is no separate 
hot lab and preparation room, so both functions are carried out in the same shielded area. 
Moreover, mobile units have a lift for disabled patients and patients needing assistance who 
cannot use the stairs.
There are also space constraints in all areas. The average distance between patient and staff 
may be smaller than in a more spacious static environment, and the time of exposure may be 
longer as the dispensing, injecting and measurement of residual activity all take place in the 
same room. The patient empties their bladder in a toilet provided by the host hospital, as 
close as possible to where the mobile unit is parked. Patients will therefore need to be 
accompanied to the toilet, and this potentially increases the radiation exposure of mobile 
technologists relative to static centre technologists.
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5.4.1 M o b i le  U n i t  S ta f f  doses d u r in g  d i f fe r e n t  ta sks
Data were obtained from 64 patients scanned on the mobile unit, at an average throughput of 
6 patients per day and with 2 staff sharing the handling of the patients. In the mobile PET/CT 
unit the dispensing phase contains many tasks, which include unpacking, residual tasks and 
dispensing. However, all these tasks were classed as dispensing because unpacking normally 
occurred just once a day and because all the other tasks were carried out sequentially in the 
same room with no time gap. As can be seen from Figure 5-37, in most of the cases the 
injection phase exposed workers to a high dose, and in some cases the W.C phase was also 
high. Figure 5-38 shows that the amount of "others" doses in the mobile unit is > 10%, and 
that the mean of the injection phase is 33% of the total whole body dose per patient of 5.67 
±2.66 pSv.
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Figure 5-37: Total whole body dose per patient from all phases in the Mobile unit at PMC l
The aims of this section were to find the average whole body dose per patient per staff 
member and to calculate maximum number of patients can be scanned per day per staff 
member. According to the ICRP regulations (see Chapter 2) the maximum annual dose per 
staff member is 6 mSv in order to remain below the level for classification. The total working 
days per year for Mobile PET/CT unit staff are 135, since PET/CT staff members work 45 
weeks per year, 3 days per week. The maximum dose limit per day is 40 pSv, thus allowing 
up to 7 patients per day per staff member (see the calculations in Box 3.3).
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Dose limit = 6000 pSv/staff/year, total working days/ year = 3 days x 45 weeks = 135. 
Maximum total exposure dose pSv/day/staff = 6000 pSv -s- 135 days = 44.0 pSv/day
The average whole dose from EPD readings is 6 pSv/patient
42 pSv/day + 6 pSv/patient = 7* patients/day/staff
*From the calculation in Box 3.3 each staff member can handle a maximum of 7 patients 
without exceeding the dose limits.
Box 3.3: Calculations of number of patients per day per staff based on EPD position
0.72; .13; 2%
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Figure 5-38: Average whole body dose (pSv) per patient per phase in the Mobile PMC l
5.4.2 Effect of EPD location on staff doses in the mobile unit in PMC1
Figure 5-39 shows the effect of the EPD location over a 20 day period when the average 
patient number per day was 9. In day 13, two wheelchair patients were served, explaining 
why the shirt EPD reading was relatively high.
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Figure 5-39: Effect of the EPD position (Mobile PMC1)
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The study was undertaken at two different locations with different types of PET/ CT mobile 
unit. Both the facilities were equipped with the Siemens Biograph series 6 slice CT scanner. 
The facilities were well planned and consist of the areas as described below.
5.5.1 Hot lab
The hot lab includes a specially designed chair where patient history is taken and where the 
patient is cannulated. Next, the 18F-FDG is prepared and the patient is guided to the waiting 
area. The hot lab is equipped with a well shielded dispensing area shielded by an L-shaped 
shield and disposal unit wherein the residual syringes are disposed, minimizing the radiation 
exposure. The dose calibrator is also present, located close by but behind the shield where the 
dose can be measured accurately. All the procedures are performed with forceps by the 
technician so as to reduce exposure.
5.5 Mobile PET/CT Unit Disgn 2
Figure 5-40: The Hot Lab
5.5.2 Control room
This area is restricted to staff and is used for all the control and communication during the 
scan (Figure 5-44). The clinician performs the scan from the control room, but is able to 
monitor the patient through lead shielded glass. The control room is equipped with a 
microphone and speakers for communication with the patient in the scanning room.
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1Here, the patient is injected with the activity and asked to wait for about 60 minutes, to allow 
the tracer to be taken up in the body. A special seat is provided for comforting the patient, 
and patient chair has a special call facility button, which upon activation will call the clinician 
in the control room for assistance.
5.5 .3  U p ta k e  ro o m  [ In je c t io n  ro o m ]
In ection Chair
Figure 5-41: The Uptake room
5.5.4 Scanning room
The scanning room is the largest area of the whole facility and houses the PET/CT scanner. 
The room is equipped with a multipart monitor and also has an alarm facility to enable the 
patient to seek assistance. A key characteristic of the scanning room is the lead shielding, 
which is thickest in this area. The scanning room walls have an unusual design whereby the 
walls are mostly lead lined but separate the control room by a lead lined glass and the uptake 
room by means of a sliding shutter. A typical view of the scanning room is shown in Figures
5-42 and 5.43.
CT Gantry
Figure 5-42: Scanner Room showing CT gantry
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PET Gantry
Figure 5-43: PET Gantry
There are key differences between the two facilities (Figure 5-46 and Figure 5-44) that could 
lead to large variations in the doses measured between different areas within the facilities. 
One of the facilities is equipped with a support unit which has 2 uptake areas, 1 reception and 
1 WC. Thus, the number of patients managed in the area will be high compared to a static 
unit. Also, because of the presence of the WC, the assistance time needed by the patients 
going to the WC is shorter. Thus, the radiation dose to the assisting staff is lower.
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Figure 5-44 (A) PET/CT mobile unit without support vehicle (PMC2)
Figure 5-45: (A) PET/CT mobile unit without support vehicle (PMC2A)
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Figure 5-46: (B) PET/CT mobile with support vehicle (PMC2B)
Figure 5-47: (B) PET/CT mobile unit with support vehicle
SUPPORT vehicle
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Table 5-14: comparison between the accumulated staff doses for all PMC2 staff
Staff/Task SI S2 S3 S4 S5 Average STD
Dispensing 0.47 0.56 0.31 0.46 0.43 0.45 0.09
Injection 2.09 3.93 1.69 2.52 2.63 2.57 0.85
Residual 0.15 0.41 0.14 0.15 0.43 0.25 0.15
WC 0.22 0.50 0.55 0.40 0.20 0.37 0.16
Scanning 0.60 0.54 0.62 1.00 0.68 0.69 0.18
Departure 0.15 0.50 0.16 0.30 0.50 0.32 0.17
Total 3.67 6.44 3.47 4.83 4.86 4.65 1.19
Max* 1,634 932 1,730 1,242 1,234
Max*= Maximum number of patients can be served by the staff member/yr.
5.5.5 Measurement considerations
The experimental design adopted at this mobile unit comprised measurements of staff doses 
received during the entire working day for all the staff working in the mobile PET/CT unit. 
The staff doses were measured for 21 days and subdivided for each patient. The work cycle 
was divided into the six phases described in chapter 3. The staff dose for each cycle for each 
patient was recorded and timed precisely. The data collected for each staff member over the 
entire pool of patients were then averaged to obtain the average staff dose in each phase. This 
method was repeated for each staff member at both units. The average staff dose for each of 
the staff members in each of the phases is displayed in Table 5-14.
5.5.6 Average staff dose from each task
The highest doses measured from all phases were 0.56 pSv in dispensing, 3.93 pSv in 
injecting, 0.43 pSv in residual, 0.55 pSv in WC, 0.68 pSv in scanning, and 0.50 pSv in the 
departure phase.
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Table 5-14: comparison between the accumulated staff doses for all PMC2 staff
Staff/Task SI S2 S3 S4 S5 Average STD
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Injection 2.09 3.93 1.69 2.52 2.63 2.57 0.85
Residual 0.15 0.41 0.14 0.15 0.43 0.25 0.15
WC 0.22 0.50 0.55 0.40 0.20 0.37 0.16
Scanning 0.60 0.54 0.62 1.00 0.68 0.69 0.18
Departure 0.15 0.50 0.16 0.30 0.50 0.32 0.17
Total 3.67 6.44 3.47 4.83 4.86 4.65 1.19
Max* 1,634 932 1,730 1,242 1,234
Max*= Maximum number of patients can be served by the staff member/yr.
5.5.5 Measurement considerations
The experimental design adopted at this mobile unit comprised measurements of staff doses 
received during the entire working day for all the staff working in the mobile PET/CT unit. 
The staff doses were measured for 21 days and subdivided for each patient. The work cycle 
was divided into the six phases described in chapter 3. The staff dose for each cycle for each 
patient was recorded and timed precisely. The data collected for each staff member over the 
entire pool of patients were then averaged to obtain the average staff dose in each phase. This 
method was repeated for each staff member at both units. The average staff dose for each of 
the staff members in each of the phases is displayed in Table 5-14.
5.5.6 Average staff dose from each task
The highest doses measured from all phases were 0.56 pSv in dispensing, 3.93 pSv in 
injecting, 0.43 pSv in residual, 0.55 pSv in WC, 0.68 pSv in scanning, and 0.50 pSv in the 
departure phase.
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Table 5-15: Comparison of staff doses and process duration whilst using cannulation ( ‘no
butterfly ( ‘BF’)
DOSE( jiSv) TIM E (min)
No BF Using BF No BF Using
3 3 1 3
3 5 2 2
3 5 1.18 6
1 2 1.3 2
2 2 1.4 2
Total 12 17 6.88 15
Average 2.4 3.4 1.3 3
Standard Deviation 0.9 1.5 0.4 1.7
In the cases of patients in whom the cannulation process is not possible, a butterfly is used in
the vein to inject l8F-FDG. This increases the total dose and exposure time of the staff giving 
18 •the F-FDG injection. There were, in total, 5 such cases and the exposure time and dose for 
the respective staff involved was recorded as shown in Table 5-15. It is clear that the total 
average dose to the same staff was 1.7 times greater with a butterfly than that without. Also, 
the exposure time was 2.3 times the normal value.
Table 5-16: Comparison of staff doses and process duration for the WC phase.
DOSE (pSv) TIM E (min)
Not using lift Using lift Not using lift Using lift
1 2 6 6
1 2 7 10
1 2 5 10
0 1 5 7
1 4 4.5 8
Total 4 11 27.5 41
Average 0.8 2.2 5.5 8.2
STD 0.4 1.0 1.0 1.8
There were five cases in which the patient was immobilized and needed to use a wheel chair 
and the lift. The average dose to the staff taking care immobilized patients was increased by a 
factor of 2.75 and the total exposure time for the same staff was increased by a factor of 1.49 
(Table 5-16).
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Figure 5-48: Average staff dose per task per patient in pSv
Figure 5-48 shows the distribution of the average staff dose per task. The injection phase 
provides the greatest contribution (55%) to the total average staff dose received by an 
individual working in this PET/CT unit. The scanning and despensing phases contribute the 
next highest doses, but are very much lower than that of the injection phase. The contribution 
from the residual, W.C. and departure phases is relatively small.
4.50
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C o m p a r is o n  b e t w e e n  s t a f f  m e m b e r s  in  b o t h  
t h e  m o b i l e  P E T /C T  u n i t s
Dispensing Injection Residual W.C
Phases Scanning Departure
Figure 5-49: Comparison of doses received during each task for all the staff at the mobile
PET/CT unit.
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Figure 5-49 shows very clearly that the radiation exposure in the injection phase is the 
highest for all staff members. Differences between staff members are generally small, except 
for Staff Member 2 who received an anomalously high dose during the injection phase, 
possibly due to injection technique or extended staff-patient interaction.
Average staff dose and maximum potential patient throughput
■ Average total staff doses from all tasks gSv/patient
17.30 x 102
SI S2 S3 S4 S5
Figure 5-50 : Comparison of average dose per patient for each staff member, and the 
corresponding maximum patient throughput that maintains a total annual dose <6 mSv/yr
Figure 5-50 shows the average dose per patient received by each staff member, and the 
corresponding maximum number of patients per year that the staff member can treat whilst 
maintaining their total annual dose < 6 mSv/yr. This annual dose limit is that set by the 
Ionising Radiation Regulations 1999, Regulation 17 (individuals exceeding this dose become 
classified: see chapter 2). The error bars represent the standard deviation for each value.
Table 5-17 and Table 5-18 show the average staff dose (±STD) for all the staff, in the 
different phases at mobile facilities ‘A ’ and ‘B \
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Table 5-17: Average staff dose in each phase at facility “A ”
Task Facility “A ” dose jliSv ±STD
Dispensing 0.52 0.40
Injection 2.15 1.05
Residual 0.31 0.29
W C 1.08 0.89
Scanning 0.95 0.75
Departure 0.78 0.65
Total staff average doses pSv/patient 5.79 4.02
Patient dose rate/h at lm  at release at “A ” 9.75 2.70
Table 5-18: Average staff dose in each phase at facility “B”
Task Facility “B” dose pSv ±STD
Dispensing 0.76 0.40
Injection 2.44 0.97
Residual 0.57 0.48
W C 0.61 0.33
Scanning 1.17 0.85
Departure 0.67 0.45
Total staff average doses uSv/patient 6.21 3.47
Patient dose rate/hr at lm  at release at “B” 11.08 2.68
5.5.7 Exposure time results
Table 5-19shows the exposure time results at facilities “A” and “B”, indicating the average 
time of exposure that personnel would have experienced during the six phases. The average 
total time of exposure to radiation per patient for each radiation worker was 11.2 ± 3.47 min.
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Table 5-19: Exposure time results at facilities “A ” and “B”
Tasks
Mobile Unit A Mobile Unit B
Average 
Exposure time 
(min)
±STD
Average 
Exposure time 
(min)
±STD
Dispensing 1.51 1.02 2.24 1.16
Injection 1.75 1.07 1.86 0.63
Residual 1.17 0.82 0.95 0.32
W C 4.70 1.93 2.66 1.28
Scanning 1.70 1.11 2.19 1.96
Departure 1.84 1.72 1.21 0.63
Total Time 11.28 4.02 11.11 2.92
5.5.8 Background Radiation Exposure
Average O ccupational Background Vs Scanned patients /D a y  
from  all Units
7 n
Number of Patients / Day
Figure 5-51 : Average background dose versus number of patients/day for both mobile units.
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The average background radiation dose is plotted as a function of number of patients scanned 
per day in each facility (Figure 5-51) for comparison with radiation measurements in 
different types of PET facilities and to provide an evaluation of background radiation dose as 
the patient-per-day throughput changes. The background doses recorded in individual 
facilities as a function of number of patients per facility are displayed in Figure 5-52 and 
Figure 5-53.
O ccu p atio n a l background  versus n u m b e r o f scanned  
patients p e r day
4
Day
Average Number of Patients/ 
Day =10.14±2.34 
Average occupational 
background in pSv = 4.7±1.4
i Occupational 
Background in pSv/full 
working day at Mobile 
PET/CT Unit A 
I Number of Patients
Figure 5-52: Occupational background dose versus patients per day at location “A”
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Figure 5-53: Occupational background versus patients per day at location “B’
5.5.9 EPD Position Assessment
Table 5-20: EPD Position and Staff dose.
Position 
of EPDs
Staff
SI
Staff
S2
Staff
S3
Staff
S4
Staff
S5
Total
doses
(juSv)
Average
dose/day
(pSv) ±STD
FRO NT 16.6 26.6 14.6 22.1 24.5 1042.26 20.8 5.1
BACK 6.3 4.66 5.9 6.5 4.5 27.86 5.52 0.9
Table 5-20 displays average doses recorded for all staff members for a selection of different 
EPD positions, as well as the total staff members’ doses. There are two main positions to be 
considered, as explained above (chapter 3). Measurements clearly showed the front dose 
reading was higher than the back (by a factor of four) (Figure 5-54), confirming that 
positioning the EPD on the front side of the body gives more accurate counts.
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A v e r a g e  D o s e  f r o m  E P D  a t  B a c k  a n d  F r o n t
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Figure 5-54: Dose recorded at two EPD device positions
5.5.10 Patient dose rate at departure
Table 5-21: Average dose at 1 m distance from released patients at facilities ‘A ’ and ‘ET
Location Average Dose rate1 pSv/h at lm ±STD
A 9.75 2.7
B 10.5 2.70
Average
.
10.05
. . . . . . . .
2.7
1 for both male and female patients in each unit.
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Figure 5-55: Average doses from male and female patients at 1 m distance after departure
Table 5-21 and Figure 5-55 display patient average dose rates at two different locations and 
dose rates for male and female patients, respectively. Figure 5-55 shows the relationship 
between the injected activity and the dose rate measured at 1 m from the patient, after 
scanning (during the departure phase).
5.5.11 Discussion and Analysis
With reference to the Pie chart distribution o f staff doses in various phases it was found that 
the injection phase delivered the largest dose to staff o f all the phases, consistent with results 
published by Seierstadl et al., 2006, who concluded that 60% of the total staff dose was 
contributed by the handling o f the source and with the remaining 40% accounted for by the 
interaction with the patient. The total activity o f FDG injected into patients during this study 
was approximately 380 ± 20 MBq per patient, and the average dose received by staff 
members was 4.65 ± 1 .19  pSv per patient. This is equivalent to a total dose o f 12.2 nSv/MBq, 
which is less than the 25 nSv/MBq estimated by Seierstad et al., 2006. The value obtained 
here is closer to that o f Dignum and van Lingen (1998), who obtained 14 nSv/MBq, but their 
figure was recorded in a static unit. Our value is also o f the same order (i.e., nano Seiverts) as 
estimates by Chiesa et al., 1997 and Robinson et al., 2005.
153
Ill
Figure 5-49 the individual dose for every staff member is displayed for all the phases. Few 
differences between staff members are noted in any o f the phases, except for Staff Member 
S2 in the injection phase. It is believed that an error may have occurred in this phase during 
the injection to the patient, which caused the dose absorbed by this member o f staff to be 
anomalously high.
Figure 5-50 illustrates the maximum number o f patients that can be served by a radiation 
worker before the worker exceeds their ICRP guideline limit o f 6 mSv/year and becomes 
legally “classified” . This calculation is based on the average staff dose for each individual 
and provides an essential limit to the number o f patients that can be handled by a particular 
individual, governed by the average dose rate received by each individual. Maximum patient 
numbers vary between staff members due to individual differences with respect to radioactive 
material handling techniques.
From Table 5-19shows the exposure time results at facilities “A” and “B”, indicating the 
average time o f exposure that personnel would have experienced during the six phases. The 
average total time o f exposure to radiation per patient for each radiation worker was 11.2 ± 
3.47 min.
Table 5-19 we can see that the average exposure time per scan for each staff member is 11.2 
± 3.47 min. Also, it can be noted that time period contributed by the WC phase is 4.7 mins in 
Facility A (without a WC) compared with just 2.7 mins in Facility B. Despite differences in 
staff technique, it was observed that the difference in average exposure time between the 
units is very low. A study by Alsafi 2005 [84] observed that the average exposure times in the 
mobile PET/CT unit was 25± 14.15 min, considerably longer than the results o f this study. 
This difference may be attributable to the distance between the mobile unit and the hot WC, 
which was around 60 meters in the early study compared with 5 m in this study.
The average dose was 0.61 pSv per patient in the WC phase o f the work flow in Facility (B) 
which has a support vehicle with an inbuilt WC, while that in Facility (A) with no support 
vehicle (patients were accompanied to the hospital WC) was 1.08pSv. This result arises from 
the necessarily longer patient-staff contact time in Facility B. However, the total average staff 
dose in facility (B) was reported to be 6.21 pSv, compared with 5.79 pSv in facility (A). This
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result shows how the presence o f the internal WC can increase to background dose level, as 
confirmed by results presented in Figure 5-52 and Figure 5-53.
Even though technologists were not required to escort patients to the WC in Facility A, there 
was little difference in average exposure time between the two facilities.
Finally, we consider the placement o f the EPD for dose measurement. It can be observed in 
Figure 5-54 that the dose measured when wearing the EPD at the back gave significantly 
lower results compared those obtained when wearing the EPD on the front (as discussed in 
the methodology section). Unlike the static units, the mobile units have insufficient space to 
allow two patients to be accommodated in the injection room simultaneously. Thus the back 
dose in mobile units was smaller than that in static units where the individual staff member 
attending to a patient in front would be exposed to a further dose from the second patient 
behind (Figure 5-19 and Figure 5-20).
Figure 5-55 shows the relation between total activity injected per weight in kg o f the patient 
and the dose rate measured on departure at 1 m distance from the patient. The graph has two 
outliers which can be attributed to the difference in activity to weight ratio for the particular 
patients. Males were found to have smaller dose rates than females. This is because the 
average dose to all the males and females was the same but the comparative average weights 
of males and females vary considerably.
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6 C h a p t e r  6 :  M o n t o  C a r lo  S i m u l a t i o n s :  D o s e  p r o f i l e s  f r o m  Z u b a l  
a n d  t h e  w a t e r  t a n k  p h a n t o m
6.1 Introduction
The Monte Carlo simulation (MC) is a computational method developed in the late 1940’s at 
Los Alamos National Laboratory in New Mexico [102]. The program was developed to 
follow a large number of individual particles as they were scattered, escaped or absorbed. 
Particles would be followed and processes repeated until a statistically valid picture was 
generated [103]. The strength o f the MC simulation in the field o f ionising radiation lies in 
the possibility o f simulating a problem using a computer, without having to physically 
perform potentially hazardous experiments. MC simulations have been applied to many 
areas, e.g. safety regarding waste storage sites, and more recently in medical diagnostic and 
radiotherapy fields. Multiple versions o f MC simulations have been developed since the 
1940s, steadily extending the simulation abilities. One o f the more recent MC simulations is 
MCNPX: an “all-purpose” radiation transport code that can track nearly all particles with an 
almost indefinite range o f energies [104]. MCNPX is a physical problem simulation; with 
four main components, called “cards” : the title card, cell cards, surface cards and data cards. 
There are a range o f components in the simulation which allow for specific characteristics 
pertaining to the sources, particles, energy deposition and tallies (detectors). The geometry of 
the problem is specifically defined by parameters including radiation type, energy, materials, 
sources and number o f histories to be followed. The title card is user specified and is simply a 
title by which to identify the code. The cell, surface and data cards, however, entail much 
more detail.
The aim o f this chapter was to compare the MCNPX simulated effective dose measured doses 
in the PET/CT suite at the NHS Trust Hospital in England. Further, the shielding design and 
dose map for the unit were evaluated to enable a possible reduction o f structural as well as 
financial burden. The Zubal phantom was used to obtain the effective dose in most o f the 
sensitive organs. The MCNPC2 code was available on the cluster o f the University o f Surrey 
Department o f Physics, but the large file size o f the Zubal phantom required acquisition o f a
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license for the new edition of MCNPX Visual Editor 2.6.0.
The surface cards form the basis o f the geometry in the model. The user specifies a surface 
number and geometry (e.g., plane, sphere or parallel-piped) and identifies all coordinates for 
that geometry. This is repeated until ail structures within the model are defined. Once the 
surface cards are complete, the user can move on to the data cards where the materials to be 
used along with particle and source types, energies and tallies (detectors) are specified. Each 
material identified in the data cards must be specified by its elemental components and the 
percentage o f each element in the material, and the user also specifies what radiation type 
will be modelled in the code (e.g., photon, neutron, alpha, etc.) and how many histories will 
be followed. Source size, strength and position are also input into the data cards. Once the 
surface cards are complete and the data cards are in progress, the cell cards must be 
identified. Each cell in the cell cards is a volume composed from surfaces defined in the 
surface cards. For a simplistic example, if  a sphere is defined as a surface in the surface cards, 
then there would be two corresponding cells in the cell cards: one inside the spherical surface 
and one outside the surface.
6.2 Zubal Phantom
The anthropomorphic phantom used in this study was produced by a research group led by 
Dr. George Zubal o f the Imaging Science Research Laboratories at Yale University School o f 
Medicine [105], who identified and segmented a CT torso and MRI head slices of two living 
human males, using a high-resolution bit pad and display [106]. The phantom has been 
further developed by a research group in the University o f Surrey Department o f Physics 
under the supervision o f Professor Spyrou in 2005. Organs used to construct the Zubal model 
included adrenals, bladder, oesophagus, kidneys, lungs, liver, pancreas, prostate, skeletal 
components, skin, spleen, stomach, small and large intestine, testes, thyroid, and other 
organs. The final list consists o f those organs defined as ‘critical’ and for which ICRP has 
assigned radiation-weighting factors (ICRP, 2007[45]; see Table 2-2) as well as o f other 
organs considered as important in respect o f their biomedical applications. The phantom file 
size is around 1.8 MB. MCNPXC2 was unable to handle an input file o f such size, but this 
problem has been resolved since the beta edition o f MCNPX 2.60 was released.
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Soft
Figure 6-1 : Coronal view of Zubal complete model using MCNP plotting features [107].
Figure 6-1 illustrates different material, colour coded as light blue (bone), brown (skin), 
yellow (muscle), navy (soft tissue), blue (lung), red (adipose), green (red bone marrow) and 
light green for yellow bone marrow (note: cartilage is not shown in this view).
Muscle Bone
Red bone 
marrow
Yellow bone 
marrow
Adipose
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6.3 Pilot MCNPX study
After the necessary paperwork and meetings with the management o f a private PET/CT unit 
(PPCUE) in England, a layout o f the unit was provided. The layout detailed the ‘lead 
equivalent’ shielding, but not actual materials. The unit consists o f an injection room; hot-lab, 
control room, scanning room and hot WC (see Figure 6-2).
Table 6-1 : Summary o f PET/CT unit room locations in Figure 6-2
N Description Location1
1 Control Room A l
2 Scanning Room A2
3 Hot-Lab A3
4 Injection Room 1 A4
5 Injection Room 2 A5
6 Individual staff office A6
7 Hot W C . A7
8 Changing Room A8
9 Waiting Area A9
10 Corridor 1 AIO
11 Corridor 2 A ll
/= See Figure 6-2
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Figure 6-2: PET/CT layout at PPCUE
Figure 6-3 : Pilot dose map from MCNPX for PPCUE
Figure 6-3 shows the PPCUE unit, where the three red points were water phantoms with 
radioactive isotropic sources ( 18F). This was the first run, to check the shielding calculation 
and the design. It was important to check the dose map at the unit even for a run with a small 
number o f histories (less than 106). From Figure 6-3 it is clear that in location A10 (the 
corridor between the hot-lab and injection rooms) there was a high exposure rate, noting that 
the hot-lab did not contain any radioactive source. After reviewing the EPD doses record 
(with permission o f PPCUE management) for two staff members for a period o f 8 days with 
an average workload 6.5± 1.35 patients/day, it was found that the average staff doses/day 
were exceeding 30 pSv (~ 6.75 mSv annual), which is above the classification level. The first 
recommendation was that all the injection rooms should be redesigned.
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Figure 6-5: Pilot dose map from MCNPX for PPCUE after adding a wall in the injection 
room.
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Figure 6-5 illustrates the benefit o f adding a wall to the injection room, reducing expected 
calculated staff doses per annum by a factor o f 1.5. Also, recommendations were given to the 
staff about spending unnecessary time in location A 10.
6.4 MCNP Input files
The MCNP input file contains summary data specifying the problem, for example geometry, 
material descriptions, location and characteristics o f the neutron, photon, or electron sources, 
types o f tallies, etc. MCNPX measurement units are as follows:
1- Length in centimetres
2- Energy in MeV
3- Time in shakes (sec)
4- Mass density in g cm'3
5- The maximum number o f particles that can be simulated is 2.0x109. Any input files written 
by the MCNP code should have six builders: cells, surfaces, source definition, tallies, 
number o f histories and time o f run.
6.4.1 MCNPX Geometry
The input file geometry is described by cells cards, surfaces cards, and materials cards.
6.4.1.1 Cell Card
The MCNPX Cells are defined on cell cards. Each cell is described by a cell number, material 
number, and material density followed by a list o f operators and signed surfaces that bound 
the cell. The number o f characters is very limited as each MCNPX code line is restricted to 
80 characters. Consequently, the cell number must begin in columns 1-5. The material is 
described by the material density as well as the atomic number (Z)[104].
6.4.1.2 Surface Card
Most o f the geometry shapes are available in MCNPX e.g. sphere, cylinder. The surface card 
is described by a surface number, surface location, type (plane or sphere), and surrounding 
cells.
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The remaining input data for MCNP are mode card, particle importance, source specification, 
tally specification, material specification, and problem cut-offs. The mode card instructed 
MCNPX to focus on photon transport only and neglect other processes.
The particle importance card (IMP) for photons, electrons, and neutrons is used to specify * 
relative cell importance in the sample problem. For example, if  there are four cells in the 
problem, the IMP card will have four entries. The IMP card is also used to help particles 
move more easily to important regions o f the geometry and to reduce the running time.
A source definition card SDEF is one o f four available methods o f defining starting particles. 
The SDEF card defines the basic source parameters, some of which are source position in x y 
z (POS), starting cell number (Cell= cell number from the cell card), starting energy default 
in MeV (ERG) and source particle type (BAR) which could be electron, photon or all.
The tally cards are used to specify the output o f the Monte Carlo calculation, e.g. flux at a 
point, etc. Output is requested with one or more tally cards. Tally specification cards are not 
required, but if  none is supplied, no tallies will be printed when the problem is run and a 
warning message is issued. MCNP provides six standard neutrons, six standard photons, and 
four standard electron tallies, all normalized to be per starting particle. However, only project 
tallies F6 and F8 were used here because we are concerned only with photons. For dose 
calculations from the measurements, a dose conversion factor was used. The tallies are 
identified by tally type and particle type. Tallies are generally given the numbers 1, 2,3, 4, 5, 
6, 7, 8, or increments o f 10 thereof, and are given the particle designator N or P or E (or N,P 
only in the case o f tally type 6 or P,E only for tally type 8). Thus as many tallies can be 
defined as necessary. F6:P, F16:P, F106:P, and F236:P are all legitimate energy deposition 
tallies; they could all be for the same cell(s) but with different energy or multiplier bins, for 
example. Similarly F5: P, F I5: P, and F305: P are all photon point detector tallies. Having 
both an F I: N card and an F I: P card in the same INP file is not allowed. The tally number 
may not exceed three digits[102].
6.4.1.3 Data Card
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The materials cards (Mm) specifies both the isotopic composition o f the materials and the 
cross-section evaluations to be used in the cells. The following card is an example o f the 
(Mm) containing material m, where m cannot exceed 5 digits (Mm ZAID1 fraction 1 ZAID2 
fraction2). The m on a material card corresponds to the material number on the cell card. The 
consecutive pairs o f entries on the material card consist o f the identification number (ZAID) 
o f the constituent element or nuclide followed by the atomic fraction (or weight fraction if 
entered as a negative number) o f that element or nuclide, until all the elements and nuclides 
needed to define the material have been listed.
Problem cut-off cards are used to specify parameters for some o f the ways to stop execution 
o f MCNP. For our problem we used only the history cut-off (NPS) card. The mnemonic NPS 
is followed by a single entry that specifies the number o f histories to transport. MCNP will 
terminate after NPS histories unless it has terminated earlier for some other reason.
6.5 PET/CT input file
The same geometry for the PET/CT PPCUE unit was used, however, with other materials. 
The centre was installed in a simply constructed building comprising breeze block walls with 
a single course o f brick cladding and internal plasterboard partitions. Space was at a premium 
and distances from the proposed resting bays to the control room were less than 4 m. The 
suite was adjacent to an area occupied by non radiation workers and the building was close to 
other buildings containing offices. The wall material was solid concrete blocks (density 2000 
kg/m3). All the tables, computers desks and other furniture, etc, were excluded from the 
design. A Zubal phantom was used in this study. The phantom was fixed in the scanning 
room at location A2. Although all sensitive organs were attached by an F6 tally detector, two 
detectors were fixed to the liver (F6 and F8) for cross checking to ensure that the simulation 
was running correctly. F6 is an energy deposition averaged over a cell in MeV/g and *F8 is an 
energy distribution o f pulses created in the detector by radiation in MeV.
6.6 Alternative phantoms
It was not possible to use two phantoms in the same file because o f the large cell numbers, 
unless the phantom was rebuilt from the zero point. However, a tank o f water with 
dimensions of 170 cm x 55 cm x 15 cm was fixed at bed level in a room o f dimension 750 cm 
x 600 cm x 300 cm (scanning room). A radioactive source with 0.511 MeV energy was 
located in the tank and the Zubal phantom was fixed at three locations (lm , 2m, and 4m from 
the tank).
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Two kinds o f tallies were used in this simulation: *F8 and F6. F6 was fixed at many locations 
in the phantom such as the liver, bladder, and skin. For cross checking, the *F8 tally was 
used.
6.7 Results and Dose calculations
6.7.1 Dose Calculations
The F6 results were multiplied by 1.60218xl0‘l() to convert readings into Gy. The *F8 results 
were first divided by the mass o f the liver (1434 g) and then treated as F6 results. Effective 
doses were obtained from summing the F6 absorbed doses weighted by the radiation 
weighting factor (1 for photon) and the tissue weighting factors according to ICRP Report 60. 
The results were expressed in Sv per source photon. The mesh tally results were expressed in 
Sv/h per source photon per second. Therefore, they were divided by 3600 (seconds per hour) 
to obtain the unit Sv per source photon. Note that the results in the following paragraphs are 
all normalized by the number o f source photons and the words “per photon” are omitted from 
the units.
6.7.2 Comparison of F6 and *F8 tallies
The following table summarises the absorbed doses to the liver at various distances from the 
source.
Table 6-2 : Comparison o f F6 and *F8 tallies Absorbed dose
jitaorbcd A ta o .h e d  « ,«  H o,,, *F8
1 3.55x10 3.53x10 -0.6%
2 1.27X10'18 1.28xl018 +1.2%
4 3.89xl0‘19 3.89X10'19 -0.2%
The differences were in the similar range o f relative errors o f the F6 tallies. Thus, using the 
track average tallies, i.e. F6 tallies, instead o f the more accurate *F8 tallies, is justified. 
Figure 6-6 shows the effective dose from exposure to a FDG source (400 MBq) at 1m. From 
the figure it is clear that there is good agreement (< 2% difference) between the two methods 
o f dose calculation. The effective dose from the EPD has been calculated for comparison 
with the MCNPX calculations. However, the difference between the MCNPX and the EPDs 
is around 45%. This is due to many factors, e.g. if the simulated unit is totally empty there 
will be less photon scattering.
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Figure 6-6: Effective dose in nSv from exposure to a 400MBq l8F at lm  distance
6.7.3 Comparison of effective doses from the Zubal phantom and water-tank-source 
mesh tally with ISO dose conversion
The following figure shows the effective dose distribution from a patient represented by a 
water tank. The source is uniformly distributed in the water, but the ‘dose’ within the tank 
(body) is not real, as explained below.
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Figure 6-7 : Dose Distribution in water tank (looking down the Y axis).
The tally mesh is superimposed onto the geometry and is independent o f the geometry. The 
tally calculates the average track length in each tally element and derives the photon fluence 
in these elements. This fluence is the fluence in water if the tally element is overlying a 
volume of water. If the volume is in air, the derived fluence is the fluence in air. If the 
volume is partly in air and partly in water, the derived fluence is again averaged regardless o f 
the actual material. When the fluence is known, MCNP(X) uses one o f the fluence-to-dose 
conversion coefficient sets to obtain the effective dose (whereby the fluence is binned by 
energy and then the coefficient o f each energy bin is multiplied by the corresponding 
fluence). The set o f coefficients to be used is specified by the user and here was chosen to be 
the set for ISO isotropic irradiation. Note that these coefficients were calculated with fluence 
in air as one o f the assumptions. Thus, only the tally elements in air are will give the correct 
values o f dose. For all the tally elements that enclose materials other than air, the values are 
incorrect since the fluences averaged over the other materials are multiplied by the fluence- 
in-air-to-dose conversion coefficients. This might also be the reason behind the observed 
increase in dose near the walls. If the tally elements are partly in the concrete and partly in 
air, we would see an increase in the average fluence. Thus, the dark red region in the above 
figure that corresponds to the water tank has to be ignored.
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Table 6-3: Effective Dose comparison between mesh and F6 tallies
Distance
(m)
Effective dose from F6 (Sv) 
[water tank as patient, 
Zubal phantom as staff]
Effective dose from mesh 
(Sv)
[water tank as patient, mesh 
tally with ISO conversion for 
dose]
Relative
dose
[F6/mesh[
1 3.71xl018 3.57xl018 1.04
2 1.33xl018 1.15xl018 1.16
4 3.71xl019 3.28X1019 1.13
From the above considerations, there is an uncertainty in the order o f 10 -  15 % with the 
mesh results, relative to those from more accurate simulations that actually tally the energy 
deposition in each organ. Note that the -1 %  difference in tallies between F6 and *F8 found in 
the previous section is o f little significance.
6.8 Comparison o f effective dose from the Zubal phantom and water tank 
sources
Figure 6-8 shows the effective dose distribution from a Zubal phantom patient. 60% of the 
source is in the liver, 20% in bladder and 20% in the skeletal muscle. Therefore, it can be 
seen that the “dose” in the body is highly non-uniform. The outlines o f the liver and the 
bladder are clearly visible. Again, this “dose” distribution within the body is not real, as 
discussed in the previous section on “dose” in the water tank.
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Figure 6-8: Effective dose from a Zubal phantom (looking down the Y axis)
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We can see that the two sets o f dose distributions have similar orders o f magnitude. Figure 6- 
9 shows the effective dose from the water tank source relative to the dose from the Zubal 
phantom source. The subsequent two plots show the relative doses along X = -100 and Z = 0.
e fftc tiv * dote from weter t jn k  source re ljtive  to th jt  from Z u b jl phantom
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Figure 6-9 : Effective dose from the Zubal phantom (looking down the Y axis)
Large fluctuations in relative doses occur inside the phantoms. As discussed before, they 
have to be ignored. For the relative doses in the Y direction, the water tank source 
consistently over-estimates the dose by a factor o f about l .5 to 2.5. In the simulation, the +Y 
direction is the Zubal phantom’s head and the -Y direction is the feet. Thus the difference in 
doses is largely due to the irregular nature o f the phantom outline. However, the relative 
doses in the X directions are generally around 0.7. Thus, the water tank source produces 
uncertainties in the range o f -30% to +100%. This is not an unreasonable result when using 
the water tank approximation given that there are so many factors affecting the dose. 
Providing we are aware o f the limitations, we can safely use the water tank as source and the 
mesh tally with dose conversion coefficients to obtain fast simulations with reasonable 
accuracy.
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7.1 Discussion and Analysis
7.2 Summary
7 C h a p te r  7: D isc u ss io n , O b se rv a tio n  an d  C o n c lu s io n s
Table 7-1: Summary o f average effective dose per staff per patient
UNIT
Average 
dose/pa tient/sta ff 
pSv
Estimated Number of 
patient can be 
scanned/year
Max exposure
jliSv/ h
PAMICL 5.4 2.3 1111 3.33
PAMICLB 4.97 0.93 1207 3.33
NHSTH-1 7.4 3 810.8 3.33
Mobile PMC1 5.67 2.66 1058 3.70
Mobile PMCA 5.79 4.02 1036 3.70
Mobile PMCB 6.21 3.47 966 3.70
Average 5.91 0.83 1031±135 3.5±0.2
This chapter starts with a summary o f the preceding results, and suggests recommendations 
based on observations from the different units visited. Table 7-1 is a summary o f the average 
dose per patient per staff member at both static and mobile PET/CT units. By dividing the 
annual staff dose limit (6000 pSv/year) by the average dose/patient, an estimate for the 
number o f scanned patients per annum per staff member can be found (Fourth column in the 
Table 7-1, coloured green). Overall, the average staff member dose per patient was 
5.91±0.83pSv and the estimated number o f scanned patients per annum was 1031 ± 135 
patients. Observation o f the staff during the PET/CT workflow phases includes the following 
situations where staff dose exposure increase:
7.2.1 P atien t p repara tion
There are no standard procedures common to all PET/CT sites in terms o f patient preparation 
before injection. From the observations, having a written questionnaire may reduce time and 
avoid unnecessary exposure. A glucose test must be done before the injection. Removing all 
jewellery and accessories during this part is important. Prisoners, children, and any other 
persons needing to be accompanied need scan procedures and steps to be clearly explained to 
both patient and parent/carer/security guard. Also, during uptake time, the CT scan, and the 
PET scan the parent/carer/security guard should stay in a safe place. Drawing dose map 
distributions in each room helps to fix colour signs in the floor. These signs give a guide 
where they should stand to get as low dose as possible.
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7.2.2 Hot-lab
Observations o f some of the hot labs showed that the location o f the FDG dispensing area 
lead to the FDG shielding jar (which usually lifts open) being too close to the wall, where the 
lead bricks can produce Bremsstrahlung X-rays. At another site, one o f the hot lab walls was 
made o f low Z materials, leading to high observed background readings (>4 pSv/day, which 
is double the expected background in an uncontrolled area) in the neighbouring counsel room 
and reception. Also, most o f the staff members forget to wear their finger TLDs during the 
dispensing phase. This might explain the low observed finger doses.
7.2.3 Injection Room
In most o f the PET/CT units, as well as in some mobile units, there are two beds in the 
injection room; one located near the door and the other at the end o f the room. The distance 
between them is less than 1 m. Deciding which arm will be used for fixing the cannula and 
injection plays an important role in the staff positioning during the injection (
Figure 7-1). In some cases the staff member must use the right arm for the patient in Bed 1, 
that means the staff will be between the bed and the wall. In that case the patient is close to 
the staff. When injecting two patients in the same room, an EPD fixed at the back position of 
the staff member showed that the back exposure dose during the PET/CT phase contributed 
between 27 and 40% o f the injection phase Figure 5-20.
I  ' : i l  i c j i I Bed 2
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Figure 7-1: Injection Room at NHSTH-2 with two beds
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Accompanying elderly persons along a busy or narrow corridor with automatic doors 
increases the time of exposure. Showing patients the WC location before the injection would 
be beneficial. Walking in close contact with an injected patient for unimportant reasons over 
a long time increases the accumulated dose, and it is recommended that the staff member 
should not be to the front or back o f patient, since the best position is to their left or right 
side.
7.3 Observations and Recommendations
Here we summarise observations and recommendations based on results from this study.
7.3.1 Dispensing
Limitation o f space must be considered
Staff body size: small staff move easily and take less time during this phase 
Paper work is required for records
If  any new FDG box is delivered during the day this leads to an increase in background
radiation in the mobile unit 
FDG pot should not be left open 
Forceps must be used properly.
Do not spend more time than strictly needed during dispensing.
Staff members with less experience take longer to draw the patient FDG dose.
Locate the FDG storage cupboard close to the dispensing unit.
7.3.2 Injection
Patients with poor veins need to use butterfly valve rather than cannula.
Injection o f second patient, when a previously injected person remains in the room, will
increase radiation exposure to staff.
Placing the new FDG box in the injection room increases the background level.
Staff should avoid being too close to the patient during injection 
Verbal communication with patient should take place prior to the injection.
Patients requiring immediate attention, or who are very ill, or who faint, may require staff to 
be very close; this increases staff exposure.
7.2.4 WC Phases
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7.3.3 Residual
Do not pick up the syringe without using forceps 
Failing to flush during the injection leads to high residuals.
Ensure the activity remains in the syringe, and avoid drips 
Ensure the residual syringe is capped.
Ensure proper disposal o f the syringe.
Maintain a maximum distance from active materials.
7.3.4 WC
Explain location o f WC to patient.
Using lift increases staff dose
Close contact with patient increases staff dose.
Using wheelchair if  needed increases staff dose.
Ensure the route to the WC is clear so the patient can go alone when capable o f doing so.
7.3.5 Scanning
Do not stand too close to the patient, especially near the head end
Positioning a patient who requires high maintenance [i.e. deaf, very ill, weak legs] increases 
staff dose.
Helping a patient to put their arm over their head increases staff dose.
Avoid the need to repeat scans because o f poor patient preparation [i.e. patient not positioned 
properly on the table, drop trousers further due to zip, etc]
Poor communication with the patient may lead to increased staff dose in a later phase.
7.3.6 Departure
Avoid long post scan conversations.
Avoid being too close to the patient while conversing.
If  the patient does not rendezvous with the relative, the longer wait increases staff dose. 
Patients waiting for ambulance / transportation increase staff dose.
If  the patient does not understand where they are going next due to poor communication they 
will linger for longer.
7.3.7 Other
If  there is no gap between patients, extra pressure on staff can lead to mistakes.
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There are therefore several areas that can be improved in the workflow to reduce dose 
without discomfiting the patient or reducing the quality o f the scan can be implemented by 
making the staff more aware o f what can be done. The pressure o f greater throughput o f the 
patient will not diminish.
In light o f these observations and recommendations there are several areas that can be 
improved in the workflow to reduce dose without discomfiting the patient or reducing the 
quality o f the scan. These can be implemented by increasing staff awareness, and is important 
when considering that the pressure o f greater patient throughput is unlikely to diminish.
7.4 Conclusions
The present study was undertaken at six locations, in static and mobile PET/CT units with 
varying designs, to identify the potential phases and events providing the greatest 
contribution to the total staff exposure level. From analysis o f the statistics from 1300 patient 
scanning procedures, it was deduced that the injection phase o f the whole PET/CT work 
cycle contributed around 55% of the total average staff dose. The measurements were 
accurately timed for each o f the work cycle phases, as explained in the methodology. The 
timing analysis showed that the average exposure time per PET/CT cycle varied between 
11.2±3.47 minutes and 25± 14.15, depending on location. The total average staff dose across 
all units in the study was 5.91 ±0.83 pSv per patient and 14.8 nSv/MBq.
The analysis o f EPD position revealed that placing the EPD on the front upper left side would 
give results more representative o f the actual dose. Placing the EPD on the back 
underestimated the staff dose rate by almost a factor o f 4.
One o f the facilities was equipped with a support unit consisting o f a WC. The difference in 
design showed a decrease in staff dose contribution in the WC phase, but the average 
background dose observed increased by 21.6%.
Total whole body dose per phase per patient displayed significant variability, as illustrated in 
Chapter 5, for both mobile and static sites. From the available data, we cannot identify the 
main reasons that led to the variability. However, the variability in the whole body dose 
during the PET/CT scan procedure in most o f the phases (such as dispensing, injection, and 
scanning) was based on both the state o f the patient and on the skill o f the staff member.
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It was also affected by missing data and by the limitations and the position o f the 
measurement device. The EPD employed here does not display fractions o f less than 1 pSv, 
which means that a zero value in the LCD display does not mean that the actual reading is 
necessarily zero (e.g. if the EPD recorded 0.99 pSv the LCD will display 0 pSv, only 
switching to 1 pSv when the reading exceeds 1 pSv). However, using the Easy EPD software 
to interface with the device solves this problem. As shown in Chapter 5, most o f the whole 
body dose is received during the injection phase, due to difficulties associated with gaining 
venous access and to staff-patient interaction during the injection (e.g. asking and answering 
additional questions about the scans; communication difficulties with patients who may need 
more time for explanations; using a butterfly needle rather than a cannula) (Figure 7-2). 
Several approaches to reducing staff dose in the injection phase will be investigated in future 
work. However, explaining the scan procedure to the patient fully before reaching the 
injection room as well as ensuring that the patient has removed all the accessories (e.g. tight 
rings that they might later need help with) before the injection can help.
Figure 7-2 A and B: Cannula and shielded injection pump.
Other suggestions include translating the pamphlet that explains the scan procedures into 
different languages, and including clearer photos. In addition, fixing a cannula before the 
injection rather than using a butterfly needle will reduce the exposure dose, as the injection 
dose can be left in the hot lab while venous access is gained. Furthermore, using an automatic 
shielded pump for injection, which can be connected to the patient directly, would mean that 
the staff can stay within an acceptable distance (more than 1 m). Painting lines on the ground 
o f the injection room may also help to remind staff to limit close contact with patients.
In the dispensing phase, staff members do not currently calculate the estimated volume o f the 
FDG that gives the required activity, and this leads to re-dispensing until the required activity 
has been reached, especially for older consignments as the half life time o f 18F-FDG is 
relatively short at 110 minutes.
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The activity can be reduced significantly and this leads to an increase in the injected volume. 
In addition, completing paper work inside the hot lab during the dispensing and residual 
phases increased the exposure time. Using a calibrator that is connected to the computer to 
record the residual automatically would reduce the exposure.
In the WC phase it can be concluded that the main reason for increased exposure is 
dealing with patients who need assistance during this phase (e.g. disabled and older people). 
However, using non-clinical helpers during this phase can assist in reducing the exposure 
dose. Also, having a WC onboard in the mobile unit should significantly reduce the staff 
dose. This will be investigated further and a design will be suggested in future work.
In the scanning phase, staff members reported that some injected patients need extra 
assistance with positioning on the scanner bed and removing accessories, and the majority 
ask questions about the scan. As was mentioned before, the staff member should check that 
the patient has removed all the accessories prior to this phase. Marking the area around the 
scanner with a coloured line would remind the staff member o f the distance where they 
should stand. With some scanner models, it is possible for the technologist to control the 
scanner bed from the console room at the end o f the scan. This may not be possible for 
patient safety purposes however, but adding movable arms to the scanner bed may allow the 
staff to use the control keyboard from the staff room.
Regarding the departure phase, the main reason for higher exposure doses is prolonged close 
contact with injected patients in closed areas, for example when using the lift with the patient. 
In most units, staff should ensure that the patient does not stay in the unit after having 
changed, and should schedule the movement o f the patient and staff members (e.g. staff 
members should not stay in the waiting area unnecessarily). Using a helper may be a good 
idea; however the helpers’ uniform should be different to the staff members’ uniform to avoid 
the helper being asked any questions about the scans. Also, adding CCTV monitoring in the 
waiting area may be useful.
Other exposure sources include any unexpected exposure due to close contact with an 
injected patient, as well as carelessness. Several recommendations to minimize these 
exposures have been given in the preceding sections. However, increased regular training can 
assist by increasing the skill o f the staff members, as well as by raising the awareness o f 
unnecessary contact.
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Although the mobile unit differs from the static unit in terms o f the design and the 
dimensions, the injection phase is also the phase with highest exposure. In mobile units the 
injection and residual measurements are combined into a single phase because they take place 
sequentially in the same room. In this joint phase, there are many factors that could affect the 
whole body dose, for example the injection difficulties that have been mentioned previously. 
However, the recommendations for this kind o f environment are different and have an 
economic impact as ideally the mobile unit should be redesigned to provide more space and 
better workflow. Using an extra mobile unit for dispensing and injecting patients in a separate 
preparation room, and providing a WC with a one-way pathway for patients, would minimize 
occupational exposure and also increase the throughput of patients, although at very high 
cost. It can be seen from Figure 7-3 how the sequence o f a one-way pathway would avoid 
unexpected exposure to staff, as well as reducing staff member doses during the WC phase by 
approximately 10%. The WC could be in an external mobile unit.
500
cm w.c INJECTI INJECTI INJECTION ON ON
ROOM ROOM ROOM HOT LAB
130X230 N. 3 N. 2 N. 1
cm 130X230 130X230 130X230
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EXIT 
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DESK
N
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Figure 7-3: Suggested layout for mobile injection unit
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Whole body dose and exposure time in the WC phase for the mobile unit are based on 
the location o f the WC as well as the state o f health o f the patient. As the mobile unit does 
not have a WC, the patients use a hospital WC. Patients need to be accompanied to the WC, 
and in some locations the route to the WC is narrow and crowded, and may require that the 
staff member and the patient use doors which are not automated. Furthermore, using the lift 
is slow and involves close contact with the patient. For this case, using non-clinical helpers 
can help to reduce the staff member whole body doses and also assist generally with 
workflow to improve throughput. However, the mobile unit management should request that 
the host hospital provide for easy access to the WC and a room for preparation and 
cannulation o f the patient.
Suggesting reasons for "Other" contributions to exposure was not straightforward, but 
it can be concluded that some unexpected exposure is due to close contact with injected 
patients while the patient is passing through the staff area. The staff area is located in the 
centre o f the mobile unit, between two hot areas as can be seen from Figure 5-36. 
Consequently, a revision o f the workflow and shielding may be useful. It is suggested that 
distance measurements are also included in any future investigation o f sources o f exposure, in 
particular for the injection and scanning phases as well as the WC on the mobile unit. This 
could be more easily accomplished if the dose measurements were recorded automatically 
and electronically using the EPD reader and software. An independent observer may also be 
required to perform distance measurements while the staff member is carrying out the tasks in 
the different phases.
Monte Carlo code was used to compare the MCNPX simulated effective dose measured 
doses in the PET/CT suite at the NHS Trust Hospital in England. Further, the shielding 
design and dose map for the unit were evaluated to enable a possible reduction o f structural 
as well as financial burden. The Zubal and water tank phantom were used to obtain the 
effective dose in most o f the sensitive organs. The effective dose in most o f the sensitive 
organs was obtained from F8 and F6 tallies. It has been found that the effective dose in most 
o f the sensitive organs lees than the measured by 40% with a great agreement with F8, F6 and 
the mesh tallies. The shielding design was evaluated by the mesh tally and by plotting the 
dose map distribution inside the unit. It has been found that there was a high dose rate 
between the hot-lab and the injection rooms concluding with adding two walls to reduce the 
dose rate which shows good redaction.
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